Home Blog

Changing pharmacist and technician roles due to the pandemic

Ed Cohen, PharmD, FAPhA: Over the past 2 years we have seen and received many emergency use privileges. The technicians were able to get vaccinated against the flu and COVID-19. We see the PREP [The Public Readiness and Emergency Preparedness] Emergency law and decrees by individual states. Now things are looking up a bit. We don’t feel that urgency like we did in the beginning. There are rumors that the PREP law could expire. We are already seeing some activity in states where they are reversing some of these emergency orders. With this sunset comes the potential loss of privileges for some of the things pharmacists may have been doing, which will surely impact technicians. Without some proactive movement within pharmacy boards or the legislative process, technicians may lose the opportunity to get vaccinated. It’s an area that I’m passionate about because I really believe that pharmacy has grown, and all of a sudden there’s talk of bringing pharmacy back to where we started, where we were at the start of the pandemic.

Traci Poole, PharmD, BCACP, BCGP: Without the technicians stepping in and taking on some of these additional roles, the season would have been much longer for us. We were criticized and the technicians able to administer vaccines and tests helped enormously. If many states haven’t addressed this issue in their policies and regulations, and haven’t legislated for techs to administer, I’m afraid my community pharmacy brethren are going to have a very long flu year and COVID-19 simultaneously, depending on what happens with the boosters.

I’m also concerned about pediatric capacity, because those poor pediatric practices are probably going to be completely overwhelmed with new approvals for children. This relieves some of the burden on these offices to be able to offer other vaccines, even up to your recommended childhood vaccine schedule. I am a bit worried. I’m not clear, and you may know it. In Tennessee, we fixed that problem. In many other states, they also take care of it when it comes to the administration of technicians. But I don’t know to what extent the country has done that. It would be unfortunate if they dropped this deadline and did not make it a standard of pharmacy practice.

Ed Cohen, PharmD, FAPhA: With any immunization experience in building programs, you all know what you see in 1 state is just 1 state. There are 50 states and 50 individual vaccination programs across the country. There are no 2 alike. It was a great opportunity for the pharmacy profession to have a federal executive order that said things could be the same in all states. It has been very refreshing over the past 2 years. The loss of this authority at the federal level is enormous. I don’t think individual states take the ball and move forward with it. Many of them pick it up and back off. Do any of you have any information on what’s going on in your state?

Wesley Nuffer, PharmD, BCPS, CDCES: We are very similar to Traci in that our state advocacy group acted relatively quickly and got the technicians authorized by state law to do so. It’s not a new idea. There were a few states doing this before the COVID-19 pandemic. When I first heard about it, I was totally against it because I felt it was going to take away an essential role from the pharmacist. But then I spoke to pharmacists in those states and found that it freed them up to have the conversations we need to have. These are the pieces of education and information that pharmacists can provide. The actual task is what the technician helps alleviate. To pick up on Tracy’s point, we need it, and we need it badly in community practice today. I totally agree that this is an area where we now have students in pharmacy school who have done hundreds of vaccines already, and it’s a great thing that they can bring to the table. It’s something the techs have shown they can do well, and it would be a tragedy to see that backtracked.

Ed Cohen, PharmD, FAPhA: We’ve heard so much talk about making the technician role a career path and not just a job. By giving them these advanced privileges and opportunities, if you take them away, it destroys the idea of ​​career paths and reinforces that we don’t value techies. As pharmacists, if you’ve ever worked behind the counter, you know how valuable the technician is. If only those in decision-making positions could experience this and see firsthand how valuable it is to have good technicians and this career path for them. It would change all their minds.

Transcript edited for clarity.

KINNATE BIOPHARMA INC. Management report and analysis of the financial situation and operating results. (Form 10-Q)

Investors should read the following discussion and analysis of our financial
condition and results of operations together with our financial statements and
related notes included elsewhere in this Quarterly Report on Form 10­Q. This
discussion contains forward-looking statements that involve risks and
uncertainties, including those described in the section titled "Special Note
Regarding Forward-Looking Statements." Our actual results and the timing of
selected events could differ materially from those discussed below. Factors that
could cause or contribute to such differences include, but are not limited to,
those identified below and those set forth under the section titled "Risk
Factors" included elsewhere in this report.


We are a clinical stage biopharmaceutical company focused on the discovery and
development of small molecule kinase inhibitors for difficult-to-treat,
genomically defined cancers. Our mission is to expand the reach of targeted
therapeutics by developing products that are designed to address significant
unmet need. Our Kinnate Discovery Engine, which starts with the identification
of an unmet need among validated oncogenic drivers, utilizes our deep expertise
in medicinal chemistry and the tailored ecosystems of our partners to develop
our targeted therapies. We focus our discovery and development efforts on three
patient populations: (1) those with cancers that harbor known oncogenic drivers
(gene alterations that cause cancers) with no currently available targeted
therapies, (2) those with genomically well-characterized tumors that have
intrinsic resistance to currently available treatments (non-responders), and (3)
those whose tumors have acquired resistance over the course of therapy to
currently available treatments. Our Kinnate Discovery Engine, together with the
biomarker-driven approach of our drug development strategy and our continual
translational research and early global expansion in development, may enable us
to develop drugs with an increased probability of clinical success while
reducing the cost and risk of drug development.

Our most advanced product candidate is KIN-2787, which is a Rapidly Accelerated
Fibrosarcoma (RAF) inhibitor we are developing for the treatment of patients
with lung cancer, melanoma, and other solid tumors. Unlike currently available
treatments that target only Class I B-Rapidly Accelerated Fibrosarcoma (BRAF)
kinase alterations, we have designed KIN-2787 to target Class II and Class III
BRAF alterations, where it would be a first-line targeted therapy, in addition
to covering Class I BRAF alterations. In April 2021, we filed an IND for
KIN-2787 with the FDA. In May 2021, the FDA cleared our IND for KIN-2787 and we
initiated KN-8701, a Phase 1 clinical trial evaluating KIN-2787. We began dosing
KIN-2787 in humans in the second half of 2021. In the second quarter of 2022, we
initiated the combination portion of KN-8701 to study KIN-2787 in combination
with binimetinib in patients with NRAS-mutant melanoma. In addition, in the
second quarter of 2022, KIN-2787 was granted Orphan Drug Designation by the FDA
for the treatment of stage IIb-IV melanoma.

Additionally, we are evaluating KIN-3248, a Fibroblast Growth Factor Receptors
(FGFR) inhibitor, for the treatment of patients with intrahepatic
cholangiocarcinoma, a cancer of the bile ducts in the liver, and urothelial
carcinoma, a cancer of the bladder lining as well as other solid tumors.
KIN-3248 is designed to address clinically observed kinase domain mutations in
FGFR2 and FGFR3 that drive resistance to current therapies. In January 2022, the
FDA cleared our IND for KIN-3248 and in the first quarter of 2022 we initiated
KN-4802, a Phase 1 clinical trial for KIN-3248. We began dosing KIN-3248 in
humans in the second quarter of 2022. KIN-3248 has demonstrated proof of concept
in preclinical models showing activity across both initial FGFR 2/3 genomic
alterations and a broad range of common resistant variants that arise from first
generation FGFR 2/3 targeted therapies.


————————————————– ——————————


We are also advancing a number of other small molecule research programs,
including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in our KIN004 program
to target the treatment of ovarian carcinoma, triple-negative breast cancer and
metastatic castration-resistant prostate cancer.

In May 2021, we announced the closing of a Series A preferred stock financing of
our China joint venture, Kinnjiu Biopharma Inc. (Kinnjiu), to enable the
potential development and commercialization of certain targeted oncology product
candidates across Greater China (People's Republic of China (PRC), Hong Kong,
Taiwan, and Macau). Contributions from noncontrolling interest members totaled
$35.0 million before issuance costs of $0.2 million. As of June 30, 2022, we
held an approximately 58% equity interest in Kinnjiu. In the third quarter of
2022, we announced that KN-8701, the Phase 1 clinical trial evaluating KIN-2787,
was initiated in Taiwan by Kinnjiu.

Since our inception in 2018, we have devoted substantially all of our resources
to research and development activities, including with respect to our RAF and
FGFR programs and other research programs, business planning, establishing and
maintaining our intellectual property portfolio, hiring personnel, raising
capital, and providing general and administrative support for these operations.

We do not have any products approved for commercial sale, and we have not
generated any revenue from product sales or other sources since inception. Our
ability to generate product revenue sufficient to achieve profitability, if
ever, will depend on the successful development and eventual commercialization
of one or more of our product candidates which we expect, if it ever occurs,
will take a number of years. We also do not own or operate, and currently have
no plans to establish, any manufacturing facilities. We rely, and expect to
continue to rely, on third parties for the manufacture of our product candidates
for preclinical and clinical testing, as well as for commercial manufacturing if
any of our product candidates obtain marketing approval. We believe that this
strategy allows us to maintain a more efficient infrastructure by eliminating
the need for us to invest in our own manufacturing facilities, equipment and
personnel while also enabling us to focus our expertise and resources on the
development of our product candidates.

To date, we have financed our operations primarily through proceeds from the
issuance of common stock (including our IPO) and private placements of our
convertible preferred stock. As of June 30, 2022, we had cash and cash
equivalents and short-term and long-term investments of $279.6 million,
exclusive of $29.4 million at Kinnjiu. Based on our current operating plan, we
believe that our current cash and cash equivalents and short-term and long-term
investments will be sufficient to fund our planned operating expenses and
capital expenditure requirements into early 2024.

We have incurred significant losses since the commencement of our operations.
Our consolidated net loss for the six months ended June 30, 2022 was $54.0
million, and we expect to continue to incur significant and increasing losses
for the foreseeable future as we continue to advance our product candidates and
any future product candidates from discovery through preclinical development and
into clinical trials as we seek regulatory approval for these product
candidates. Our net losses may fluctuate significantly from period to period,
depending on the timing of expenditures on our research and development
activities. As of June 30, 2022, we had an accumulated deficit of $197.1

We expect our expenses and capital requirements to increase significantly in our ongoing operations as we:

• advancing our RAF and FGFR programs through clinical development;

• advance the development of our other research programs on small molecules,

including our CDK12 inhibitor and next generation programs for our product


• expand our pipeline of product candidates through our own product discovery and

   development efforts;

• seek to discover and develop additional product candidates;


————————————————– ——————————


• seek regulatory approvals for any successful product candidates

   clinical trials;

• establish a sales, marketing and distribution infrastructure to market

any approved product candidates and related additional commercial manufacture


• set up operational, financial and management systems;

• attract, hire and retain other clinical, scientific, management and

administrative staff;

• maintain, develop, protect and enforce our intellectual property portfolio,

including patents, trade secrets and know-how; and

• Operate as a public company.

We will require substantial additional funding to develop our product candidates
and support our continuing operations. Until such time that we can generate
significant revenue from product sales or other sources, if ever, we expect to
finance our operations through the sale of equity, debt financings or other
capital sources, which could include income from collaborations, strategic
partnerships or marketing, distribution, licensing or other strategic
arrangements with third parties, or from grants. We may be unable to raise
additional funds or to enter into such agreements or arrangements on favorable
terms, or at all. Our ability to raise additional funds may be adversely
impacted by potential worsening global economic conditions and the recent
disruptions to, and volatility in, the credit and financial markets in the
United States and worldwide resulting from the ongoing COVID-19 pandemic and
otherwise. Our failure to obtain sufficient funds on acceptable terms when
needed could have a material adverse effect on our business, results of
operations or financial condition, including requiring us to have to delay,
reduce or eliminate our product development or future commercialization efforts.
Insufficient liquidity may also require us to relinquish rights to product
candidates at an earlier stage of development or on less favorable terms than we
would otherwise choose. The amount and timing of our future funding requirements
will depend on many factors, including the pace and results of our development
efforts. We cannot provide assurance that we will ever be profitable or generate
positive cash flow from operating activities.

The global COVID-19 pandemic continues to evolve. The extent of the impact of
the COVID-19 pandemic on our business, operations and development timelines and
plans remains uncertain, and will depend on certain developments, including the
duration and spread of the outbreak and its impact on our development
activities, ongoing and planned future clinical trial enrollment, current and
future trial sites, clinical research organizations (CROs), contract
manufacturing organizations (CMOs), and other third parties with whom we do
business, as well as its impact on regulatory authorities and our key scientific
and management personnel. To the extent possible, we are conducting business as
usual, with necessary or advisable modifications to our employee travel and work
processes, including having our employees work from home (which our employees
did almost exclusively between March 2020 and June 2021) and as part of a hybrid
model both in our offices and also from home (which we are currently executing).
Although some of the governmental orders and guidelines have terminated or are
now less restrictive than when originally implemented, we will continue to
actively monitor the evolving situation related to COVID-19 and may take further
actions that alter our operations, including those that may be required by
federal, state or local authorities, or that we determine are in the best
interests of our employees and other third parties with whom we do business. At
this point, the ultimate extent to which the COVID-19 pandemic may affect our
business, operations and development timelines and plans, including the
resulting impact on our expenditures and capital needs, remains uncertain and is
subject to change.


————————————————– ——————————


We were incorporated in the State of Delaware in January 2018, and our principal
executive offices are in San Francisco, California. Our research and development
team is primarily based in San Diego, California, with a portion of our
management team based in San Francisco, California.

Components of our operating results


To date, we have not generated any revenue and we do not expect to generate revenue from product sales or other sources in the foreseeable future.

Operating Expenses

Research and Development

Research and development expenses represent a significant portion of our operating expenses and consist primarily of external and internal expenses incurred in connection with the discovery and development of our product candidates.

External charges include:

• expenses incurred in the context of discovery, preclinical and clinical

development of our product candidates, including under agreements with third parties

parties, such as consultants and CROs;

• the manufacturing cost of the compounds to be used in our preclinical and clinical studies

studies, including under agreements with third parties, such as consultants and

   CMOs; and

• costs associated with consultants for chemistry, manufacturing and controls,

development, regulatory, statistical and other services, including the costs of

   technology and facilities.

Internal expenses include employee-related expenses, including salaries and benefits, travel expenses, and stock-based compensation expenses for employees engaged in research and development functions.

We expense research and development expenses in the periods in which they are
incurred. External expenses are recognized based on an evaluation of the
progress to completion of specific tasks using information provided to us by our
service providers or our estimate of the level of service that has been
performed at each reporting date. We track external expenses on the basis of
lead programs and other programs. However, we do not track internal costs on a
program specific basis because these costs are deployed across multiple programs
and, as such, are not separately classified. We utilize third party contractors
for our research and development activities and CMOs for our manufacturing
activities and we do not have our own laboratory or manufacturing facilities.
Therefore, we have no material facilities expenses attributed to research and

Product candidates in later stages of development generally have higher
development costs than those in earlier stages. As a result, we expect that our
research and development expenses will increase substantially over the next
several years as we advance our product candidates through preclinical studies
into and through clinical trials, continue to discover and develop additional
product candidates and expand our pipeline, maintain, expand, protect and
enforce our intellectual property portfolio, and hire additional personnel.


————————————————– ——————————


The successful development of our product candidates is highly uncertain, and we
do not believe it is possible at this time to accurately project the nature,
timing and estimated costs of the efforts necessary to complete the development
of, and obtain regulatory approval for, any of our product candidates. To the
extent our product candidates continue to advance into clinical trials, as well
as advance into larger and later-stage clinical trials, our expenses will
increase substantially and may become more variable. We are also unable to
predict when, if ever, we will generate revenue from our product candidates to
offset these expenses. Our expenditures on current and future preclinical and
clinical programs are subject to numerous uncertainties in timing and cost to
completion. The duration, costs and timing of preclinical studies and clinical
trials and development of our product candidates will depend on a variety of
factors, including:

• the timing and progress of preclinical and clinical development activities;

• the number and scope of preclinical and clinical programs that we decide to pursue;

• our ability to maintain our current research and development programs and to

   establish new ones;

• establishment of an appropriate safety profile with a toxicology allowing the IND


• successful patient enrollment in, and initiation and completion of,

   clinical trials;

 • per-subject trial costs;

• the number of clinical trials required for regulatory approval;

• the countries in which the clinical trials are conducted;

• the time required to recruit eligible subjects and initiate


• the number of subjects participating in clinical trials;

• dropout and dropout rate of subjects;

• any additional safety monitoring requested by the regulatory authorities;

• the duration of subjects’ participation in clinical trials and follow-up;

• successful completion of clinical trials on safety, tolerability and

satisfactory efficacy profiles for applicable regulatory authorities;

• receipt of regulatory approvals from applicable regulatory authorities;

• the timing, receipt and terms of any marketing and post-marketing clearances

approval commitments from applicable regulatory authorities;

• the extent to which we establish collaborations, strategic partnerships or

other strategic agreements with third parties, if any, and the performance of

   any such third party;

• obtain and retain research and development personnel;

• establishing commercial manufacturing capabilities or making arrangements with



————————————————– ——————————


• Development and timely delivery of commercial grade drug formulations

be used in our ongoing and planned future clinical trials and for commercial purposes

   launch; and

• obtaining, maintaining, defending and enforcing patent and other claims

intellectual property rights.

Any changes in the outcome of any of these factors could significantly impact
the costs, timing and viability associated with the development of our product

General and Administrative

General and administrative expenses consist of salaries and benefits, travel and
stock-based compensation expense for personnel in executive, human resources,
finance and administrative functions; professional fees for legal, patent,
consulting, accounting and audit services; and expenses for technology and
facilities. We expense general and administrative expenses in the periods in
which they are incurred.

We expect that our general and administrative expenses will increase over the
next several years as we hire additional personnel to support the continued
research and development of our programs and growth of our business. We also
expect to continue to incur increased expenses as a result of operating as a
public company, including expenses related to accounting, audit, legal,
regulatory, compliance with the rules and regulations of the SEC, Sarbanes-Oxley
Act of 2002, as amended (Sarbanes-Oxley Act), and those of any national
securities exchange on which our securities are traded, director and officer
insurance, investor and public relations, and other administrative and
professional services.

Other Income, Net

Other Income, Net

Other income, net, primarily includes interest income generated from our cash equivalents in interest-bearing money market accounts and short- and long-term investments.

Operating results

Comparison of three and six month periods ended June 30, 2022 and 2021

The following table summarizes our operating results for the periods indicated:

                                                                               Three Months Ended June 30,                                Six Months Ended June 30,
                                                                                2022                 2021             Change              2022                 2021             Change
                                                                                     (in thousands)                                            (in thousands)
Operating expenses:
Research and development                                                   $       19,767       $       16,242     $       3,525     $       39,414       $       28,908     $      10,506
General and administrative                                                          7,639                5,327             2,312             15,051               10,142             4,909
Total operating expenses                                                           27,406               21,569             5,837             54,465               39,050            15,415
Loss from operations                                                              (27,406 )            (21,569 )          (5,837 )          (54,465 )            (39,050 )         (15,415 )
Other income, net                                                                     337                  124               213                494                  148               346
Net loss                                                                          (27,069 )            (21,445 )          (5,624 )          (53,971 )            (38,902 )         (15,069 )
Net loss attributable to redeemable convertible noncontrolling interests                -                    -                 -                  -                    -                 -
Net loss attributable to Kinnate                                           $      (27,069 )     $      (21,445 )   $      (5,624 )   $      (53,971 )     $      (38,902 )   $     (15,069 )


————————————————– ——————————


Research and development costs

The following table summarizes our research and development expenses incurred during the periods indicated:

                                                 Three Months Ended June 30,           Increase           Six Months Ended June 30,           Increase
                                                  2022                 2021           (Decrease)          2022                2021           (Decrease)
                                                       (in thousands)                                          (in thousands)
External expenses:
RAF                                          $        4,728       $        5,624     $       (896 )   $      10,082       $      10,228     $       (146 )
FGFR                                                  3,266                3,083              183             6,107               5,576              531
Other programs and other unallocated costs            3,555                2,202            1,353             7,572               4,214            3,358
Total external expenses                              11,549               10,909              640            23,761              20,018            3,743
Internal expenses                                     8,218                5,333            2,885            15,653               8,890            6,763

Total research and development expenditure $19,767 $16,242 $3,525 $39,414 $28,908 $10,506

Research and development expenses were $19.8 million for the three months ended
June 30, 2022 compared to $16.2 million for the three months ended June 30,
2021, an increase of $3.5 million. The increase was primarily attributable to an
increase of $1.4 million in external expenses for non-lead programs reflecting
increased spend in early-stage pipeline research, as well as an increase of $2.9
million in internal research and development expenses as a result of a
significant increase in research and development personnel and higher
stock-based compensation. These increases were partially offset by a decrease of
$0.9 million in our RAF program attributable to decreased manufacturing activity
and pre-clinical research costs during the second quarter of 2022. Research and
development expenses included $0.9 million incurred at Kinnjiu during the three
months ended June 30, 2022 as the entity began operations in the second quarter
of 2021. For the six months ended June 30, 2022, research and development
expenses were $39.4 million compared to $28.9 million for the same period in
2021, an increase of $10.5 million. Similar to the three months ended June 30,
2022, the increase was primarily driven by an increase of $3.4 million in
external expenses for non-lead programs reflecting increased spend in
early-stage pipeline research, as well as an increase of $6.8 million in
internal research and development expenses as a result of a significant increase
in research and development personnel and higher stock-based compensation.
Research and development expenses included $1.6 million incurred at Kinnjiu
during the six months ended June 30, 2022. We expect research and development
expenses to continue to increase throughout 2022 due to higher external costs
and increasing headcount in connection with advancing our RAF, FGFR and other
programs into later stages of development.

General and administrative expenses

General and administrative expenses were $7.6 million for the three months ended
June 30, 2022 compared to $5.3 million for the three months ended June 30, 2021,
an increase of $2.3 million. For the six months ended June 30, 2022, general and
administrative expenses were $15.0 million compared to $10.1 million for the
same period in 2021, an increase of $4.9 million. These increases were primarily
driven by an increase in headcount, higher stock-based compensation and
increased consulting and professional services expenses. We expect general and
administrative expenses to continue to be similar to these levels throughout

Other Income, Net

Other income, net was $0.3 million for the three months ended June 30, 2022
compared to $0.1 million for the three months ended June 30, 2021, an increase
of $0.2 million. For the six months ended June 30, 2022, other income, net was
$0.5 million compared to $0.1 million for the same period in 2021, an increase
of $0.3 million. These increases were primarily driven by a higher average
investment balance during both the three and six months ended June 30, 2022
compared to the same prior year periods, as our excess cash was more fully
invested, as well as a general increase in interest rates during 2022.


————————————————– ——————————


Cash and capital resources

Sources of liquidity

On December 7, 2020, we completed our IPO. In connection with our IPO, we issued
and sold 13,800,000 shares of our common stock at a price to the public of
$20.00 per share resulting in gross proceeds of $276.0 million before deducting
underwriting discounts and commissions and other offering expenses.
Additionally, in January 2022, we filed a shelf registration with the SEC on
Form S-3ASR (File No. 333-261970). The shelf registration statement included a
prospectus supplement for an at-the-market offering (ATM Offering) to sell up to
an aggregate of $150.0 million of shares of our common stock that may be issued
and sold from time to time under a sales agreement with SVB Leerink LLC. To
date, no shares have been issued and sold pursuant to the ATM Offering. In March
2022, we filed certain post-effective amendments to the Form S-3ASR for the
purpose of, among other things, converting the registration statement to the
proper submission type for a non-automatic shelf registration statement and
providing that the base prospectus included in the registration statement covers
the offering, sale and issuance by us of up to $350.0 million in the aggregate
of the securities identified in the registration statement in one or more
offerings. The $150.0 million of common stock that may be offered, issued and
sold in the ATM Offering is included in the $350.0 million of securities that
may be offered, issued and sold by us under the base prospectus. Prior to our
IPO, we funded our operations primarily through private placements of our
convertible preferred stock with aggregate gross proceeds of $191.6 million.

Our primary uses of cash to date have been to fund our research and development activities, including with respect to our RAF and FGFR programs and other research programs, business planning, establishing and maintaining our intellectual property portfolio, hiring staff, raising capital and providing general and administrative support to these operations.

Future funding needs

To date, we have not generated any revenue. We do not expect to generate any
meaningful revenue unless and until we obtain regulatory approval of and
commercialize any of our product candidates, and we do not know when, or if,
that will occur. Until such time as we can generate significant revenue from
product sales, if ever, we will continue to require substantial additional
capital to develop our product candidates and fund operations for the
foreseeable future. We expect our expenses to increase significantly in
connection with our ongoing activities as described in greater detail below. We
are subject to all the risks incident in the development of new
biopharmaceutical products, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may harm our
business. We expect our expenses to increase significantly, as we:

• advancing our RAF and FGFR programs through clinical development;

• advance the development of our other research programs on small molecules,

including our CDK12 inhibitor;

• expand our pipeline of product candidates through our own product discovery and

   development efforts;

• seek to discover and develop additional product candidates;

• seek regulatory approvals for any successful product candidates

   clinical trials;


————————————————– ——————————


• establish a sales, marketing and distribution infrastructure to market

any approved product candidates and related additional commercial manufacture


• set up operational, financial and management systems;

• attract, hire and retain other clinical, scientific, management and

administrative staff;

• maintain, develop, protect and enforce our intellectual property portfolio,

including patents, trade secrets and know-how; and

• Operate as a public company.

In order to complete the development of our product candidates and to build the
sales, marketing and distribution infrastructure that we believe will be
necessary to commercialize our product candidates, if approved, we will require
substantial additional funding. Until we can generate a sufficient amount of
revenue from the commercialization of our product candidates, we may seek to
raise any necessary additional capital through the sale of equity, debt
financings or other capital sources, which could include income from
collaborations, strategic partnerships or marketing, distribution, licensing or
other strategic arrangements with third parties, or from grants. To the extent
that we raise additional capital through the sale of equity or convertible debt
securities, the ownership interest of our stockholders will be or could be
diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect the rights of our common stockholders. Debt
financing and preferred equity financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific
actions, including restricting our operations and limiting our ability to incur
liens, issue additional debt, pay dividends, repurchase our common stock, make
certain investments or engage in merger, consolidation, licensing or asset sale
transactions. If we raise funds through collaborations, strategic partnerships
and other similar arrangements with third parties, we may be required to grant
rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves. We may be unable to raise additional funds or
to enter into such agreements or arrangements on favorable terms, or at all. Our
ability to raise additional funds may be adversely impacted by potential
worsening global economic conditions and the recent disruptions to, and
volatility in, the credit and financial markets in the United States and
worldwide resulting from the ongoing COVID-19 pandemic and otherwise. If we are
unable to raise additional funds when needed, we may be required to delay,
reduce or eliminate our product development or future commercialization efforts.

Based on our current operating plan, we believe that our current cash and cash
equivalents and investments will be sufficient to fund our planned operating
expenses and capital expenditure requirements into early 2024. We have based our
projections of operating capital requirements on our current operating plan,
which includes several assumptions that may prove to be incorrect, and we may
use all of our available capital resources sooner than we expect.

Due to the many risks and uncertainties associated with the research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our working capital requirements. Our future financing needs will depend on many factors, including:

• the scope, timing, progress, results and costs of research and development

our product candidates and the conduct of preclinical studies and clinical trials;

• the scope, timing, progress, results and costs of research and development

   other product candidates that we may pursue;


————————————————– ——————————


• the costs, timing and results of regulatory review of our product candidates;

• the costs of future activities, including product sales, medical affairs,

marketing, manufacturing and distribution, for each of our product candidates

for which we receive marketing authorization;

• the costs of manufacturing commercial-grade products and sufficient inventory

support the commercial launch;

• revenue, if any, from the commercial sale of our products, if

of our product candidates receive marketing authorization;

• the cost and timing of attracting, hiring and retaining qualified personnel to

support our operations and continued growth;

• the costs of preparing, filing and prosecuting patent applications, maintaining

and enforce our intellectual property rights and defend the intellectual property

   property-related claims;

• our ability to establish and maintain collaborations, strategic partnerships or

marketing, distribution, licensing or other strategic agreements with third parties

parties on favorable terms, if at all;

• the extent to which we acquire or license other product candidates and

   technologies, if any;

• the timing, receipt and amount of sales or milestone payments related to or

royalties on our current or future product candidates, if any; and

• Costs associated with operating as a public company.

A change in the outcome of any of these or other factors with respect to the
development of any of our product candidates could significantly change the
costs and timing associated with the development of that product candidate.
Furthermore, our operating plans may change in the future, and we may need
additional funds to meet operational needs and capital requirements associated
with such operating plans.

We lease office space in San Diego, California and San Francisco, California. In
June 2021, we entered into an agreement to lease 8,088 rentable square feet of
office space located in San Diego, California (SD Lease) for a period of five
years and four months with a lease commencement date of March 2022.
Additionally, we have an option to extend the SD Lease for an additional five
years at the end of the initial term. In August 2021, we entered into an
agreement to lease 5,698 rentable square feet of office space located in San
Francisco, California (SF Lease) for an initial term that commenced on January
1, 2022 and expires June 30, 2026. Additionally, we have an option to extend the
SF Lease for an additional three years at the end of the initial term. As of
June 30, 2022, we have $0.8 million and $3.7 million in current and long-term
operating lease liabilities, respectively.

In addition, we have entered into agreements in the normal course of business
with certain vendors for the provision of goods and services, which includes
manufacturing services with CMOs and development services with CROs. These
agreements may include certain provisions for purchase obligations and
termination obligations that could require payments for the cancellation of
committed purchase obligations or for early termination of the agreements. The
amount of the cancellation or termination payments vary and are based on the
timing of the cancellation or termination and the specific terms of the
agreement. These obligations and commitments are not separately presented.


————————————————– ——————————


Cash flow

The following table sets forth the primary sources and uses of cash for the
periods indicated:

                                                               Six Months Ended June 30,
                                                                 2022               2021
                                                                     (in thousands)
Net cash used in operating activities                        $     (44,628 )     $  (30,901 )
Net cash used in investing activities                              (41,353 )       (201,675 )
Net cash provided by financing activities                              777  


Net decrease in cash, cash equivalents and restricted cash ($85,204) ($197,089)

Operating Activities

Net cash used in operating activities during the six months ended June 30, 2022
was $44.6 million. This consisted of our consolidated net loss of $54.0 million
offset by a net decrease in working capital of $1.4 million, primarily due to a
decrease in accounts payable and accrued expenses and an increase in prepaid
expenses and other assets partially offset by a net increase in operating lease
right-of-use assets and liabilities, net of stock compensation expense of $9.7
million, depreciation expense of $0.2 million and amortization/accretion of
investments of $0.9 million.

Net cash used in operating activities during the six months ended June 30, 2021
was $30.9 million. This consisted of our consolidated net loss of $38.9 million
offset by a net increase in working capital of $0.5 million, primarily due to an
increase in accounts payable and accrued expenses partially offset by an
increase in prepaid expenses and other assets, net of stock compensation expense
of $6.6 million and amortization/accretion of investments of $0.8 million.

Investing activities

Net cash used in investing activities during the six months ended June 30, 2022
was $41.3 million and related primarily to purchases of short-term and long-term
investments totaling $92.5 million partially offset by the sales and maturities
of short-term and long-term investments totaling $53.7 million. Additionally,
purchases of property and equipment totaled $2.6 million during the six months
ended June 30, 2022.

Net cash used in investing activities during the six months ended June 30, 2021
has been $201.7 million and related to purchases of short-term and long-term investments totaling $201.6 millionas well as purchases of property, plant and equipment for an amount of $35,000.

Fundraising activities

Net cash provided by financing activities during the six months ended June 30,
2022 was $0.8 million, which consisted of proceeds from the issuance of common
stock upon stock option exercises and under our employee stock purchase plan of
$0.4 million and $0.4 million, respectively.

Net cash provided by financing activities during the six months ended June 30,
2021 was $35.5 million. This consisted of contributions from noncontrolling
interest owners of $34.9 million, net of offering costs, proceeds from the
issuance of common stock upon stock option exercises of $0.1 million and
proceeds from the issuance of common stock under our employee stock purchase
plan of $0.5 million.


————————————————– ——————————


Off-balance sheet arrangements

We currently do not have, and did not have during the periods presented, any
off-balance sheet arrangements, as defined in the rules and regulations of the

Critical Accounting Estimates

Our consolidated financial statements are prepared in accordance with generally
accepted accounting principles in the United States. The preparation of our
consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities,
costs and expenses, and the disclosure of contingent assets and liabilities in
our financial statements. We base our estimates on historical experience, known
trends and events and various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily
apparent from other sources. We evaluate our estimates and assumptions on a
periodic basis. Our actual results may differ from these estimates.

Our critical accounting policies and estimates are described in the section
titled "Management's Discussion and Analysis of Financial Condition and Results
of Operations-Critical Accounting Policies and Significant Judgments and
Estimates" in our Annual Report on Form 10­K filed with the SEC on March 28,
2022 and the notes to the financial statements appearing elsewhere in this
Quarterly Report on Form 10­Q. During the three and six months ended June 30,
2022, there were no material changes to our critical accounting policies and
estimates from those discussed in our Annual Report on Form 10­K filed with the
SEC on March 28, 2022.

© Edgar Online, source Previews

The right choice | B.Sc Nursing and B.Pharma: Experts Highlight Key Differences


(The Right Choice’ is a series by The Indian Express that tackles common questions, misconceptions and doubts surrounding undergraduate admissions. You can read the stories here.)

Students interested in the medical track often debate between choosing the Bachelor of Science in Nursing (BSc Nursing) program or the Bachelor of Pharmacy (B Pharma) – two popular courses in the field. An overview of their eligibility criteria, the programs, structures and job opportunities they offer.

B.Sc Nursing is a four-year undergraduate program focused on knowledge and skills related to the field of nursing. It equips students for patient care.

B. Pharma is a four-year undergraduate program, which trains students in the manufacturing and distribution of drugs.

“While B.Sc. Nursing students work with patients in need, B.Pharmacy students are well versed in drug development,” said Lakshmamma Tadakara, Director of GITAM Nursing School. at GITAM University (deemed to be).


For the B.Sc nursing course, aspirants must have a 10 plus 2 degree or equivalent in the science stream with English, Physics, Chemistry and Biology as compulsory subjects. For B.Pharma, applicants must have English, Physics or Biology, Chemistry and Mathematics as compulsory subjects, as well as 10 plus 2 or an equivalent qualification.

Course structures

B.Sc Nursing program subjects include: English, Anatomy, Physiology, Nutrition, Biochemistry, Nursing Basics, Psychology, Introduction to Computers, Sociology, Pharmacology , pathology, genetics, surgical medical nursing, community health nursing, microbiology, environmental science, child health nursing, mental health nursing, communication and information technology education, midwifery and obstetrical nursing, nursing research and management of nursing services and education.

Human anatomy and physiology, pathophysiology, biochemistry, pharmaceutical microbiology, pharmacology, pharmaceutical practice and clinical pharmacology, pharmaceutical analysis, pharmaceutical chemistry, pharmacognosy, pharmacy, biotechnology, pharmaceutical jurisprudence and ethics, industrial pharmacy, pharmaceutical industrial management, corrective mathematics or biology, level Basic computer applications, communication skills and environmental science are the core courses of the B.Pharma course.

Job opportunities

Students of the B.Sc. Nursing degree can become a medical coder, medical writer, clinical researcher, in addition to becoming a nurse in public and private hospitals, nursing homes, clinics, and health services. They can also choose to work as a nurse abroad, and each country has its own tests and selection procedure for the same.

B. Pharmacy students can work as pharmacists in public and private hospitals, clinics and health services. Additionally, they can also be a drug inspector, chemist or pharmacist, and quality control and manufacturing chemist. The course also offers the possibility of opening one’s own manufacturing unit.

Talking about the demand in the field, Tadakara said, “The demand for B.Pharma related jobs has increased since Covid-19, and hence, students are also showing more interest in it now.”

How to make the final choice?

Both programs have different curricula and provide different skill sets. Therefore, aspirants cannot change when it comes to job opportunities. The choice therefore largely comes down to their interest.

Lovely Professional University (LPU) School of Pharmaceutical Sciences Coordinator Navneet Khurana said, “B.Sc. Nursing candidates have different knowledge and skills they acquire during the program compared to B.Pharm candidates. Therefore, the majority of jobs they want to do do not overlap.

‘B.Sc. Nursing is about patient care, the student should only choose the program if he or she is interested in bedside patient care. If the student is more interested in manufacturing and distributing drugs, he can take the B. Pharm program,” Dr. Khurana added.

Strengthen the links in the chain

Siyyum is Hebrew for the end. Typically, it is used in a religious context and refers to the completion of the study of a significant portion of the Talmud, which is cause for celebration. The Sharsheret Coming Together summer barbecue on August 1 included a Talmud Berachot tractate siyyum, which allowed everyone to mark the occasion with a meal of meat. The barbecue took place during the nine days of Av, days that commemorate tragedies in Jewish history as they lead up to the fasting day of Tisha b’Av. This is a time when many observant Jews abstain from eating meat. But if you join a siyum, you can. The evening offered both the opportunity to learn the Talmud, and through that the opportunity to eat on the barbecue.

The world siyyum could also refer to another ending – the end of the period of isolation we have experienced for more than two years of covid. The Sharsheret gathering marked an opportunity to come together in person, after the long months of pandemic separation. Throughout the evening, there was a palpable sense of relief and joy as people were once again able to come together in person to support the work of this important organization.

Sharsheret – Hebrew language channel – was founded over 20 years ago by Rochelle Shoretz, a young woman who had been diagnosed with breast cancer and longed to connect with other young cancer patients and survivors. Ms Shoretz, who at the time was a mother of two little boys, enlisted the help of friends to set up a formal network of young women with cancer, who could connect with each on many levels. She called the group Sharsheret because each woman was a link in a chain of support.

Receive The Jewish Standard newsletter by email and never miss our best stories

Rochelle, an accomplished lawyer and advocate for cancer patients, died in 2015; but his organization has flourished, and now it’s a national resource serving thousands of cancer patients and survivors. According to its website, the organization focuses on the needs of “the Jewish breast and ovarian cancer community.”

Sharsheret CEO Elana Silber said the organization has about 37 employees nationwide, with offices in New York, New Jersey, Los Angeles, Chicago and Florida, and a budget of more than $5 million. She cited an approximate number of employees, as Sharsheret is “still growing”, she said. “We recruited four new people this year. And that’s not counting the hundreds of volunteers across the country, who donate resources and time, many of whom serve as links in Sharsheret’s chain of support.

Elana Silber is the CEO of Sharsheret. (Miryam Wahrman)

The barbecue, which drew over 500 people, was held at Congregation Ahavath Torah in Englewood; a similar rally on August 3 was held in Woodmere, one of Long Island’s five towns. The evening began with informative videos on Sharsheret, followed by the siyum ceremony. It was led by Dr Robert Alter of Englewood, who is a haematologist/oncologist at the John Theurer Cancer Center at Hackensack University Hospital.

After the siyyum, Sharsheret Board Chair Stacey Schwartz introduced Jewish community leader, educator and poet Maya Bernstein, who is a cancer survivor. Ms Bernstein recited several poems, including her poignant ‘The Oncotype’, where she detailed her longing for ‘days and nights filled with unexceptional trouble, like lost keys or pens running out of ink’.

Ms Silber introduced Sharsheret’s latest initiative, led by Teaneck’s Joy and Michael Goldsmith and their daughter Amanda Goldsmith Fein. When Ms Goldsmith was diagnosed with breast cancer, her three daughters, Amanda, Melissa and Jennifer, faced the challenge of supporting their mother through this crisis. “The hardest thing about being a mother is being in a position where your kids feel like they have to do for you,” Ms Goldsmith said. Ms. Fein, who was 22 at the time, felt very lonely. She contacted Sharsheret, hoping to start a student support group. This led to the idea of ​​YAD, Young Adult Caring Corner, a peer and friend support system for young adult children of cancer patients. (Yad is the Hebrew word for hand.)

“Adversity often brings opportunity,” Goldsmith said. YAD’s website describes the initiative’s goals: “It’s scary when someone you love is diagnosed with cancer. You might wonder how you can support them, and you might feel selfish for wanting to take care of yourself too; to want to keep doing the things you love – seeing your friends, doing your hobbies, going to school and work. We’re here to help you understand your loved one’s diagnosis, how you can help them (even from afar), and how you can take care of yourself while taking care of them.

Ms. Silber said YAD includes a college campus program. “We are present on all campuses with a Jewish community,” she said. Sharsheret helps educate students about their risks. “We talk about genetics,” she said. We try to promote ‘know your family history’ from your mother’s side and from your father’s side.

Dr. Robert Alter conducted the siyyum. (zmargstudios)

While BRCA gene mutations that can increase the risk of breast and ovarian cancer are more prevalent among Ashkenazi Jews than in the general population, the recommendations call on everyone to begin BRCA genetic testing once they have reached the age of 25; this is when the risk of these cancers begins to increase. Knowing the family history is empowering, especially since there are many cases of cancer that result from genetic factors other than BRCA, which have yet to be identified.

Ms Silber explained that the covid pandemic was “isolating for people and certainly for people with cancer”. Sharsheret created “experiential programming” during the pandemic, “so we could be with them at home and during treatment,” she said.

“I feel blessed that we can be there for people when they were alone, so they don’t feel so alone. That being said, there’s something to be said for being in a room with hundreds of people who are going through similar experiences.

Ms Silber noted that while Sharsheret events often attracted mostly women, this time around there were also many men in attendance. “We are focused on educating men about their risk” for hereditary breast cancer, she said. “BRCA mutations and other mutations are also passed on to men,” she said. Not only do men pass on the genes, but some men with BRCA mutations are also at high risk for breast cancer and other types of cancer. “We have programs specifically targeting men,” Ms. Silber said.

Heidi Fuchs of Teaneck, trustee of Touro College of Pharmacy, has volunteered with Sharsheret for years. She and her sons knew Mrs. Shoretz and her sons years ago when Mrs. Shoretz was first diagnosed. “It hits home when it’s someone your age and so young,” Ms Fuchs said at the barbecue. She and her family have joined Team Sharsheret on annual walks and she knows many women who have had breast or ovarian cancer. “I can probably name 10 women in our shul who are survivors,” she said. “That’s how widespread it is.”

Maya Bernstein, poet and cancer survivor, shared her story. (zmargstudios)

An 84-year-old woman who wished to remain anonymous was at the barbecue with family members. She said her own mother, who had a BRCA mutation, survived breast and ovarian cancer and lived to be 97. She doesn’t have the cancer gene, the woman said, but her brother inherited the BRCA mutation and passed it on to two daughters. who both developed breast cancer at a much younger age. “For the past two years, Sharsheret hasn’t been able to run these events, but they’re not giving up,” she said. “People I’ve spoken to feel the warmth, care and efficiency of what Sharsheret does. It’s min hashamayim” – from heaven – “that these people can be so successful and do such work .”

Information about Sharsheret is available at www.sharsheret.org. The YAD program is at www.sharsheret.org/yad.

Dr. Miryam Z. Wahrman of Teaneck is a professor of biology at William Paterson University and author of “The Hand Book: Surviving in a Germ-Filled World” and “Brave New Judaism: When Science and Scripture Collide.”

Vax Skeptics Eye Hospital Board Seats; A pharmacist refuses the morning after pill

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative healthcare reporting each week.

Vax tenure skeptics aim to run Florida hospital

Four conservative candidates — three of whom are known to be skeptical of COVID vaccine mandates — are campaigning to join the board of a public hospital in Florida, highlighting how elections for obscure offices are becoming the vanguard of political battles in the wake of the pandemic, according to a report by the Washington Post.

The candidates, who are running for positions on the board of directors at Sarasota Memorial Hospital, a safety hospital in the Tampa area, are campaigning on a platform of “medical freedom.” The term has been favored by conservative movements and propagates the idea that patients do not have enough control over their medical care. Proponents believe the lack of access to drugs touted by politicians but rejected by doctors, such as ivermectin, and COVID vaccine mandates are examples of how patients have lost autonomy over their health.

“Calling it a vaccination is a joke,” said Victor Rohe, a longtime Republican activist and one of the board nominees. Job. “All it really is is a government-mandated gunshot to inoculate people that the government owns your body, not you.”

The other nominees are Joseph S. Chirillo, MD, a retired physician, and nurses Patricia Maraia and Bridgette Fiorucci.

While health policy experts believe the conservative candidates are unlikely to win the Sarasota Hospital Board election, their campaign still bears witness to how ideologies around medical issues like that COVID, abortion and vaccines have fallen on party lines – and how local elections could become the next battlefront.

“All you have to do is watch how [school boards] have now become very political … and how school boards have ignored the science of education,” said Michele Issel, PhD, professor emeritus of public health at the University of North Carolina at Charlotte. “There is this new disregard for the professional training that doctors have, and a disregard for the science of what is best for the population. »

Jury sides with pharmacist who refused to give morning after pill

According to a report by BNC News.

Andrea Anderson, a patient living in small town Minnesota, sued pharmacist George Badeaux in 2019 after she said she was forced to travel 100 miles round trip to fill her prescription for an emergency contraceptive. Badeaux, who worked at the only pharmacy in town, refused to fill Anderson’s prescription because it would violate his beliefs. Anderson therefore had to drive for hours in the middle of a snowstorm to get his medication, his complaint said.

“I can’t help but wonder about other women who may be turned away,” Anderson said in a statement responding to the ruling. “What if they accept the pharmacist’s decision and don’t realize that this behavior is wrong? What if they have no other choice? Not everyone has the means or ability to go through hundreds of miles to get a prescription filled.”

Although the jury ruled that Badeaux did not violate Anderson’s civil rights, they decided that his actions inflicted emotional harm and Anderson was entitled to $25,000 in damages.

Badeaux’s attorney, however, says she is unlikely to receive any money because the jury did not find that he discriminated against Anderson on the basis of the sex.

“We are extremely pleased with the jury’s decision,” attorney Charles Shreffler said in a statement. “Health professionals should be free to practice their profession in accordance with their beliefs.”

A pioneer in gene therapy research presides over a toxic workplace

Jim Wilson, MD, PhD, a researcher who has led the field of developing gene therapies for rare diseases, for years led a toxic work environment at the highly acclaimed gene therapy program at the University of Pennsylvania, a STAT investigation found.

Current and former program staff – many of whom requested anonymity for fear of reprisal – said STAT that Wilson and other members of the management team tolerated an abusive workplace where bullying and harassment were commonplace. Wilson himself, they said, could be intolerant and dismissive, and at times yelled at or belittled staff members who rebuffed his demands.

Workplace culture had consequences, including a case in which key growth plans for at least one research program were derailed, the investigation found. Moreover, it has led to a massive exodus of talent. Between 2017 and 2020, 126 employees resigned or were terminated from the gene therapy program, a number that represented about half of all staff.

Jennifer Royal-Fitch, a former recruiter for the program, said STAT she resigned in March 2021 after seeing “with my own eyes how people have been abused” by Wilson and other executives on her management team.

The University of Pennsylvania conducted an investigation of Wilson’s lab last year, which confirmed some of the harassment and bullying allegations. However, the STAT report found that internal investigations shielded Wilson from some liability. In response, the university said its investigation was conducted appropriately and it was taking steps to improve conditions in Wilson’s lab.

In a statement in response to STAT‘s, Wilson said he did not initially “enjoy the challenges of managing the phenomenal growth of our organization”.

“I sincerely regret that some of our staff were uncomfortable working in this environment,” he said.

  • Amanda D’Ambrosio is a reporter on the business and investigative team at MedPage Today. She covers obstetrics and gynecology and other clinical news, and writes about the US healthcare system. Follow

ABC-AHP-NCNPR Botanical Adulterant Prevention Program Releases Guidance Document for Laboratories … | New

AUSTIN, Texas, Aug. 09, 2022 (GLOBE NEWSWIRE) — The ABC-AHP-NCNPR Botanical Adulterant Prevention Program (BAPP) has released a laboratory guidance document (LGD) on Indian frankincense ( Boswellia serrata ) oleogum* resin and its extracts. Indian frankincense has been valued for thousands of years for its fragrance and medicinal properties and is commonly referred to as boswellia in the global botanical industry.

Retail sales of boswellia dietary supplements experienced a rapid increase in the early to mid-2010s in the United States, particularly in the mass retail channel, but sales have since leveled off or even declined. After 2019, boswellia dietary supplements dropped the top 40 selling botanical ingredients. In 2021, US retail sales totaled US$8,940,589 in mass market and natural channels combined.

Published data on boswellia adulteration have focused primarily on undisclosed mixing or substitution with oleogum resins from other Boswellia species, in particular B.freana, B.papyriferaand B. sacra. These materials can be used as legitimate substitutes where there are locally accepted interchangeable uses. Sometimes they can be used as adulterants, if their inclusion is not transparently disclosed on certificates of analysis or ingredient labels, possibly due to local supply shortages or misidentification of the B. serrata along the supply chain.

The new LGD was authored by Nilüfer Orhan, PhD, an expert in natural product chemistry and analysis, with contributions from Burak Temiz, Hale Gamze Ağalar, PhD, and Gökalp İşcan, PhD, of Anadolu University in Eskişehir, Turkey . It provides an assessment of 46 analytical methods for their ability to authenticate Boswellia serrata oleogum resin and its extracts. It should be noted that the LGD presents images of a side-by-side HPTLC (high-performance thin-layer chromatography) fingerprint comparison of B. serrata and seven others Boswellia species, as well as myrrh ( Commiphora myrrha ). These HPTLC images were developed specifically for BAPP for boswellia LGD. Twenty-four herbal medicine quality control experts from academia and the herbal industry in the United States and internationally provided collegial feedback on the document to ensure its accuracy and relevance to to current world market conditions.

“Due to their morphological and chemical similarities and similar medicinal uses, a multitude of oleogum resins have historically been marketed interchangeably and often without botanical specificity,” explained Roy Upton, president of the American Herbal Pharmacopoeia. “During the last decades, Boswellia serrata emerged as the preferred source of boswellia, at least from a nomenclatural point of view. This document is perhaps the most detailed review of the differences of these resins done in English and should give any manufacturer using a boswellia ingredient clarity on what it has, as well as perhaps expanding the specifications to allow for the Interchangeable use of species that are most similar.

Stefan Gafner, PhD, ABC’s Chief Scientific Officer and BAPP’s CTO, commented, “Two issues make the authentication of Boswellia serrata particularly difficult extracts. Some of the published data on the content of the purported anti-inflammatory constituents, boswellic acids, in Boswellia species appear to be based on misidentification of species. Therefore, the exact composition of confounding species can be difficult to determine. Additionally, some of the commercial extracts are processed in a way that alters the relative amounts of naturally occurring boswellic acids, leading to a proprietary ingredient that has a very different composition to that found in oleogum resin. . We hope that the information provided in the new LGD BAPP will resolve these and other issues and be useful to quality control analysts working with Boswellia serrata -derived ingredients.

Boswellia oleogum resin and LGD extract is the 14th publication in the LGD series and the 74th peer-reviewed publication published by the BAPP. As with all BAPP publications, the LGDs are freely available to all ABC members, registered users of the ABC website, and all members of the public at program website (registration required).

*An oleogum resin is a natural mixture of resin (a viscous mixture of terpenes), gum (a viscous exudate composed of polysaccharides [complex sugars]), volatile oil and especially small amounts of other substances.

About the ABC-AHP-NCNPR Botanical Adulterant Prevention Program

The ABC-AHP (American Herbal Pharmacopoeia)-NCNPR (National Center for Natural Products Research at the University of Mississippi) Botanical Adulterant Prevention Program is an international consortium of professional nonprofit organizations, research laboratories analysis, research centers, industry trade associations, members of industry, and other parties interested in herbs and medicinal plants. The program advises industry, researchers, health professionals, government agencies, the media and the public on various challenges related to adulterated botanical ingredients sold commercially. To date, more than 200 U.S. and international parties have financially supported or otherwise endorsed the program.

To date, the BAPP has published 74 extensively peer-reviewed articles, including Botanical Adulterants Prevention Bulletins, Laboratory Guidance Documents, and Botanical Adulterants Monitor e-Bulletins.

About the American Botanical Council

Public Relations American Botanical Council 512-926-4900 ext. 129 [email protected]

Copyright 2022 GlobeNewswire, Inc.

Gerresheimer: invests up to 94 million dollars in a production plant in the United States

  • Major expansion into the North American market
  • Supported by the US Biomedical Advanced Research and Development Authority (BARDA) through a 70/30 cost-shared cooperative agreement
  • New state-of-the-art forming lines in North Carolina dramatically increase annual glass vial production capacity in the United States

Morganton, NC, August 09, 2022 – Gerresheimer AG, a leading provider of health and beauty care solutions and drug delivery systems to the pharmaceutical, biotech and cosmetics industries, announced today investments to rapidly expand its manufacturing, supply and logistics capabilities for glass vials in the United States The project will be supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the U.S. Department of Health and Human Services (HHS) Assistant Secretary for Preparedness and Response (ASPR) with contract support from the Department. of Defense (DOD). It will expand Gerresheimer’s capability with new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging. BARDA has agreed to provide up to approximately US$66 million to Gerresheimer AG for this project. The investment is part of Gerresheimer’s global expansion plan and follows its Formula G strategy process.

Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with Type 1 interchangeable vials (borosilicate and/or aluminosilicate glass) and Gx Elite glass vial capacity. Funding for BARDA, with contract support from the DOD Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and Army Contracts Command (ACC), will enhance states’ capabilities United to respond to current and future public demands. health emergencies. The vials can be used in vaccination campaigns against infectious diseases, such as COVID-19 and others. This facility expansion will further strengthen Gerresheimer’s leadership position in the elite best-in-class flask market.

“Gerresheimer is honored to support the US government in strengthening its pharmaceutical supply chain for current and future medical emergencies,” said Dietmar Siemssen, CEO of Gerresheimer AG. “The agreement confirms our role as a supplier of system-critical products, such as pharmaceutical primary packaging solutions and drug delivery systems for the healthcare industry. This investment follows our Formula G process strategy and accelerates our growth in this important market,” he added.

As part of the project, the existing facility in North Carolina will be expanded with the installation of new vial forming lines and a new warehouse. As the investment will lead to an increase in the number of people employed, new offices will also be part of the expansion plan.

The company is committed to sourcing the vast majority of its raw materials from US domestic suppliers to improve levels of responsiveness, reliability, quality and domestic supply chain integration. Gerresheimer further incorporates sustainable design principles to implement energy efficiency measures, comply with stormwater management requirements, and reduce waste for upgrades and expansion.


  1. Army Contracts Command – Aberdeen Proving Ground – Joint COVID Response Division, 6472 Integrity Court, Building 4401, Aberdeen Proving Ground MD 21005-3013 is the procurement award and administration office.

  2. This project was supported in whole or in part by federal funds from the US Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under grant number W58P05-22-2-0008.

Contact Hurry
Ueli Utzinger
Group Senior Director Marketing & Communication
T +49 211 6181-250

Contact Investor Relations
caroline nadilo
Senior Director of Investor Relations
T +49 211 6181-220

About Gerresheimer

Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very wide range of products for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is a provider of innovative solutions, from concept to delivery of the final product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and focus on quality and customer orientation. To develop innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated in 2021 an annual turnover of around 1.5 billion euros. With its products and solutions, Gerresheimer plays an essential role in people’s health and well-being.

“We don’t take their jobs”

Patent drug dealers in Nigeria said on Monday they should be praised for bringing primary health services to the grassroots instead of being seen as charlatans, especially by members of the Pharmaceutical Society of Nigeria, PSN .
Prince Joel Odo, National President of the National Association of Patent and Proprietary Medicine (NAPPMED), said so in an exclusive interview with THE WHISTLER.

He said: “We get on well with PSN, but they see us as charlatans. We do not challenge them in any way. But a practical problem in Nigeria is underestimating anyone. I saw where a car belonging to a professor of mechanical engineering packed up and he resorted to some roadside mechanics. What matters are those on the ground.

“Pharmacists do not heal wounds. I do that more than them. As resellers of patent medicines, we practice returns. I don’t deal with what I can’t handle. Without patent drug dealers, no one can identify diseases in local areas. The pharmacists aren’t there, but they don’t believe we’re doing anything because they see us as people taking their jobs.

On the decisions of the PSN to be in charge of licensing resellers of patent medicines in Nigeria, Prince Odo said, “We believe in getting licenses but it should go through a normal channel. The PSN is not the organization that granted us the licenses before. It was directly from the Ministry of Health. Former health minister ABC Nwosu delegated them to assist the ministry. But they want to hijack the procedure.

“I believe in licensing because if you buy a vehicle for commercial purposes today, in addition to having details of the vehicle, you would also belong to a union before picking up passengers along the road.

“Pharmacists should allow us to operate. They know our problems. They should praise us for the good work we are doing in this country. In my village of about 15,000 inhabitants, there are no pharmacies. Also, we don’t have a standard hospital. Patent drug dealers serve them. The government must encourage patent medicine dealers for their good jobs. The government should stop colluding with pharmacists to bother patent drug dealers.

He commended the Society for Family Health and the World Health Organization for partnering with NAPPMED to ensure quality health care at the grassroots. He said the two healthcare giants “believe that we are the people who have the structures and we are everywhere.”

Gwinnett High School Students Spend Summer Doing Real-World Research at Georgia Gwinnett College | New

Jury finds pharmacy did not discriminate against woman by refusing to fill ‘morning after pill’ prescription

By Rebekah Riess and Kelly Murray, CNN

A jury in Atkins County, Minnesota, found on Friday that a pharmacy did not discriminate against a woman by refusing to fill her prescription for emergency contraception, court records show. .

However, the jury found that the pharmacist caused the woman emotional harm in the amount of $25,000.

According to the original complaint, Andrea Anderson, a mother and approved adoptive parent, obtained a prescription in January 2019 for Ella – otherwise known as the “morning after pill” or emergency contraception – after her birth control failed. regular.

His doctor sent the prescription to McGregor Thrifty White Pharmacy, but duty pharmacist George Badeaux told Anderson he couldn’t fill his prescription because of his “beliefs.”

Badeaux “did not specify what his beliefs were or why they interfered with his ability to perform his job as a medical professional,” according to the complaint.

Anderson finally found a pharmacy that was ready to fill her prescription — after driving more than 100 miles round trip in a snowstorm, the complaint said.

Badeaux’s attorney, Charles Shreffler, said in a statement that he and his client were “incredibly pleased with the jury’s decision.”

“Health professionals should be free to practice their profession in accordance with their beliefs,” the statement said. “Mr. Badeaux is unable to participate in a proceeding that requires him to dispense drugs that could end innocent human life in the womb. Every American should have the freedom to operate according to their ethical and religious beliefs. doctors, pharmacists and other medical care providers are no different.”

CNN has contacted attorneys for Thrifty White Pharmacy for comment.

Gender Justice, the advocacy group representing Anderson, had argued that denying Anderson service because of her reproductive health care needs was unlawful gender discrimination and violated Minnesota human rights law. .

The group said it would appeal the jury’s decision to the state Court of Appeals.

“To be clear, Minnesota law prohibits sex discrimination and that includes refusing to fill emergency contraception prescriptions,” said Jess Braverman, legal director of Gender Justice. “The jury was not deciding the law, it was deciding the facts of what happened here in this particular case. We will appeal this decision and will not stop fighting until the people of Minnesota can get the health care they need without interference from providers who put their own personal beliefs ahead of their legal obligations and ethics towards their patients.

Since a major pharmaceutical trade deal in 2017, the so-called morning-after pill has become the most widely used over-the-counter emergency contraception in the United States.

Since the overturning of Roe v. Wade, there are concerns that some types of contraception may not be available, and demand for emergency contraception and longer-acting contraception, including the morning after pill, has increased.

™ & © 2022 Cable News Network, Inc., a WarnerMedia company. All rights reserved.

CNN’s Kieth Allen also contributed to this story.

Pharmacy graduate programs aim to increase workforce diversity


By Patrick Smith and Whitney Tarpy

University of Mississippi

Pharmacy students at the University of Mississippi work in a laboratory in the Department of Biomolecular Sciences. The School of Pharmacy is increasing its efforts to attract and retain a diverse population of graduate students to encourage underrepresented minority students interested in research and graduate programs. Photo by Kevin Bain/Ole Miss Digital Imaging Services

To educate prospective students in the area about the pharmaceutical sciences field and career paths, the Office of Research and Graduate Programs at the University of Mississippi School of Pharmacy is investing in increased outreach efforts and recruitment.

The school’s efforts focus on diverse undergraduate student populations throughout the state and beyond.

Funds allocated by the Dean’s office allowed ORGP and representatives from the school’s academic units to visit colleges and conferences across the state, presenting on various career options for a graduate degree in pharmaceutical sciences.

“Building a diverse student body and fostering an inclusive environment is an important part of our school’s equity-in-action plan,” said Soumyajit Majumdar, Associate Dean for Research and Graduate Programs. “An increased representation of students from diverse backgrounds supports a strong and innovative academic environment, guided by unique perspectives and creativity.

“This ultimately supports the creation of a diverse and globally competitive biomedical workforce in pharmaceutical sciences and impacts public health outcomes.”

These diversity awareness efforts have also been supported by the university. The UM Graduate School provided a grant to ORGP to establish partnerships with institutions serving minorities in Mississippi.

With this funding, administrators and faculty members have successfully launched multiple efforts.

Majumdar spoke with students and faculty at Alcorn University and its chemistry department. Paul Boudreau, assistant professor of pharmacognosy, attended virtual fairs with Tougaloo College and Jackson State University, while others participated in Belhaven University’s in-person fair.

Additionally, the ORGP-supported School of Pharmacy outreach team attended the Society of Advancing Chicanos/Hispanics and Native Americans in Science conference and the annual Biomedical Research Conference for Scientists. minority. The office plans to do this again for the SACNAS 2022 conference in October.

Outreach and recruitment efforts have also increased on the Ole Miss campus. Graduate program faculty and administrators met with participants from McNair’s Scholars and Mississippi IDeA Network of Biomedical Research Excellence Research Scholars programs.

The school has also launched mentorship training through the prestigious Center for Enhancing Research Mentorship Experiences to better equip graduate faculty to work with diverse students.

New programs are also in preparation. The university’s Diversity and Community Engagement Division awarded a $25,000 grant to ORGP to support the creation of a summer research experience program for underprivileged minority students. represented.

This new program will help encourage underrepresented minority students interested in research and graduate programs.

Scheduled to begin in May 2023, the 10-week experience will allow students to participate in pharmaceutical science research and learn from professors at the School of Pharmacy.

“Student development and building inclusive excellence in the School of Pharmacy and in the broader STEM field is integral to our school’s mission,” said Donna Strum, Dean of Ole Miss Pharmacy. “This summer research experience will give underrepresented minority students the opportunity to get hands-on insight into our school’s extensive research capabilities.”

The school offers master’s and doctoral degrees in three of its academic departments: Biomolecular Sciences, Pharmacy and Drug Administration, and Pharmacy Administration.

The ORGP, with each academic unit, provides professional and personal development opportunities to its student populations. Events included career planning, emotional intelligence, public speaking and networking.

HPPSC CBT Schedule 2020 released, here is how to download the schedule for various posts @hppsc.hp.gov.in


HPPSC CBT Schedule 2020, hppsc.hp.gov.in: The Computerized Screening Test (CBT) schedule for various positions has been published by the Himachal Pradesh Personnel Selection Commission (HPPSC) on its official website, hppsc.hp.gov.in. The schedule has been released for a number of positions including Drug Inspector, Assistant Professor, and more. Candidates for Computerized Drug Testing (CCT) can now head to the official HPPSC website, hppsc.hp.gov.in and view the revised schedule. .

Himachal Pradesh Personnel Selection Commission or HPPSC had issued a brief notification, according to the notification, the commission has issued the TCC Schedule for Drug Inspector, Class II (Classified), Assistant Professor (Pharmacy) in pharmacognosy, class I and others on their official website.

Steps to download HPPSC CBT Schedule 2020 for Various Posts online:

  1. Access the official website of the Himachal Pradesh Personnel Selection Commission (HPPSC), hppsc.hp.gov.in.
  2. On the homepage, find and click on the section called “What’s New”.
  3. Find and click on the link that reads, “Press Note – Regarding Computerized Drug Test(s) for Various Messages.”
  4. You will be directed to a new window.
  5. In the new window, find and click the PDF link for a short notification.
  6. The schedule will open in front of you on your screen.
  7. Print or/and download the document for future references.

Also Read: Post Pandemic Hyderabad IT Industry Surge: HYSEA to Host Annual Innovation Summit

Also Read: SSC JE Vacancies 2019-2020 @ssc.nic.in: Here are details of application forms, eligibility and more

Assistant Professor (Pharmacy) in Pharmacognosy, Class I (Classified) in the Department of Technical Education, Vocational and Industrial Training, HP computerized screening tests have been scheduled by the authorities to be carried out on November 6, 2020.

Also Read: UPSC Civil Services 2019 All Candidates’ Scores Released Here’s How to Download Score Sheet @ upsc.gov.in

The Faculty of Pharmacy of the EMU is waiting for its new students


The Faculty of Pharmacy of the Eastern Mediterranean University (EMU) is expecting its new students during the autumn semester of the academic year 2022-2023. Established in the 2011-2012 academic year, EMU’s Faculty of Pharmacy offers training through its 10-semester B.Pharm program and 12-semester Pharm.D program. The Faculty of Pharmacy of EMU educates qualified pharmacists and scientists, who have designed the principles and ethical concept of the profession of pharmacist, possessed international high-level equipment that can serve as the first community health adviser, and acquired property to pursue the latest scientists. and technological advances in this profession. The faculty contributes to scientific research in our scope at the universal and regional levels and uses the knowledge gained for the benefit of the community through the professional service of pharmacy. With its qualified academic staff and high-tech laboratories, the Faculty of Pharmacy at EMU is among the best and most respected faculties of pharmacy in our region and is able to impart the knowledge necessary to obtain employment in the international pharmaceutical industry and other branches of this profession.

Opportunity to study and do an internship abroad

The Faculty of Pharmacy is proud to be the first academic member accepted by the International Pharmacy Federation (FIP) of Cyprus and the second among the faculties of pharmacy in Turkey in 2012. Our faculty is also represented by EMUPSS (Eastern Mediterranean University Pharmacy Students Society) as a member association of the ‘International Federation of Pharmacy Students’ (IPSF) offering a student exchange program which enables EMU students to conduct clinical pharmacy practice and community in different countries. Moreover, within the framework of this collaboration, the Faculty of Pharmacy of the EMU welcomes pharmacy students from all over the world.

High-tech laboratories

The Faculty has student laboratories equipped with the latest technological and educational infrastructure necessary for pharmaceutical sciences, including HPLC, GC-MS, FT-IR, UV spectrophotometer, laminar flow, microwave reactor, tablet machine, dissolution device, granulator , homogenizer, viscometer, cabinet climate, incubators, granulometer, powder mixer, grinder, water baths, microscopes, etc. All laboratories are equipped with smart boards. The “Garden of Medicinal and Aromatic Plants” is set up in front of the building of the Faculty for the study of Pharmaceutical Botany and Pharmacognosy. Despite being a young faculty, the Faculty of Pharmacy has published about 50 scientific papers in the reputable journals recognized by Science Citation Index (SCI).

Provides quality education

In a statement on the subject, the Dean of the Faculty of Pharmacy at UEM, Prof. Dr. Müberra Koşar, said: “The profession of pharmacist belongs to the primary health care professions. Pharmacy is a discipline in the service of public health and is also part of the group of preventive health services. Due to the fact that it contains many disciplines, the title of pharmacist is taken as a result of multidisciplinary training. For this reason, he has a wide range of knowledge and areas of work.

The years spent in college have an important place in people’s lives, and for this reason, they should be spent well. Therefore, it is ideal that the university and college you choose are both science-based and student-friendly. EMU is student-friendly with its large, functional on-campus facilities and downtown location. Even though the Faculty of Pharmacy is a relatively new faculty, it provides quality education opportunities to our students with its young and dynamic professors and infrastructure. In addition, students will have the opportunity to communicate with international pharmacy students as part of the EMUPSS student community and participate in social and scientific activities. You, our esteemed guests, who will join us, will also find many social opportunities in our city.

The EMU Faculty of Pharmacy awaits young pharmacist candidates, with its dynamic, hardworking and successful young teachers, its modern infrastructure and its social support. If you want to spend this important part of your life in a country with idyllic nature, a student-friendly campus and a faculty that embraces you in every way, EMU Faculty of Pharmacy and we are waiting for you.

Drug Discovery Services Market Size, Scope, Growth Opportunities, Trends by Manufacturers and Forecast to 2029 – Instant Interview

New Jersey, United States – This unique Drug Discovery Services Market The report begins with planned goals to help industry owners make better and smarter decisions. It covers important market growth data and insights on market essentials, market trends, market share and market size for new entrants. It provides a clear picture of market tactics to help business owners achieve bigger gains. Regional market expansion, trade regulations, technological innovations and new product launches are some of the key topics discussed in this Drug Discovery Services Market analysis report. He quickly takes stock of the major impact of COVID-19 on the entire global economy.

The Drug Discovery Services Market research report is the best way to get a detailed overview of industry growth, competitive analysis and clear view of the target customers. It focuses on the whole market scenario to gather all the minute details regarding the factors that are working best for the growth of the market and the business. Key projections for business growth are also highlighted here. Customer needs are the main factor for expanding the product portfolio and consequently growing the business. By fully understanding the customers, it becomes easy for the central participants not to encounter any difficulty while developing or marketing any product or service. Understanding the customer is an important success factor for any beginner. It aims to provide all the details relating to the customer. It also becomes easy to develop an effective and beneficial strategy for business growth.

Get Sample Full PDF Copy of Report: (Including Full Table of Contents, List of Tables and Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=24226

Key Players Mentioned in the Drug Discovery Services Market Research Report:

Abbott Laboratories Inc., Advinus Therapeutics, Agilent Technologies Ubiquigent, Albany Molecular Research Inc., AstraZeneca PLC, Aurigene, Bayer AG, Charles River Laboratories International, ChemBridge Corporation, Covance.

Drug Discovery Services Market Segmentation:

Drug Discovery Services Market, By Process

• Target selection
• Target validation
• Track access identification
• Lead Optimization
• Validation of candidates

Drug Discovery Services Market, By Type

• Medicinal chemistry services
• Biology services
• Drug Metabolism and Pharmacokinetics (DMPK)

Drug Discovery Services Market, By Drug Type

• Small molecule drugs
• Biological drugs

Drug Discovery Services Market, By Therapeutic Area

• Oncology, Neurology
• Infectious and immune system diseases
• Diseases of the digestive system
• Cardiovascular illnesses
• Other therapeutic areas

This Drug Discovery Services Market report helps a number of investors, shareholders as well as companies understand the difficult areas of marketing ideas, technical development, key issues and systematic analysis in order to to achieve long-term competitive gain in the industry. It then discusses the fundamental facets of the market along with the market drivers, restraints, existing issues, upcoming opportunities, and forecasts. This Drug Discovery Services market study presents some accurate insights about the customers to develop technological strategies to make the investment worthwhile. It uses both primary and secondary methods to offer wide-ranging industry data to help you make business choices and introduce new items into the market.

Inquire for a discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24226

To prepare the table of contents, our analyst did extensive research on the following:

Presentation of the report: It includes key Drug Discovery Services market players covered in research study, research scope, market segments by Type, market segments by Application, years considered for research study and the objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and key market trends are shed light on. It also provides growth rates of major producers operating in the Drug Discovery Services market. Further, it offers production and capacity analysis where marketing price trends, capacity, production, and production value of the Drug Discovery Services market are discussed.

Market Share by Manufacturers: Here, the report provides details about manufacturers’ revenue, production and capacity by manufacturers, prices by manufacturers, expansion plans, mergers and acquisitions and products, market entry dates, distribution and market areas of major manufacturers.

Market Size by Type: This section focuses on the product type segments where production value market share, price and production market share by product type are discussed.

Market Size by Application: Along with an overview of the Drug Discovery Services market by application, it gives a study on the consumption of the Drug Discovery Services market by application.

Production by region: Here, production value growth rate, production growth rate, import and export, and key players in each regional market are provided.

Consumption by region: This section provides consumption information in each regional market studied in the report. Consumption is discussed according to country, application and product type.

Company Profiles: Almost all major players of the Drug Discovery Services Market are profiled in this section. The analysts provided information on their recent developments in the drug discovery services market, products, revenue, production, business and company.

Market forecast by production: The production and production value forecasts included in this section are for the Drug Discovery Services market along with major regional markets.

Market forecast by consumption: The consumption and consumption value forecasts included in this section are for Drug Discovery Services market along with major regional markets.

Value chain and sales analysis: It thoroughly analyzes customers, distributors, sales channels and value chain of the Drug Discovery Services market.

Main conclusions: This section provides a quick overview of important findings from the research study.

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/drug-discovery-services-market/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. data and technical advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768

E-mail: [email protected]

Website:- https://www.verifiedmarketresearch.com/

CVS and Walgreens birth control policies underscore Supreme Court sway

CVS and Walgreens birth control policies underscore Supreme Court sway

Experts have said the Supreme Court may be set to review a standard set in 1977 on how far employers must go to accommodate a worker’s religious beliefs.

  • Federal law requires employers to make “reasonable” accommodations for workers’ religious beliefs.
  • Legal experts say the policies adopted by drugstore chains appear to be within the law.
  • Debate on the issue has intensified since the Supreme Court overturned Roe v. Wade in June.

WASHINGTON — The nation’s largest drugstore chains have come under scrutiny in recent weeks for policies that allow pharmacists to refuse to dispense a contraceptive if it conflicts with their religious or moral beliefs.

For the most part, experts say, the law is on their side.

Title VII of the Civil Rights Act of 1964 requires companies to accommodate workers’ religious beliefs as long as the request does not create “undue hardship” for the employer. How far employers should go is up for debate – but the Supreme Court has repeatedly signaled an interest in expanding religious rights, not limiting them.

Help Terms of Service Privacy Policy Your California Privacy Rights / Privacy Policy Our Ethical Principles Sitemap

© 2022 USA TODAY, a division of Gannett Satellite Information Network, LLC.

Synthetic embryo models may grow organs for transplantation

Credit: Weizmann Institute of Science

Without eggs, sperm or uterus: synthetic mouse embryo models created only from stem cells

An egg meets a sperm – it’s a necessary first step at the beginning of life. In research on embryonic development, it is also a common first step. However, in a new study published August 1, 2022, in the journal Cell, researchers at the Weizmann Institute of Science have developed models of synthetic mouse embryos outside the womb starting with just stem cells grown in a Petri dish. This means they are grown without the use of fertilized eggs. This method opens up new horizons for studying how stem cells form various organs in the developing embryo. It may one day allow the cultivation of tissues and organs for transplantation using synthetic embryo models.

A video showing a synthetic mouse embryo model at day 8 of its development; it has a beating heart, yolk sac, placenta, and emerging blood circulation.

“The embryo is the best organ-building machine and the best 3D bio-printer – we tried to mimic what it does,” says Professor Jacob Hanna of Weizmann’s Department of Molecular Genetics, who led the Research Team.

Hanna explains that scientists already know how to restore mature cells to “stem.” In fact, the pioneers of this cellular reprogramming won a Nobel Prize in 2012. However, to go in the opposite direction, that is, to cause stem cells to differentiate into specialized body cells, let alone form whole organs, proved to be much more difficult.

“Until now, in most studies, specialized cells were often difficult to produce or aberrant, and they tended to form a hodgepodge instead of well-structured tissue suitable for transplantation. We have succeeded in overcoming these obstacles by unlocking the self-organizing potential encoded in stem cells.

Researchers on synthetic mouse embryos

(From left to right): Dr Noa Novershtern, Prof. Jacob Hanna, Alejandro Aguilera-Castrejon, Shadi Tarazi and Carine Joubran. Credit: Weizmann Institute of Science

Hanna’s team built on two previous advances in her lab. A was an effective method for reprogramming stem cells to a naïve state – that is, their earliest stage – when they have the greatest potential to specialize in different cell types. The otherdescribed in a scientific article in Nature in March 2021, was the electronically controlled device the team had developed over seven years of trial and error for growing natural mouse embryos outside the womb. The device keeps embryos bathed in nutrient solution inside continuously moving beakers, simulating how nutrients are delivered by material blood flow to the placenta, and tightly controls the exchange of oxygen and atmospheric pressure. In previous research, the team had successfully used this device to grow natural mouse embryos from day 5 to day 11.

This is how synthetic mouse embryo models were grown outside the womb: a video showing the device in action. Continuously moving beakers simulate the natural supply of nutrients, while oxygen exchange and atmospheric pressure are tightly controlled.

In the new study, the team set out to develop a synthetic embryo model solely from naïve mouse stem cells cultured for years in a Petri dish, without having to start with a fertilized egg. This approach is extremely valuable because it could, to a large extent, circumvent the technical and ethical problems associated with the use of natural embryos in research and biotechnology. Even in the case of mice, some experiments are currently unfeasible because they would require thousands of embryos, while access to models derived from mouse embryo cells, which grow by the millions in laboratory incubators, is virtually unlimited.

“The embryo is the best organ building machine and the best 3D bio-printer – we tried to imitate what it does.”

Before placing the stem cells in the device, the researchers separated them into three groups. In one, which contained cells destined to develop into embryonic organs themselves, the cells were left as they were. The cells of the other two groups were pretreated for only 48 hours to overexpress one of two types of genes: the master regulators of the placenta or the yolk sac. “We gave these two groups of cells a transient boost to give rise to extraembryonic tissues that support the developing embryo,” says Hanna.

Development of synthetic models of mouse embryos

Development of synthetic embryo models from day 1 (top left) to day 8 (bottom right). All of their early progenitor organs had formed, including a beating heart, emerging bloodstream, brain, neural tube, and intestinal tract. Credit: Weizmann Institute of Science

Shortly after being mixed inside the device, the three groups of cells came together into clumps, the vast majority of which failed to grow properly. But about 0.5% – 50 out of about 10,000 – then formed spheres, each of which later became an elongated structure resembling an embryo. Since the researchers had labeled each group of cells with a different color, they were able to observe the formation of the placenta and yolk sacs outside the embryos and the development of the model taking place as in a natural embryo. These synthetic models developed normally until day 8.5 – almost halfway through the mouse’s 20-day gestation – the stage at which all the first organ progenitors were formed, including a beating heart, circulation blood stem cells, brain with well formed folds, nervous system tube and intestinal tract. Compared to natural mouse embryos, the synthetic models displayed 95% similarity in both the shape of the internal structures and the gene expression patterns of the different cell types. The organs seen in the models gave every indication of being functional.

Mouse embryo Day 8

Day 8 of a mouse embryo’s life: a synthetic model (top) and a natural embryo (bottom). The synthetic models displayed 95% similarity in both the shape of the internal structures and the gene expression patterns of the different cell types. Credit: Weizmann Institute of Science

For Hanna and other stem cell and embryonic development researchers, the study presents a new area: “Our next challenge is to understand how stem cells know what to do – how they self-assemble into organs and find their way to their assigned points inside an embryo.And because our system, unlike a uterus, is transparent, it can prove useful in modeling birth and implantation defects in human embryos.

In addition to helping to reduce the use of animals in research, synthetic embryo models could in the future become a reliable source of cells, tissues and organs for transplantation. “Instead of developing a different protocol to grow each type of cell – for example, kidney or liver – we may one day be able to create a synthetic embryo-like model and then isolate the cells we need. We will not need to dictate to emerging organs how they should develop. The embryo itself does it better.

Innovative method for growing synthetic mouse embryo models from stem cells

A diagram showing the innovative method of culturing synthetic mouse embryo models from stem cells – without egg, sperm or uterus – developed in Professor Jacob Hanna’s lab. Credit: Weizmann Institute of Science

Reference: “Post-Gastrulation Synthetic Embryos Generated Ex Utero from Mouse Naïve ESCs” by Shadi Tarazi, Alejandro Aguilera-Castrejon, Carine Joubran, Nadir Ghanem, Shahd Ashouokhi, Francesco Roncato, Emilie Wildschutz, Montaser Haddad, Bernardo Oldak, Elidet Gomez-Cesar August 1, 2022, Cell.
DOI: 10.1016/j.cell.2022.07.028

This research was co-directed by Shadi Tarazi, Alejandro Aguilera-Castrejon and Carine Joubran from Weizmann’s Department of Molecular Genetics. Study participants also included Shahd Ashouokhi, Dr. Francesco Roncato, Emilie Wildschutz, Dr. Bernardo Oldak, Elidet Gomez-Cesar, Nir Livnat, Sergey Viukov, Dmitry Lokshtanov, Segev Naveh-Tassa, Max Rose and Dr. Noa Novershtern Weizmann’s molecular genetics. Department; Montaser Haddad and Professor Tsvee Lapidot of Weizmann’s Department of Immunology and Regenerative Biology; Dr. Merav Kedmi from Weizmann’s Central Life Sciences Facilities Department; Dr. Hadas Keren-Shaul of the National Center for Personalized Medicine Nancy and Stephen Grand Israel; and Dr. Nadir Ghanem, Dr. Suhair Hanna and Dr. Itay Maza from Rambam Health Care Campus.

Professor Jacob Hanna’s research is supported by the Dr. Barry Sherman Institute for Medicinal Chemistry; the Helen and Martin Kimmel Institute for Stem Cell Research; and Pascal and Ilana Mantoux.

Dr. Charles A. Carter appointed chair of the Department of Pharmaceutical and Clinical Sciences – News


On January 1, the departments of Clinical research and Pharmaceutical sciences merged into a single department called Department of Pharmaceutical and Clinical Sciences (PCS). Dr. Charles A. Carter served as interim president, helping to initiate and lead the initial transition phase.

On July 1, he was named the department’s new director.

In its letter of recommendation to Dean Michael L. Adams, the search committee noted the energy, vision, and positivity that Carter brought to his work leading the department and the College. “Committee members said his work over the past six months as a temp in the newly created department was a ‘much higher threshold than an interview,'” Adams concluded.

A native of Kenmore, New York, Carter moved to North Carolina in 1996. He earned his Bachelor of Science degree from Buffalo State University of New York, a Doctor of Pharmacy degree from the Health Sciences Center of the University of Tennessee and an MBA from Christian Brothers University. . He also completed a residency in bioinformatics and drug information and a fellowship in research design methodology.

“Dr. Carter embodies the mission and spirit of Campbell University.

Carter joined the Campbell University family in August 2015. His initial appointment was as Associate Professor at the Clinical Research Department. He has taught in the Bachelor of Science in Clinical Research (BSCR), Master of Science in Clinical Research (MSCR), Doctor of Pharmacy (PharmD) study programs, as well as Interprofessional education courses and internships. In addition to her teaching responsibilities, Carter mentors and advises students on their educational and post-graduate journeys. He also advises student-run organizations on campus, including the Graduate Clinical Research Organization (GCRO), the Industry Pharmacists Association (IPHO), and the Kappa Psi Pharmaceutical Fraternity.

Before joining the College of Pharmacy and Health Sciences (CPHS), Carter served as Executive Director of Medical Affairs for Salix Pharmaceuticals, Inc. in Raleigh, North Carolina from 2012 to 2015. From 1994 to 2012, he founded and operated Pharmaceutical Strategic Initiatives, LLC and focused his energies on the company vision and services. . Pharmaceutical Strategic Initiatives was a leading provider of strategic consulting, clinical research design and strategy, regulatory readiness, medical and scientific content creation, health outcomes research, key opinion leader and advocacy development. Strategic Pharmaceutical Initiatives clients included 28 pharmaceutical and medical device companies.

Carter was previously director of research and clinical services at the National Institute of Drug Therapy located in Memphis, Tennessee. He has been an investigator in over 30 Phase 3, Phase 4, and health economics and outcome research studies.

Dr. Scott Asbill, Associate Dean of Academic Affairs, Professor of Pharmacy and Senior Member of the President’s Search Committee, shared: “Dr. Carter embodies the mission and spirit of Campbell University. He served as interim president for about six months and did a tremendous job moving the department forward.

Carter possesses a servant attitude and aspires to demonstrate it to those he meets. When asked why he accepted the position of president, he replied, “I feel called to serve, so I serve. Carter enjoys working at Campbell and is excited about his new responsibilities and the merging of departments.

Governor Hochul Announces Completion of $17 Million Housing Development in Onondaga County

Governor Kathy Hochul today announced the completion of a $17.2 million affordable housing development in the Town of Camillus, Onondaga County. The new complex offers 60 affordable, energy-efficient homes with family-friendly amenities. Camillus Heights is designated a Housing Opportunity Project because it is located in a well-resourced area with a high performing school district.

“My administration continues to be focused on revitalizing downtowns and increasing the supply of affordable housing for all New Yorkers,” Governor Hochul said. “By delivering new affordable housing to communities across the state, we can help ensure New York families have access to the tools they need to succeed today and in the future. Affordable housing developments like Camillus Heights are key to improving quality of life and providing a more affordable and secure future for generations of New Yorkers.”

Camillus Heights complements Governor Hochul’s extensive plans to make housing more affordable, equitable and stable. The Governor introduced and successfully secured, in the 2022-2023 State Budget, a new five-year, $25 billion comprehensive housing plan that will increase housing supply by creating or preserving 100,000 affordable homes in New York, including 10,000 with support services for vulnerable people. populations, as well as the electrification of 50,000 additional households.

The development consists of 16 two-storey residential buildings with a total of 60 apartments and a self-contained community building. The apartments are affordable for households earning between 30 and 80% of the region’s median income. The developer is Christopher Community, Inc.

Camillus Heights was designed to meet the requirements of the New York State Energy Research and Development Authority’s Low Rise New Construction program and is expected to achieve LEED silver certification. Energy efficient features include Energy Star appliances, LED lighting, high performance space conditioning equipment, windows, insulation and air sealing.

Camillus Heights is less than a mile from the village of Camillus where there is a grocery store, pharmacy, banks, restaurants and retail. The development has its own bus shelter on site. The development is located in the West Genesee Central School District.

State funding for Camillus Heights included federal low-income housing tax credits that generated $11.9 million in equity and $3.6 million in grants from New York State Homes and Community Renewal. NYSERDA provided $63,000 in support. The Community Preservation Corporation provided a permanent loan of $1.2 million insured by SONYMA.

Homes and Community Renewal Commissioner RuthAnne Visnauskas said: “Camillus Heights provides 60 families with affordable living in a community with well-performing schools and easy access to public transportation, grocery stores and restaurants. In addition to energy-efficient features and recreational spaces, the development provides a healthy and comfortable environment for families to grow and prosper in. Kudos to Christopher Community for making this project possible and helping us expand the housing supply in Onondaga County.

Doreen M. Harris, President and CEO of NYSERDA, said: “With the completion of the Camillus Heights project, residents of Onondaga County now have better access to safe, highly efficient and resilient affordable housing with many features, from heating and cooling equipment to state-of-the-art appliances, which provide a healthier, more comfortable living environment. This project and others like it will enable all New Yorkers to benefit from the transition to a clean energy economy and support Governor Hochul’s commitment to achieve 2 million climate-friendly homes in communities across the state by 2030.”

Senator Chuck Schumer said: “Every family and senior in Onondaga County deserves safe, affordable housing, and I’m proud that the Federal Low-Income Housing Tax Credit, which I fought so hard for, has provided the millions needed to revitalize this area with 60 new energy-efficient and affordable housing units. I commend Governor Hochul for this essential push for affordable housing, and I will continue to fight for every dollar of federal support needed to lay the foundation for a brighter future for downtown New York.

State Senator John W. Mannion said: “Affordable housing is the cornerstone of strong families and a strong Central New York City. Completion of the $17 million housing development in Camillus Heights means 60 new units – all energy efficient – ​​are now available to meet the needs of our community. I commend Governor Hochul for his commitment to expanding affordable housing options across the state and for working with the Legislature to make record investments to support New York’s comprehensive housing plan. .

Assemblyman William Magnarelli said: “Camillus Heights only adds to the value of our community by providing affordable, energy-efficient housing options close to the center of the village. Christopher Communities and New York State are coordinating efforts to increase economic growth and community development while developing affordable and safe places to live.

Camillus Town Supervisor John Fatcheric said: “The Town of Camillus is proud of its comprehensive planning to include the addition of Camillus Heights Affordable and Energy Efficient Homes in its well-balanced variety of housing for the community. The balance between affordable housing, senior housing and single-family dwellings; alongside apartments, condominiums and townhouses demonstrate the commitment the city seeks to meet the needs of all its residents. the city offers, are just a few of the reasons Camille is a great place to live, work and raise a family.”

Jaime Tuozzolo, vice president and mortgage officer of the Community Preservation Corporation, said: “As a nonprofit housing finance corporation, CPC is proud to invest in projects like Camillus Heights that help achieve the unique housing and development goals of the region and community. We are proud to be part of a project that will be a catalyst for bringing people together, providing stability for its tenants, and serving as a critical affordability resource for the Camillus community My thanks to Christopher Community for his vision and commitment to this project, to Governor Hochul, UNHCR Commissioner Visnauskas, NYSERDA and all of our partners and stakeholders.”

Justin Rudgick, President and CEO of Christopher Community, Inc., said: “We are extremely excited about the completion of the new $17 million construction project in Camillus Heights. This affordable housing initiative in the town of Camillus, offers families 60 beautiful units, in 16 two-story townhouses. We greatly appreciate the partnership with New Homes and Community Renewal of York State, Community Preservation Corporation and all who made this housing project possible. »

Acceleration of the rise of the CNY

Today’s announcement complements “CNY Rising,” the region’s comprehensive plan to generate robust economic growth and community development. The regionally designed plan focuses on capitalizing on global market opportunities, strengthening entrepreneurship and creating an inclusive economy. Today, the region is accelerating CNY Rising with a $500 million investment from the state through the Upstate Revitalization Initiative. The state’s $500 million investment will spur private businesses to invest well over $2.5 billion — and the region’s plan, as submitted, calls for up to 5,900 new jobs. More information is available here.

Two hundred pharmacists fled Nigeria in one year, association says

Olabode Ogunjemiyo, national chairman of the Association of Hospital and Administrative Pharmacists of Nigeria (AHAPN), says about 200 of its members have fled the country for greener pastures.

Mr. Ogunjemiyo revealed this during a press conference during his 23rd annual national scientific conference on the theme “COVID-19 experience: Expanding the role of pharmacists in the health system” in Lafia.

“I remember one of my colleagues traveling from Owo, Ondo State where we practice to Benin in Edo State. He was kidnapped along the way. As soon as he was released, he immediately left the country with his family”, explained the president of the AHAPN. “So those are the main reasons.”

He added, “Over the past year, we have lost about 200 pharmacists to brain drain. Most of them went to Canada and other developed countries.

According to Mr. Ogunjemiyo, more pharmacists are at the higher level and few at the lower level as the latter are always looking for greener pastures abroad.

He added that the association expects more than 1,000 pharmacists across the country from grassroots within hospital and administrative positions, and those in other areas of pharmacy practice to attend the conference which kicked off. today.

“It should be noted that Nasarawa State is hosting the conference of any professional group of this magnitude for the very first time since its inception,” he said. “It is indeed a great honor for the government and people of Nasarawa State as the name of the state will be included in the pharmaceutical lexicon.”

Mr. Ogunjemiyo also mentioned that during the conference, the association would pay a courtesy visit to state dignitaries, organize a health march against drug addiction, health awareness for natives at the Emir’s palace. of Lafia, a public assembly and plenary sessions.

“It is part of our corporate social responsibility carried out regularly and at conferences of this magnitude. It is intended to complement the efforts of the Nasarawa government to improve the health of the people.

About 1,000 natives are expected to benefit from medical awareness and they will benefit from free pharmaceutical care.

“Malaria, blood pressure control, height and weight control, blood sugar are some of the issues to look at. They will also benefit from free consultations and advice,” he said.


University of Michigan refuses to consider mom of five for heart transplant over COVID vaccine

Despite a mother of five’s desperate plea to University of Michigan (UM) Hospital for a life-saving heart transplant, the state-run facility won’t budge from its refusal to consider her for a surgery until she is vaccinated against COVID-19.

University Hospital, which has close ties to vaccine maker Pfizer, also rejected 35-year-old Katie Shier’s request for a religious exemption.

In a recent heartbreaking email about her condition, Katie Shier describes how the pump she relies on to keep her heart beating got engulfed in bacteria that no longer respond to the round of antibiotics she was prescribed by doctors at the University of Michigan. .

As a result, Shier was repeatedly hospitalized with blood infections. She and her husband Ron fear it could eventually lead to sepsis, which can be fatal.

“It’s like nobody at UM cares what they’re doing to us and our kids,” Ron Shier told The Epoch Times.

Ron Shier, who works full-time as a mental health counsellor, said his children, aged 3 to 11, constantly worry that mum “isn’t coming home from the hospital”.

The University of Michigan (UM) has close ties with Pfizer that date back at least to 2008, when it purchased the pharmaceutical company’s giant Ann Arbor facility and all of its contents.

According to a 2008 Press release from the university, the college quickly recruited 13 Pfizer scientists after taking over its facilities, most of them still working for the state college today. Ten of them were specifically hired to staff UM’s College of Pharmacy.

David Canter, senior associate vice president and executive director of UM’s North Campus Research Complex, led Pfizer’s pharmaceutical research operation in Ann Arbor; and Scott Larsen, who received the Pfizer Achievement Award in 2007, is now a research professor of medicinal chemistry at the university.

Several executive-level Pfizer employees are also university alumni, including Pfizer director Lynne Pauer and 2020 graduate Sarah Kusisto, a senior executive at Pfizer in Portage, Michigan.

Additionally, last year, Pfizer was one of three companies that the university Tauber Institute for Global Operations has chosen to receive its annual longevity awards.

According to UM’s website, the award is given “in recognition” to companies “for their commitment to operations training through their active participation in Tauber team projects.”

Pfizer also remains a major employer in Michigan, with its largest manufacturing plant located in Kalamazoo where it manufactures its prescription drug Paxlovid, a pill the FDA approved last year for the treatment of COVID.

She provided The Epoch Times with notarized permission to speak to UM about her case. Clearance was sent to the university’s transplant team, clinical ethics services and CEO Marschall Runge with a request for comment on his case.

He was also sent to the eight-member Board of Regents, elected officials who govern the public hospital. None of them answered.

On July 29, Mary Masson, director of public relations for the university, issued a one-line statement via email to The Epoch Times in response to Shier’s case, but declined to answer questions, even refusing to provide Epoch Times his phone. Number.

“Michigan Medicine does not discuss ongoing litigation,” was the sole response from the taxpayer-funded hospital.

The Epoch Times asked the hospital for a copy of its COVID vaccine mandate policy, whether it only applied to transplant patients, and under what circumstances does it grant or plan to grant one. a religious exemption.

The Epoch Times has never inquired about the ongoing litigation.

Last month, the Pacific Justice Institute filed a lawsuit in court on behalf of Shier and another college transplant patient against the state university’s board of trustees seeking a declaratory waiver from the COVID vaccination policy. of his transplant center and his refusal to consider both Shier and the other patient’s request. for a religious exemption.

The other patient, who needs a kidney transplant, is not as critical as Shier.

Both were on the list for a transplant but were removed after the university adopted a new policy that the COVID vaccine would be required to remain on the list.

The complaint accuses the regents “of breaching their duty of care to patients by imposing arbitrary and capricious dictates and effectively giving patients the choice to die or submit to government-inspired dictates that are not to legitimate medical purposes”.

Katie Shier told The Epoch Times that she strongly opposes the vaccine because she believes it is dangerous and will cause her already fragile heart, which is only functioning at 7% of its full capacity, to fail.

She said she believed their concerns were validated by the growing number of people who said they had heart problems after being injected with COVID.

“It’s just an evil experiment on humanity,” Shier said, “and I don’t want to be a part of it.”


Alice Giordano is a former news correspondent for the Boston Globe, the Associated Press and the New England bureau of the New York Times.

People in the News: August 1, 2022

People in the News: A roundup of new hires, promotions and awards in West Michigan.

MGA’s new leader focuses on Industry 4.0 and talent development

MManufacturing Growth Alliance named Elizabeth Bernhard as the new CEO. The Alliance is a subsidiary of the Benton Harbor-based Kinexus Group, a nonprofit business development organization, and works with Michigan manufacturers to encourage growth and maintain industry competitiveness.

Bernhard brings more than a decade of management experience to this position. As a child watching her father teach shop lessons, Bernhard said she never imagined herself ending up in manufacturing, but she has worked in space for years.

As Director of Professional and Continuing Education, she led Kalamazoo Valley Community College’s high-demand workforce training programs and partnerships with Urban Alliance and Momentum Urban Employment Initiative. She also created and oversaw KVCC’s Community Life Enrichment Program.

While serving as Director of Engagement and Academies at Urban Alliance, Bernhard built relationships with companies in the manufacturing industry through the implementation of the Momentum technical training program. Most recently, she oversaw statewide partnership initiatives for talent development at Youth Solutions Inc. as the Partnership Engagement Manager.

“I never imagined myself in this role, but I feel like all of my past roles have led me to this point,” Bernhard said.

The Growth Alliance’s mission to serve small manufacturers through education, resources and advocacy attracted Bernhard to this role. As executive director, she hopes to focus on Industry 4.0 readiness and talent development. Many smaller manufacturers lack the resources to engage in long-term strategic planning, and the Alliance aims to equip them with the knowledge, funding and resources to embrace Industry 4.0.

Having worked with key talent groups like veterans, young people and returning citizens in previous roles, Bernhard said she feels ready to help small makers “provide creative and sustainable solutions to create a pipeline of diverse talent”.

She also hopes to increase MGA’s advocacy efforts by strengthening lines of communication with state leaders.

— Reported by Abigail Ham.


  • Eric Frederick was named the Michigan High Speed ​​Internet Officefirst Director of Connectivity. Frederick received his bachelor’s degree from Northern Michigan University and his master’s degree in urban and regional planning from Michigan State University. He has spent the past decade at Connected Nation Michigan, most recently as president of broadband planning and executive director. Frederick will now work to meet the goals of the state’s 2021 Broadband Roadmap and develop Michigan’s first five-year broadband strategy and digital equity plan. “As the state’s first-ever Director of Connectivity, Eric will lead our new Broadband Internet Office as it develops the infrastructure necessary to invest our resources effectively and efficiently to achieve our goals,” said said Lieutenant Governor Garlin Gilchrist in a statement.


  • 6:00 p.m. Hospitality Partners LLC hired Rachel Flat as project manager. Platt brings 14 years of experience in the hospitality industry, most recently as Regional Project Administrator for The Christman Co. 6PM Hospitality is a Zeeland-based property development and management company. The company currently operates one hotel in Holland and has similar roles at three other hotels planned in Manistee and Battle Creek. Former Suburban Inns CEO Peter Beukema formed 6PM Hospitality late last year, previously recounting MiBiz that he identified a “huge opportunity for third-party (hotel) management done right”.


  • Marketing LKF hired Shelby Carter as an account manager and specialist in statistical analysis reports as well as Lucy Wild as an account coordinator. Carter is a 2018 graduate of Grand Valley State University and previously worked as an account manager at Imperial Beverage. Wilde is a 2020 graduate of Calvin University who previously worked as a marketing coordinator at the nonprofit Eagle Village near Reed City. “The addition of two new account employees almost simultaneously gives our team the opportunity to share our proven methods and procedures with new team members while giving us access to new perspectives from a new generation of IT professionals. marketing,” said Heather Isch, President and CEO of LKF.


  • children’s food basket is seeking a Director of Development to lead community engagement, strategic planning and donor relations efforts. The nonprofit organization focuses on ending childhood hunger in communities across western Michigan, serving more than 9,000 school children in Kent, Muskegon, Ottawa and Allegan counties. The organization is looking to hire someone with a bachelor’s degree and 10 years of relevant experience, including four years of experience in a supervisory role. Candidates should have strong written and verbal communication skills, budget management skills, and proficiency in Microsoft Office suite and CRM.
  • Nick Colvin was appointed to the board of directors for Grand Grand Rapids NAACP. A senior advisor at Warner Norcross + Judd LLP, Colvin specializes in economic development, impact investing and government relations. He is a graduate of the University of Michigan and Harvard Law School and a member of the Michigan State Bar. He is also a member of the board of Ele’s Place West Michigan. Colvin will serve a two-year term on the NAACP Board of Directors.
  • DA Blodgett – St. John’s named Joel Bell as program manager. Bell holds a bachelor’s degree in psychology from Calvin University and a master’s degree in social work from Western Michigan University, where he is now an adjunct professor in the School of Social Work. He brings over 20 years of experience in the child protection and mental health fields, most recently as Branch Manager for Bethany Christian Services operations in Southwest Michigan. At DA Blodgett, he will oversee 15 programs aimed at helping children and empowering families.
  • The Western Michigan Literacy Center appointed Marcus Small as director of the nonprofit’s Personalized English in the Workplace program, where he will develop English education service partnerships with businesses in West Michigan. The program provides personalized training in English in a work context, helping employers attract talent from wider backgrounds. Originally from Southern California, Little and his family moved to Grand Rapids in 2014 and served eight years as pastor of Berean Baptist Church.


  • Linda Witteprogram director and manager Grand Rapids Community College‘s Workforce Training Health Programs, received the Pride of the Profession award from the American Medical Technologists Association. The award honors members who have demonstrated a commitment to the profession and to service in their community. Witte manages the GRCC’s Physician Assistant, Certified Practical Nurse, Pharmacy Technician and Phlebotomy Skills programs and is currently helping to develop the Professional Direct Support Program.
  • Hope College named Heidi Kraus Vice-Provost for Academic Affairs. Kraus has been Professor of Art and Art History at Hope since 2012 and previously served as Department Head, De Pree Gallery Director and Global Learning Director. She is also an active researcher focused on neoclassicism and a student research advisor to the Mellon Scholars Program. Kraus succeeds psychology professor Daryl Van Tongeren, who served as interim associate provost from 2021. As associate provost, Kraus will work closely with the college’s deans and faculty leadership to support the teaching, scholarship and faculty development, and improving the academic program.


  • Accounting firm based in Ada Dan Carter CPA Advisors PLC recently appointed Mike Volk as main. Volk joins the company after 21 years as executive vice president of finance, chief financial officer and treasurer of Davenport University. With previous experience in the non-profit, healthcare and education sectors, Volk will focus on forensic accounting, business valuation and advisory services while participating in corporate accounting and tax practices. ‘company. Volk said he wanted to use his experience at Davenport to help companies lacking in-house expertise “achieve their goals and achieve better results.”
  • Former National Bank named George Bailey as president of the Michigan market. Bailey has over 35 years of experience managing banking and business relationships and is also invested in community service as a volunteer for the National Kidney Foundation of Michigan and the Multiple Sclerosis Society of Michigan. Like Michigan Market President, Bailey will work with leaders in Southwest, Central and West Michigan to continue to grow in these regions. He will also guide the brand’s expansion into Southeast Michigan.
  • A new CEO took office last month at Kalamazoo Consumer Credit Union as Scott Sylvester took over from longtime chairman and CEO Kit Snyder on July 2. Snyder retired after 38 years with Consumers Credit Union, including serving as president and chief executive officer since 1983. Worked as a bookkeeper, senior accountant, chief information officer, and vice president of technology, then chief financial officer and chief technology officer.

— Compiled by Abigail Ham.

NLS Pharmaceuticals AG (NASDAQ:NLSP) Sees Significant Drop in Short-Term Interest

NLS Pharmaceuticals SA (NASDAQ: NLSPGet a rating) was the target of a significant drop in short-term rates during the month of July. As of July 15, there was short interest totaling 102,400 shares, down 28.3% from the June 30 total of 142,800 shares. Based on an average daily volume of 227,300 shares, the short interest ratio is currently 0.5 days. Currently, 0.8% of the company’s shares are sold short.

Changes to analyst ratings

Separately, Alliance Global Partners began covering NLS Pharmaceuticals shares in a research report on Tuesday, July 5. They issued a “buy” rating on the stock.

NLS Pharmaceuticals stock down 4.5%

Shares of NLS Pharmaceuticals Stock opened at $0.37 on Friday. The company’s fifty-day moving average price is $0.58 and its two-hundred-day moving average price is $0.90. NLS Pharmaceuticals has a 1 year minimum of $0.33 and a 1 year maximum of $3.10.

NLS Pharmaceutical Company Profile

(Get a rating)

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focused on developing treatments for narcolepsy, idiopathic hypersomnia and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).

Recommended Stories

Get news and reviews for NLS Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for NLS Pharmaceutics and related companies with MarketBeat.com’s FREE daily newsletter.

Exscientia’s Andrew Hopkins: The Man Using AI to Cure Disease | Pharmaceutical industry

It was early one morning in 1996 when Andrew Hopkins, then a PhD student in biophysics at the University of Oxford, had a brain wave as he was returning home from a late night lab meeting.

He was trying to find molecules to fight HIV and better understand drug resistance.

“I remember this idea struck me that there had to be a better way to do drug discovery other than the complex and expensive way that everyone was following,” he says. “Why couldn’t we design an automated approach to drug design that uses all the information in parallel so that even a lowly PhD student can create a drug? This idea really struck me. I almost remember the exact moment to this day. And that was the genesis of the idea that eventually became Exscientia.

It was to prove a lucrative idea. Hopkins started the company in 2012 as a spin-out from the University of Dundee, where he was then working as a professor. It uses artificial intelligence (AI) systems, which are trained to mimic human creativity, to develop new drugs. It involves using automated computer algorithms to sift through large data sets to design new compounds that can treat diseases and help select the right patients for each treatment.


Age 50

Family Married with a 10 year old daughter. He met his wife, Iva Hopkins Navratilova, at Pfizer. His company, Kinetic Discovery, merged with his to create the Exscientia Experimental Biology Laboratories.

Education Dwr-y-Felin Comprehensive and Neath College in South Wales; degree in chemistry in Manchester; PhD in Molecular Biophysics at Oxford.

Pay £415,000

Last holidays Czech Republic to visit his wife’s family at Easter.

Best advice ever given “My father worked in a factory. He told me: ‘Get a good education and find a job that you like to do. It’s worth six thousand dollars more a year. And I definitely have a job that I love to do.

Biggest Career Mistake “It is too early to tell.” He quotes Miles Davis: “It’s not the note you play that’s the bad note – it’s the note you play next that makes it good or bad.”

Words he abuses “Fundamentally”; “The heart of the problem”.

how he relaxes Reading and dog walking. “I am a bibliophile. I immerse myself in books to relax.

Jhis approach dramatically reduces drug development time. Hopkins says that for the Exscientia pipeline, it typically takes 12 to 15 months from initiating a project to identifying a drug candidate, compared to four and a half years in the traditional pharmaceutical industry.

The average drug development cost is $2 billion, according to Deloitte’s latest pharmaceutical report, and many drugs fail – the failure rate is 90% for drugs in early clinical studies ( where they are tested on humans).

Typically, drug companies make 2,500 compounds to test against a specific disease, while AI allows Oxford-based Exscientia to whittle that number down to around 250, Hopkins says. “It’s a much more methodical approach.”

Last autumn the Welsh scientist became one of Britain’s richest entrepreneurs, with a paper fortune of £400m after the company debuted on the stock market for $2.9bn on the Nasdaq in New York, making it one of Britain’s largest biotechnology companies. Hopkins’ nearly 16% stake is now worth £170m as the share price lost 60% of its value in a bloodbath for Wall Street stocks.

Exscientia was part of a transatlantic trend that is defying government attempts to build a biotech powerhouse in the UK. Abcam, a pioneering Cambridge antibody company, recently announced that it was moving its stock market listing from the UK to the US. “We are a British company; we choose to be in Oxford because we can attract global talent,” says Hopkins. “But to be considered a global company, we listed on what is the global technology index, which is the Nasdaq. What we have now is an incredibly international shareholder base from around the world.

The company developed the first AI-designed drug to enter clinical trials – a treatment for obsessive-compulsive disorder in partnership with Japan’s Sumitomo, although Sumitomo later decided not to continue. The Japanese firm is currently studying another drug developed by Exscientia, for the treatment of Alzheimer’s disease psychosis, in early human trials.

Hopkins, now 50, fell in love with science thanks to an inspiring chemistry teacher. He has worked as a scientist since the age of 16, when he had a stint in industrial chemistry at Port Talbot Steelworks in South Wales, which he says taught him the benefits of automation to increase productivity.

He spent nearly a decade at US pharmaceutical giant Pfizer, where he was on a “data warehouse” project that led to some of the first applications of machine learning in the pharmaceutical industry, with the results Posted in Nature in 2006.

Over the next five years at the University of Dundee, he deepened his research into the application of data mining and machine learning to drug discovery. He says “being a professor is actually one of the best jobs in the world” and gave him the freedom to research AI methods extensively. He maintains his ties to the university, where he holds the honorary chair of medical informatics in the School of Life Sciences.

Exscientia (meaning “of knowledge” in Latin) soon moved into the Schrödinger Building in Oxford Science Park and now employs 450 people worldwide, from Vienna to Boston, Miami and Osaka, split evenly between the AI engineering, chemistry and biology.

He’s building a new robotics lab in Milton Park near Oxford, focused on automating chemistry and biology to speed up drug development and his stated goal is “AI-designed drugs, made by humans.” robot”. Other pharmaceutical companies have also introduced some automation into their processes, but lab technology is generally similar to what it was when he was a student in the 1990s, Hopkins says.

The company is involved in 30 projects, some in partnership with large pharmaceutical companies including the French Sanofi and the American Bristol Myers Squibb (BMS). He is also working with the University of Oxford on the development of drugs that target neuroinflammation for the treatment of Alzheimer’s disease. Among the company’s solo projects, a cancer drug for solid tumors is about to enter the first clinical trials.

Exscientia is also working on a broader coronavirus pill to rival Paxlovid, the Covid-19 treatment made by Hopkins’ former employer Pfizer. This work is funded by a $1.5 million grant from the Bill and Melinda Gates Foundation, which has taken an equity stake in Exscientia. Other investors in the company include BMS, Celgene (now a subsidiary of BMS) and Germany’s Evotec, as well as Japan’s Softbank, US fund manager BlackRock and life sciences investor Novo Holdings.

Hopkins says the team has identified a set of molecules that could work as a broader treatment for Covid-19, novel mutations and other coronaviruses, and there will be more news later this year. The company is aiming for a low-cost pill that could be distributed around the world and given quickly to people who get sick to prevent serious illness and hospitalization. Covid-19 infections are rising again in 110 countries and World Health Organization Director General Tedros Adhanom Ghebreyesus has warned the pandemic is far from over.

Companies in the pharmaceutical industry have started using AI in recent years. AstraZeneca is investing heavily there for all of its research and development infrastructure, and GSK has built an AI team of 120 engineers, with plans to reach 160 next year, making it the largest internal team in this guy in the industry.

AI systems require a lot of computing power and huge data sets. Their use is expected to increase the number of new drugs approved each year – typically 40 to 50 in the United States – to many more. Hopkins confidently predicts, “This is how all drugs will be designed in the future. Over the next decade, this technology will become ubiquitous.

Peebles Pharmacy faces a staff shortage

A NATIONAL shortage of pharmacists has hit Peebles, a meeting heard.

On Friday (July 22), the High Street branch of chemist Boots was closed until 2pm.

And a notice on the door stated that the closure was due to the unavailability of a pharmacist.

You could see staff working inside and it wasn’t just the prescription department that was closed but the whole store.

For many months Boots closed for an hour at noon.

At the July meeting of the Peebles and District Community Council, Secretary Anne Snoddy said: ‘There are concerns about Boots and they have not replied to my first email.

“It was closed all day on Saturday (July 9), without notice, whether on Facebook or at the door and it is also closed at lunchtime.

“I was wondering if this was a permanent problem or if it was short term?”

Tweeddale West Councilor Drummond Begg, who is also a GP, added: “The key issue is the lack of community pharmacists nationwide.”

Boots is owned by an American healthcare giant, Walgreen Boots Alliance, and on its UK careers website there are at least 69 pharmacy vacancies across Scotland, including one in Peebles.

At Galashiels, there are two vacancies at its Gala Water Park branch, for a full-time, relief pharmacist.

Nationally, the company has more than 800 vacancies for pharmacists and 2,860 vacancies for all job types.

A Boots spokesperson said: ‘Like other pharmacies, we are having issues with pharmacist resources.

“Our teams are working hard to keep stores open, minimize disruption to customers and provide the best possible service.

“Sometimes, rather than closing a pharmacy for a day, we change our opening hours.”

Dr Begg added: “One thing that would help with efficiency would be to introduce an electronic prescription service.

“Both are Scottish Government issues.”

PCC chairman Les Turnbull said it was quite worrying that the pharmacy was not working well and asked Ms Snoddy to email Midlothian South, Tweeddale and Lauderdale MSP Christine Grahame.

In a comment to the Peeblesshire News, Ms Grahame said: ‘I am aware of concerns about this and subsequently my office responded to Ms Snoddy last week.

“On the substance of the matter, in terms of opening hours and availability, pharmacies have a contract with the NHS Board to provide services, so if the local community wishes, I am happy to write to NHS Borders to raise this issue.

“Electronic Prescription Transfer (ETP) already exists in Scotland, although it is not available in all settings as it depends on the GP practice and local pharmacies wishing to do so – it is similar to the situation in England.

“However, there will be patients at the borders who will use this type of system now.

“Again, if there is a specific concern about this, I am happy to raise it if contacted by constituents about this.

“I hope Boots will now engage with the local community to address some of these concerns.”

The Boots spokesperson said: “We apologize to the customers who have been impacted and thank them for supporting us and being kind to our team members at this time.”

The meeting was also briefed on an update on the town’s Lloyds Pharmacy.

On June 17, the Peeblesshire News reported that an 83-year-old woman had been forced to wait four hours at the pharmacy.

At a recent meeting of the Peebles and District Community Council, its secretary, Anne Snoddy, said: “Lloyds has confirmed that the problems were due to the introduction of a new IT system.

“Their regional manager has been alerted to our concerns and is supporting the pharmacy team to ensure an optimal level of service can be achieved again.

“As of this writing things have improved, they are not perfect but are getting better.”

To make insulin affordable, California wants to create its own brand

Insulin was first discovered in the 1920s by a team of Canadian scientists. They sold the patent to the University of Toronto for just $1, hoping the school would license the product to multiple companies to prevent a monopoly that would lead to high prices.

But over time, the insulin market was slowly cornered. Today, only three companies produce most of the world’s insulin. In the United States, the line between an insulin manufacturer and a patient is not straight. It zigzags between insurance companies and drug benefit managers — third parties who manage prescription drug benefits for health plans.

It’s this system that has kept the cost of insulin much higher in the United States than in other countries, as more companies benefit from the higher price, said Kasia Lipska, an associate professor at the Yale School. of Medicine.

“It creates this really weird incentive,” Lipska said.

California will try to break this incentive. The reason more companies haven’t entered the insulin market is that if they did, established manufacturers would undermine them, making it impossible to recoup their investment, said Anthony Wright, executive director of Health Access. California, a consumer advocacy group.

But California is in a different position because in addition to selling insulin, it also purchases the product each year for the millions of people benefiting from its state-funded health plans. This means that if the California product lowered the price of insulin in the market, the state would still benefit.

“That’s why California’s market power matters,” Wright said. “For a Wall Street investor, lowering the cost of insulin means you may not be able to recoup your investment. For California, lowering the price of insulin is a real savings for taxpayers as well as for our residents.

Still, there’s no guarantee that California’s plan will work. For one, insurers and drug benefit managers might not cover California insulin products, making it harder for patients to obtain them.

Sarah Sutton, director of public affairs for Pharmaceutical Research and Manufacturers of America, said a better idea would be for California to focus on “common sense solutions” to address the role pharmacy benefit managers play in pricing. insulin.

“It would bring real relief to patients right now,” she said.

Dr. Mark Ghaly, secretary of the California Health and Human Services Agency, said he hoped a state as large as California making its own insulin would significantly reduce the role of drug benefit managers in insulin pricing .

If successful, Ghaly said, he thinks California-brand insulin would be priced so competitively that patients could buy it off-the-shelf for less than going through their insurance plan.

“We expect to save hundreds of millions of dollars for California through this,” Ghaly said. “This gives us the opportunity to create a blueprint for health care affordability that has so far been beyond the reach of states and, frankly, the federal government, and it’s really exciting to see where that can go.”

NLS Pharmaceuticals (NLSP) stock: why it rose 5.21%

  • The share price of NLS Pharmaceuticals (NLSP) rose 5.21% in the previous trading session. That is why.

The share price of NLS Pharmaceutics (NLSP) – a clinical-stage Swiss biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders – rose 5.21 % in the previous trading session. Investors respond positively to NLS Pharmaceutics by announcing that the Japan Patent Office (JPO) has notified the company of its decision to grant patent application 2018-546837 for the proprietary formulation of Quilience (Mazindol ER).

Once granted, the patent will cover oral formulations containing immediate release and sustained release layers of mazindol and their use in the treatment of attention deficit/hyperactivity disorder (ADHD), excessive daytime sleepiness (EDS), including narcolepsy and idiopathic hypersomnia (IH).


“We are delighted to obtain patent coverage in another major market for our proprietary formulation of Quilience to treat ADHD, Narcolepsy and IH. Given our patent heritage and the orphan drug designations we have in the US and Europe, we believe our proprietary position on Quilience is strong. We look forward to publishing final results from our Phase 2a narcolepsy trial for Quilience in late September 2022 and also providing an update from the open-label extension study later this year.

— Alex Zwyer, President and CEO of NLS

Effects of inulin supplementation on body composition and metabolic outcomes in obese children


This was a randomized, double-blind, placebo-controlled trial conducted from August 2017 to July 2020 at King Chulalongkorn Memorial Hospital (KCMH), Thailand. The study was conducted in accordance with the Declaration of Helsinki and the Ethics Committee of Chulalongkorn University Medical School approved the study protocol (IRB No. 240/60). Participants signed informed consent forms prior to enrollment. This trial has been registered at http://www.clinicaltrials.gov under number NCT03968003. CONSORT was produced as a checklist of health research reports for randomized trials. Obese children aged 7-15 who had a BMI greater than the median plus 2 standard deviations (SD) from the WHO growth reference14 were recruited from KCMH’s Pediatric Nutrition and Pediatric Obesity clinics, as well as social media (Chula Kids Club). All the children who fulfilled the inclusion criteria as well as their parents were approached by the researchers and those who accepted the monthly follow-up and consented to the study were enrolled. Exclusion criteria were syndromic obesity, endocrine causes of obesity (e.g. hypothyroidism, growth hormone deficiency), concurrent use of drugs that influence appetite or body weight (e.g. example, corticosteroids) and participation in other concurrent weight reduction programs.

study design

The participants were randomly assigned to 3 groups: inulin, placebo and dietary fiber advice group. Randomization was performed using computer-generated permuted blocks of size 6. A research assistant who was not involved in the data collection and analysis generated the random allocation sequence and prepared the sealed envelopes. Other researchers recruited participants and blindly assigned them to each group. To ensure concealment, study products were weighed, packaged, and signed with consecutive numbers according to the randomization list by uninvolved personnel. The inulin group consumed 13 g of inulin powder extracted from Thai Jerusalem artichoke approximately 30 minutes before dinner daily. Participants were recommended to consume the powder by mixing the powder with 150ml of lukewarm water and then stirring the powder until dissolved. The placebo group consumed 11 g of isocaloric maltodextrin (Oligocarb; Ma-Jusmin Company Limited, Bangkok, Thailand) in the same way. Blinding of the placebo to match the light brown color of the inulin extract was addressed throughout the study. Both supplements came in identical foil pouches. All participants were followed monthly for 6 months. During the monthly visit, participants were asked to return all empty, half-empty and full sachets, and the information was recorded. Parents/guardians were asked to make a parental checklist and checked in with researchers during follow-up visits. The third group received structured advice (with pictures of portion sizes) to consume age-appropriate amounts of dietary fiber15.16. Research assistants conducted telephone contact every 1st and 3rd week to verify and monitor compliance and side effects.

Apart from the interventions, all groups received the same dietary advice regarding a diet low in energy (1000 to 1200 kcal/day) and low in fat (25% of total energy from fat). All participants were asked to exercise without weight bearing for 60 minutes a day at least 4-5 days a week, to maintain a physically active lifestyle and to reduce screen time.

Inulin Extraction Process

Inulin was prepared from Jerusalem artichoke (Helianthus tuberosus). Jerusalem artichoke dry energy was purchased from local distributors in Nakhon Ratchasima, Thailand. The product has been approved for human consumption by the Food and Drug Administration of Thailand (No. 30–1-14,358–1-001). The inulin extract was prepared according to the patented protocol developed by our team (Patent n° 15858, Inventor: Chonnikant Visuthranukul and Supakarn Chamni, Chulalongkorn University and National Science and Technology Development Agency, Thailand). Briefly, Jerusalem artichoke powder was decocted in water at 60-80°C for 45-90 min. The resulting slurry was filtered, mixed with absolute ethanol and incubated at room temperature overnight for inulin precipitation. Inulin was collected by filtration. All remaining moisture contents were dried at 40-50°C and pulverized to obtain the fine and homogeneous inulin powder. Inulin content was assessed based on standard methods for dietary fiber, including energy (ASTM Method D 240–76), total dietary fiber (AOAC (2016) 985.29), soluble dietary fiber (AOAC (2016) 991.42, 991.43), insoluble dietary fiber. fiber (AOAC (2016) 991.42), and fructans (Inulin + Oligofructose) (s) AOAC (2005) 997.08 + J. AOAC, 2000, 83(4); 1020–1025)17.18. The tests were carried out by a certified laboratory of the Institute of Nutrition, Mahidol University, Thailand. The degree of polymerization (DP) of the resulting inulin was determined by MALDI-TOF mass spectrometry and gel permeation chromatography coupled with multi-angle laser light scattering. Jerusalem artichoke inulin showing a large distribution of fructan polymerization containing a molecular mass of 3460 m/z, which refers to the large DP of the resulting inulin extract. Microbial and heavy metal contaminants, as well as pesticide residues were reviewed and confirmed by the Department of Science Service, Thailand. The inulin extract was kept in foil pouches and stored in a dry container at room temperature until use.

Assessment of food intake, physical activity and exercise

Food intake was assessed by a dietitian, using 3-day food records (two weekdays and one weekend day). Fiber and other nutrient intakes were calculated using the Institute of Nutrition, Mahidol University Calculation-Nutrients Version 3 (INMUCALs)19. Adherence to physical activity and exercise instructions was assessed by a physical activity questionnaire at each visit. Intensity of physical activity was defined by day/week and duration of physical activity in minutes/hours. Aerobic dancing or cycling with speed were classified as high intensity exercises. Brisk walking was classified as moderate intensity while walking from place to place for at least 10 minutes was classified as low intensity. Sedentary activity was defined as a lifestyle involving little or no physical activity that was questioned and assessed by a research assistant. Screen time, such as watching TV and playing computer, smartphone, and tablet games, was assessed separately from sedentary activity.

Anthropometry, body composition and clinical assessment

Trained personnel carried out the anthropometric measurement. Weight and height were measured without shoes and with light clothing using a stadiometer to the nearest 0.1 kg and 0.1 cm, respectively. Waist circumference was measured at the level of the navel after normal exhalation with the participants in a standing position. Hip circumference was measured at the maximum circumference of the hips. BMI was calculated as the weight in kilograms divided by the square of the height in meters (kg/m2), and the BMI z-score was calculated based on the 2007 WHO Growth Reference using the WHO Anthroplus program20. Body composition was measured by bioelectrical impedance analysis (BIA) using the InBody 770® (InBody Co., Ltd., Chungcheongnam-do, Korea). This multifrequency with 8-point tactile electrodes was evaluated in Korean children aged 6 to 18 years21 with a reproducibility of 99%. Fat mass index (FMI) and fat-free mass index (FFMI) were calculated in the same way as BMI22.

Blood pressure was measured by a tensiometer (Dinamap®). The presence of acanthosis nigricans has been documented by a pediatrician. Tanner’s staging was assessed by a self-administered photo questionnaire and verified by a pediatrician.

Metabolic profiles

Venous blood was drawn after a 12 h fast to assess biochemical parameters at the 1st and 6th study visits. Fasting blood glucose (FPG) was measured by the hexokinase method (GLUCOSE, Architech; Abbott Laboratories, Irving, TX). Serum total cholesterol, HDL-C and triglycerides were measured by enzymatic colorimetric assay (CHOLESTEROL, Architech; ULTRA HDL, Architech; and TRIGLYCERIDE, Architech; Abbott Laboratories). LDL-C was measured by a homogeneous liquid selective detergent (DIRECT LDL, Architech; Abbott Laboratories). Serum alanine aminotransferase (ALT) was determined according to the standard of the International Federation of Clinical Chemistry (ALANINE AMINOTRANSFERASE, Architech; Abbott Laboratories).

statistical analyzes

Sample size estimation: With a power of 0.80 and an alpha level of 0.05, the sample size of 55 obese children per group was estimated using one standard deviation of 0.267 and the minimum clinical difference for change in BMI z-score was 0.17.

Baseline characteristics of participants in each group were described as mean and SD or frequency and percentages. A one-way ANOVA was used to assess the difference in change in variable outcomes between baseline and Month 6. The Generalized Estimating Equation (GEE) model was used to assess changes in outcomes, which included body weight and adiposity, among three groups at three time points (baseline, three and six month). To assess the effect of time on the difference in outcomes between the three groups, the GEE model with an interaction term between the time point and the group was assessed using the likelihood ratio test. The alpha level of 0.05 was considered statistically significant for all analyses. All analyzes were performed using STATA version 16.1 (STATA statistical software: version 16. College Station, TX: STATA Corp LLC. 2019).

Could cyberdesigns provide powerful dual-action antibiotics?

Computer modeling has been used to create dual-action compounds with exciting potential as new antibiotics.

The proof-of-principle experiment raises the possibility of new antibiotics that can target harmful bacteria on two fronts and are therefore less likely to be defeated by resistant strains.

The collaboration between the University of Leeds and the John Innes Center has modeled potential new drugs based on the activity of thiophene compounds. These had previously shown promise as antibiotics before toxicity concerns prevented them from moving forward with human clinical trials.

By observing the activity of thiophenes, the team modeled new antibiotic candidates by computer, then synthesized and tested them on pathogenic bacteria Escherichia coli (E. coli).

They found that a series of biphenyl compounds inhibited the activity of harmful bacteria by targeting two enzymes, DNA gyrase and DNA topoisomerase IV, both essential for bacterial survival.

“These new compounds represent the start of a program that could lead to a new series of antibiotics,” said Professor Tony Maxwell, of the John Innes Centre, and one of the study’s authors.

“The current program represents proof of principle, and this initial success suggests that we will be able to discover even better antibiotic candidates in the future.” added the study’s first author, University of Leeds researcher Dr Kyle Orritt.

Researchers have previously discussed the implications of working with pharmaceutical companies, raising the possibility of a new source of antibiotics.

This work follows the discovery of a new opportunity to exploit the established antibacterial target DNA gyrase that offers a novel medicinal chemistry strategy.

New antibiotics are urgently needed due to the evolution of bacteria resistant to existing treatments. This problem of antimicrobial resistance (AMR) poses a huge threat to human health due to the increase in the number of incurable bacterial infections.

By 2050, AMR is predicted to be responsible for 10 million deaths worldwide each year, more deaths than cancer and costing the global economy $100 trillion.

De novo design of type II topoisomerase inhibitors as potential antimicrobial agents targeting a novel binding region, can be found in RSC Medical Chemistry https://pubs.rsc.org/en/content/articlelanding/2022 /md/d2md00049k

/Public release. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors.View Full here.

Winter is coming: everything you need to know about the EU’s 15% gas cut plan

The European Union is bracing for a worst-case scenario this winter, accusing Russia of potentially weaponizing energy.

With 12 EU countries subject to partial or complete interruptions of Russian gas, governments fear that the Kremlin will retaliate further in response to the sanctions by completely cutting off the supply.

The EU presented a new plan this week to gradually reduce gas demand to avoid shortages or blackouts this winter.

The objective is to reduce consumption by 15% from August to March. Here’s what you need to know about it.

Why a 15% reduction target?

The figure is based on a worst-case scenario calculated by the European Commission in which Russia completely cuts gas supplies before or during an unusually cold winter.

The EU would suffer from a shortage of up to 45 billion cubic meters (bcm) of gas, which represents 15% of what member states consume on average between August and March.

Gas is the main source of heating in the EU. It is also used for power generation to varying degrees.

The Commission argues that if member states take preventive action and start saving gas before Russia closes the taps, the disruption will be managed and the economic shock contained.

In the case of a normal winter, the difference would be 30 Gm3 of gas, or a reduction of 10%.

Is the discount voluntary or mandatory?

For now, reducing gas consumption will be voluntary.

Each government is committing – on paper – to reaching the 15% target by the end of March through methods such as temperature limits on air conditioning and heating, switching to alternative fuels and postponing the phasing out of nuclear energy.

Businesses, factories, public buildings and private households will all be asked to contribute to the collective enterprise, which means governments will have to mount public awareness campaigns to get people on board.

It is unclear how far Member States will be willing to go under a voluntary scheme, but unpredictable and soaring energy prices may act as a motivating factor.

In the event of a severe shortage or exceptionally high demand, the 15% reduction target will become mandatory under a so-called Union Alert, an unprecedented crisis system that could lead to painful sacrifices.

How will a Union Alert be triggered?

The initiative to declare a Union alert can be taken by the Commission itself or a group of five countries.

They will have to argue that the extreme fall in Russian gas supplies can no longer be compensated by voluntary means.

After that, the Council of the EU will be able to trigger the Union’s alert by a qualified majority vote (55% of Member States representing at least 65% of the EU population). No individual veto will be allowed.

If the Council approves this drastic decision, the 15% reduction target will immediately become mandatory. However, the timer will not start from zero: the calculation will take into account previous efforts made on a voluntary basis.

For example, if a country succeeded in reducing its gas consumption by 5% at the end of November and an EU alert is triggered at the beginning of December, the country will have to reduce its consumption by 10% until March to reach the 15 % Mark.

Member States will report to the Commission every two months, explaining the measures they are taking to comply with the mandatory target.

Could this lead to gas rationing in the EU?

Yes. If methods such as fuel switching and temperature limits are not enough to achieve the goal, some countries, such as those heavily dependent on Russian gas, may have to resort to gas rationing.

In this case, the government will intervene and regulate the distribution of gas. The EU has agreed to protect private households and essential services, such as schools and hospitals, from any rationing measures, so the burden will likely fall on the private sector.

Countries will have to decide which factories and services they allow to continue operating and which they close. Critical industries, such as food, health and defence, will be given top priority, followed by services that operate cross-border and ensure the smooth functioning of the single market.

Particular attention will also be paid to factories whose facilities can be permanently damaged if they ever stop working, such as glass, steel, ceramics, textiles and pharmaceuticals, and those that use molecules of gas directly in their production processes, like fertilizer and chemicals.

The dreaded scenario went from remote to possible within weeks.

Last month, Germany activated the second phase of its three-stage emergency plan, a prelude to rationing, as flows passing through Nord Stream 1 continued to decline at a worrying rate.

Are there any exemptions?

Three countries will be completely exempt from the Union’s alert system: Ireland, Malta and Cyprus. They are physically disconnected from the EU, so gas savings would not benefit other states.

Estonia, Latvia and Lithuania were also granted an exemption because, due to their Soviet heritage, they are still connected to the Russian power grid and could be left in the dark at any time. The exemption will only come into effect if Russia retaliates.

Along with those two opt-outs, the final deal includes a list of waivers to partially reduce the 15% target and bring it down to single-digit territory.

A derogation will apply to countries that are poorly connected to other member states and demonstrate that they export liquefied natural gas (LNG) at “full” capacity.

Spain and Portugal, who have long argued over the Iberian Peninsula unique energy landscapepushed for this change and will be among the first beneficiaries.

Another derogation will apply to countries that exceed the EU-wide gas storage target, which was recently fixed 80% on November 1. This is considered a “reward” for those who strive to store as much gasoline as possible before the winter season.

Last storage data shows that Denmark, Poland, Sweden and Portugal are already above the 80% mark, with the Czech Republic, France, Spain, Belgium and Italy coming close.

Countries that use gas molecules in critical industries and cannot replace them overnight will also be able to apply for a partial reprieve. In principle, any member state could benefit from the provision, but EU officials say its impact will be limited because only a few industrial sectors, such as fertilizers, use gas as a feedstock.

Member States that have increased their gas consumption by 8% in the last year will also be partially spared as the 15% reduction target is based on the average consumption of the last five years.

Experts from the Bruegel think tank estimate that Bulgaria, Greece, Poland and Slovakia will fall into this category.

Won’t so many exemptions make the plan useless?

The long list of exemptions and derogations casts serious doubts on the effectiveness of the Union’s alert system.

A senior EU official, speaking on condition of anonymity, admitted that the special arrangements mean that the final savings will be between 45 billion m3 (cold winter scenario) and 30 billion m3 (normal winter ), but without fully reaching the highest figure.

However, only one exemption – that of island countries – is automatic. The other derogations must be examined on a case-by-case basis by the Commission, which will then issue a commented opinion.

It remains to be seen what type of action Brussels will take if a member state applies an unjustified derogation or simply refuses to meet the mandatory 15% target.

Hungary is the only country to vote against the plan, calling it “unjustifiable, unnecessary and unworkable”. Budapest had previously declared a state of emergencyrestricting the export of energy supplies, a decision warned by Brussels which goes against the principle of solidarity and the rules of the single market.

The case shows how energy has become extremely sensitive for capitals, which are under enormous pressure from citizens to control soaring bills. EU officials are confident that “peer pressure” between states could help enforce the savings plan and prevent breaches.

Study says NJ takes too long to resolve public records complaints

Over a nine-year period studied by the Office of the State Comptroller, the New Jersey Board of Government Records took three times longer, on average, to adjudicate Open Public Records Act requests than the system. State judiciary sets to resolve such cases.

Simply put, an OPRA complaint filed today would not be satisfied until April 2024, if the typical fiscal year 2012 to 2020 deadline continues to be met.

This average of 21 months per litigation is excessive and does not create transparency in the New Jersey government, according to Acting Comptroller Kevin Walsh.

Walsh said when the state created the RCMP under the Department of Community Affairs two decades ago, it did so in hopes of getting residents’ requests answered “as quickly as possible. “.

These could range from records sought from state offices, to school districts, to utilities within individual municipalities.

As such, Walsh said, the OPRA exists as a kind of promise to the people of New Jersey.

“If I want to know why my mayor made a particular decision, what information was there, I can call and file an Open Public Records Act request and try to get that information,” he said.

But one of the recommendations Walsh’s office is now making in a new report is that the RCMP define exactly how quickly it intends to act.

“Is it six months? Is it 12 months? If the courts can do it in seven months, can the state agency to do it without a lawyer maybe respect this standard,” Walsh said.

In this regard, the comptroller’s report also suggests that the agency disclose, via its website, whether it is performing to the standard it has set for itself.

“It’s good for an agency tasked with helping transparency to be transparent about whether it’s achieving its own goals,” Walsh said.

One concession made by the report is that due to budget cuts, the RCMP now has only three staff members, down from 10, to handle a backlog of hundreds of cases each year.

The DCA has permission to hire two additional staff but has not done so, which Walsh also recommends doing.

The report doesn’t set a timeline for when the Board of Government Archives should implement the proposed changes, but Walsh said the sooner the better.

“We have made recommendations and we have an obligation to check whether these recommendations are followed,” he said.

Patrick Lavery is a reporter and anchor for New Jersey 101.5. You can reach him at [email protected]

Click here to contact an editor about a comment or correction for this story.

WATCH: These are the 50 largest retailers in America

WATCH: What are the odds of these 50 totally random events happening to you?

Stacker took the guesswork out of 50 random events to determine the likelihood of them actually occurring. They drew their information from government statistics, scientific papers and other primary documents. Read on to find out why parents-to-be shouldn’t rely on due dates — and why you should be more worried about dying on your birthday than living to 100.

Here’s where legal NJ weed is sold

The number of recreational cannabis dispensaries continues to grow, with nearly two dozen state approvals granted since the first adult recreational sales in the state in April. Here is where the open sites are.

Pharmacy manager – endTB project M/F – France

endTB is a project that aims to provide access to new treatments for patients with multidrug-resistant tuberculosis (MDR-TB). The project is carried out in partnership with Partners in Health (PIH), Interactive Research and Development (IRD), Harvard Medical School (HMS), Institute of Tropical Medicine-Antwerp (ITM), Epicenter and University of California San Francisco (UCSF) . The project is co-funded by Unitaid and some consortium partners.

Two international multicenter randomized therapeutic clinical trials are currently underway:

  • endTB for which 750 MDR-TB patients are now enrolled, and which will end in 2023,
  • endTB-Q for which one third of the 324 TB-XDR patients have yet to be recruited and which will end in 2024.

Both are carried out under the responsibility of MSF France as Sponsor in 11 sites spread over 6 countries: India (MSF project), Peru, Kazakhstan, Lesotho (PIH projects), Pakistan (IRD project) and Vietnam (UCSF project).

The project is coordinated by a central operational team, made up of around fifteen people, divided between the various partners, some of whom are based in Paris.

Context and objectives

Responsibilities for pharmaceutical activities are divided between several levels.

At the national level, study site pharmacists are responsible for the daily supply of patient medications in accordance with ICH standards for clinical trials.

At the Promoter/Central level, the Clinical Trial Pharmacist mainly assists the sites to ensure optimal management of stocks of trial drugs (Investigational Medicinal Products (IMPs) and non-IMPs) and other medical supplies, in troubleshooting problems that arise. pose; monitors consumption and expiration of trial drugs at all trial sites; ensures that orders are placed in a timely manner; visits trial sites to ensure compliance with endTB Standard Operating Procedures (SOPs) for pharmaceutical management and to train new staff joining the pharmacy trial teams; and ensures that the trial complies with all applicable regulatory requirements relating to the manufacture, handling and storage of IMPs.

Medicines are mainly supplied through MSF Logistique, for MSF and non-MSF sites.

The level of activity at the Promoter/Central level is currently significant due to the high number of patients under follow-up or in recruitment and the large stock of associated drugs, supply activities still in progress, the recent opening of additional sites , the need to anticipate the destruction of drugs before the closure of certain sites in 2023, the current increase in site supervision visits (which could not take place during the COVID-19 pandemic) and business as usual monitoring and Q/A of the pharmacy.

While the Clinical Trial Pharmacist is in charge, the Pharmacy Manager will support this effort with a focus on drug procurement and management, to ensure compliance with sponsor obligations and the best possible support to pharmacy activities at site level.

Main responsibilities

Under the supervision of the Clinical Trial Manager (from the Sponsor level), you will work closely with the Clinical Trial Pharmacist, the 3 Central Study Coordinators in charge of monitoring the countries, certain Site Pharmacists and the Site Study Coordinators of partner organizations (MSF, PIH, IRD, UCSF) and the central MSF team.

Job requirements


3 years of experience in drug supply and management – essential.

Experience in multi-site GCP compliant clinical trials – a strong asset.

Experience working in or with resource constrained health systems – an asset.


Licensed Pharmacist with a Pharmacy degree or higher – essential.

Clinical trial training – essential.

GCP certification – a major asset.

Knowledge and skills:

Knowledge of ICH-Good Clinical Practice (ICH-GCP), Good Manufacturing Practice (GMP), Good Pharmacy Practice (GPP).

Strong organizational and planning skills and networking experience.

Respect of deadlines and adaptable.

Excellent interpersonal skills and proven ability to gain buy-in and commitment from a range of people.

Proven experience working independently with minimal supervision.

Ability to work with teams in different locations.

Proven skills to work with Office.

Languages ​​:

Fluent spoken and written English (work mainly in English) – essential.

Good level of French (occasional work in French with a few interlocutors) – an asset.

Specifics of the position

Status: 5 month contract (CDD), full time position.

Based in Paris, metro Jaurès.

Salary conditions: €41.38K gross annual salary over 13 months. 22 RTT days/year. Health insurance covered 100% by MSF. Restaurant vouchers with a face value of €9 (60% covered by MSF). 50% of the paid public transport pass.

Desired start date: As soon as possible, beginning of September 2022.

How to register

Please send your application (motivation letter and CV in English, mentioning your date of availability) until August 7, 2022 included.

at https://www.msf.fr/agir/rejoindre-nos-equipes/toutes-nos-offres-emploi/pharmacy-officer-endtb-project-mw

Only candidates whose applications have been selected will be contacted.

ABC honors UIC professor for women’s health research and education

ABC this week presented the 2022 Fredi Kronenberg Award for Excellence in Botanical Research and Education for Women’s Health, according to an ABC announcement.

Mahady is an Associate Professor and Director of Clinical Pharmacognosy Laboratories at the UIC College of Pharmacy and an expert in botanical dietary supplements and herbal medicines for women’s health and other conditions.

ABC said it established the Fredi Kronenberg Award in 2018 to honor distinguished researcher, educator, and longtime ABC board member Fredi Kronenberg, PhD, who died in April 2017. Kronenberg dedicated his professional life to the study of medicinal plants and phytomedicines for women’s health. In particular, Kronenberg was at the forefront of research on black cohosh (Actaea racemosa​) for the treatment of symptoms of menopause.

Kronenberg, a pioneer in the field of integrative medicine, co-founded the Richard and Hinda Rosenthal Center for Complementary and Alternative Medicine at Columbia University. It was the first such program at an Ivy League school and the first government-funded CAM research and teaching center.

Mahady received her BSc in Pharmaceutical Chemistry from Dalhousie University in Halifax, Nova Scotia, Canada, and a PhD in Pharmacognosy from UIC.

Current focus on transcriptomics

Mahady focuses on the chemistry and pharmacology of natural products, dietary supplements and traditional medicines and their applications for women’s reproductive health conditions. His current interests include transcriptomics (the study of RNA molecules in a cell or tissue) and proteomics (the large-scale study of proteins) of natural products in cancer, sarcopenia (muscle loss due to aging ) and osteoporosis. Mahady’s research has been funded by the World Health Organization (WHO), National Institutes of Health (NIH), and other leading funding agencies.

“I deeply appreciate and am honored to receive the ABC Fredi Kronenberg Award for 2022,”Mahady said in a statement. “Fredi was a very dear friend and colleague, and I have always appreciated her passion for work and herjoy of living.”

“Hundreds of millions of women around the world still depend daily on traditional medicine and herbal medicines for their basic health needs. Herbal remedies are used to treat everything from anxiety and depression to PMS, pregnancy, menopausal symptoms and more. Yet only a fraction of these plants have been studied scientifically, so there is still a lot of work to be done in the field,” Mahady continued.

Sixth Prize in the Ongoing Series

Mahady’s award is the sixth of annual awards presented by ABC during its current awards season. Other 2022 winners include:

  • Mark Blumenthal Herbal Community Builder Award to Emily Ruff, community herbalist, director of the Sage Mountain Botanical Sanctuary in Vermont, and founder and CEO of the Florida School of Holistic Living. This annual award is given to individuals who have played a significant role in creating a sense of community among herbalists, botanical researchers, members of the herb and natural products communities and industries, and others who work in the field of medicinal and aromatic plants.
  • ABC James A. Duke Excellence in Botanical Literature Award in the Reference/Technical and Consumer/Popular categories, which this year was split into two. The award recipient in the reference/technical category is A History of the Korean Ginseng Industry(Korea Ginseng Corp.) by Il-Moo Chang, PhD, and the award recipient in the consumer/popular category is The Plant Hunter: A Scientist’s Quest for Nature’s Next Medicine​ (Viking) by Cassandra Leah Quave, PhD.
  • ABC Norman R. Farnsworth Excellence in Botanical Research Award to Guido F. Pauli, PhD, Distinguished Professor at the University of Illinois at Chicago (UIC) and Norman R. Farnsworth Professor of Pharmacognosy at the UIC College of Pharmacy.
  • The inaugural ABC Steven Foster Botanical Conservation and Sustainability Award given to United Plant Savers (UpS), a community-based nonprofit plant conservation organization. The award recognizes excellence in conservation, sustainability and regenerative agriculture efforts related to medicinal and aromatic plants. It is named in honor of botanist, author and photographer Steven Foster, who died on January 15, 2022, and commemorates his professional interest, writing and advocacy work in this area.
  • ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Max Zeller Söhne AG (“Zeller”), a Swiss company specializing in the development, production and marketing of clinically studied herbal medicines . Zeller is the leading producer of phytomedicines for the Swiss market, according to its website. The company’s history dates back to 1864.


Linked resource

Probiotics for a smooth transition into menopause

In this report, Lumina Intelligence reviews the changing perceptions of menopause, reviews some of the recent scientific studies, and zooms in on what’s currently on offer in this niche.

Tetrahydrophthalic Anhydride Thpa Market Size and Forecast Report, Breakthrough Opportunities, Growth Prospects 2031 | Taiwan News

Latest update: Which industry is the most profitable?

The Thpa Tetrahydrophthalic Anhydride Market Likely to provide excellent yields among main industries and in the world right now that are on their way to becoming the most profitable.

Report Highlights

The Thpa Tetrahydrophthalic Anhydride Market Report Provides a a comprehensive view key elements, including drivers, limitations, historical trends, current trends, technical development and future growth. This report covers both system dynamic approaches and technologies that will give business players an edge over their competitors. This survey report covers key market insights and the industry’s approach to COVID-19 in the coming years.

SMART goals:

The relevant objective of this research is to help the user understand the market. It includes its definition, key supply demand analysis, product specifications, production value, market segmentation (Type, Application and Geography), market potential, influential trends and current market challenges. An in-depth analysis of the projected market value of the global Tetrahydrophthalic Anhydride Thpa on the basis of value and volume.

Please visit: https://market.us/report/global-tetrahydrophthalic-anhydride-thpa-market/

Figure 1: Market Forecast Pictures (2021-2032)

To note: Values ​​marked with XX% are confidential data. To find out more about CAGR numbers, send a mail so that our Business Development Manager can contact you.

The report includes several factors that have contributed to the recent growth of the market. This report gives a 360 degree view of the market. The report also provides detailed statistics on current trends, technological advancements, and tools. The data is organized into chapters for ease of reading and understanding. Each chapter can be divided into segments that contain well-structured information.

The biggest companies in the world [Updated] operating in the global Tetrahydrophthalic Anhydride Thpa market profiled in the report are Denka Chemi, Anhui Meisenbao Chemical, Penpet Petrochemical, Dixie Chemical, Yongsan Chemicals, Hanyong, Puyang Huicheng, NAN YA PLASTICS, Woowon Sea & Air and Xiamen Ditai Chemicals.

Are you a startup ready to go BIG in business? Get an exclusive PDF brochure of this report @ https://market.us/report/global-tetrahydrophthalic-anhydride-thpa-market/request-sample/

The market must grow rapidly

– Geographically speaking, the global Tetrahydrophthalic Anhydride Thpa market can be roughly divided into five regions: North America (NA), Europe (EU), Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SA).

North American country-level analyzes include the United States, Canada and the rest of North America. The Europe Tetrahydrophthalic Anhydride Thpa Market analysis and forecast includes the UK, Germany, France and Rest of Europe markets. In the same way, Asia-Pacific includes India, China, Japan and rest of Asia-Pacific. Middle East and Africa includes Tetrahydrophthalic Anhydride Thpa Market Analysis and Forecast of GCC Countries, South Africa and Rest of Middle East & Africa. The Tetrahydrophthalic Anhydride Thpa market in South America is segmented into Brazil and the rest of South America.

– Due to its large player base, North America held the largest share of the global Tetrahydrophthalic Anhydride Thpa market in 2019. The Tetrahydrophthalic Anhydride Thpa market in Asia-Pacific will grow faster than the rest of the world in the coming years due to the increasing number of players.

Key Benefits for Participants and Industry Stakeholders:

– Market drivers, restraints and opportunities covered in the study

– Neutral outlook on market performance

– Recent industry trends and developments

– Competitive landscape and strategies of key players

– Potential and niche segments and regions with promising growth covered

– Historical, current and projected market size, in terms of value

– In-depth analysis of the Tetrahydrophthalic Anhydride Thpa sales market

Latest Research Studies, Through Flexible and Convenient Payment Methods | Buy this report: https://market.us/purchase-report/?report_id=70147

Key Players Operating in the Tetrahydrophthalic Anhydride Thpa Market

The growing popularity of Tetrahydrophthalic Anhydride Thpa is expected to lead to an increase in demand from major players. Manufacturers offer custom gloves and new quality models. Sellers are working hard to improve the efficiency of their market distribution channels, especially online. Tetrahydrophthalic anhydride Thpa is an active product and its improvement is supported by factors such as technology and innovation.

Some of the major players operating in the Tetrahydrophthalic Anhydride Thpa Market are:

Dixie Chemicals
Penpet Petrochemical
Yongsan Chemicals
Chemicals Xiamen Ditai
Woowon sea and air
Puyang Huicheng
Anhui Meisenbao Chemicals
Denka Chimi

To access more vendor profiles with their key offerings available with Market.us, click here: https://market.us/report/global-tetrahydrophthalic-anhydride-thpa-market/#inquiry

Thpa Tetrahydrophthalic Anhydride Market: Research Scope

The main types of Tetrahydrophthalic Anhydride Thpa are;

97% Purity Type, 98% Purity Type, 99% Purity Type, Others

The main applications of Tetrahydrophthalic Anhydride Thpa are;

Industrial, food, agricultural, pharmaceutical, others

Figure 2 Shown: BBased on geography, the global market for Tetrahydrophthalic Anhydride Thpa has been segmented as follows:

Tetrahydrophthalic Anhydride Thpa Market Size and Forecast Report, Breakthrough Opportunities, Growth Outlook 2031

Some of the critical questions answered in this report

#1: What is the Thpa Tetrahydrophthalic Anhydride market size?

#2: What are the best characteristics of a Tetrahydrophthalic Anhydride Thpa?

#3: What are the Benefits of Buying Thpa Tetrahydrophthalic Anhydride Market?

#4: What are the different types of Tetrahydrophthalic Anhydride Thpa?

#5: What will be the best apps?

#6: Who are the global leading Tetrahydrophthalic Anhydride Thpa companies?

#seven: What are the market driving factors behind the Tetrahydrophthalic Anhydride Thpa Market?

#8: What are the market trends and forecasts for the Global Tetrahydrophthalic Anhydride Thpa Market?

Grab the full detailed report here: https://market.us/report/global-tetrahydrophthalic-anhydride-thpa-market/

Contact our team of market specialists:

Global Business development teams – Market.us

Market.us (Powered by Prudour Pvt. Ltd.)

Send an email : [email protected]

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, USA

Tel: +1 718 618 4351

Website: https://market.us

More market reports: https://www.einpresswire.com/market_us/

Our customers who bought this report also bought the following reports

Car Cover Market Forecast | Future roadmap by 2031


Animal Autoimmune Disease Testing Market Statistics, Opportunities and Reports 2031


Emerging trends in the tablet coating machine market, outlook to 2031


Considerable growth and revenue of the Distributed Amplifier Market by 2031


Plate Heat Exchanger (Plate Heat Exchanger) Market Future Plans and Forecast to 2031


Southern California pharmacists vote to stop work

More than 600 pharmacists and pharmacy workers at Ralphs, Vons, Albertsons and Southern California Pavilions stores could step down following an “overwhelming” vote by members to allow union leaders to call a strike.

No date was set for a strike and negotiations with the stores continued.

United Food and Commercial Workers (UFCW), which represents workers in seven locals, filed unfair labor practice charges against the stores with the National Labor Relations Board, claiming they engaged in
“Unlawful and unjust treatment”.

The charges include retaliating against pharmacists for engaging in union activity, attempts to bribe pharmacists with bonuses rather than negotiate wage increases, and hiring temporary workers to undermine union activity.

The seven locals make up the largest union grocery contract in the country. “Essential pharmacists in Southern California have made their voices heard with this vote,” union locals said in a joint statement Friday.

“This vote gives union leaders permission to call a strike and lays the groundwork for more than 600 pharmacists across California to stand up to protect their rights and ensure they have the ability to serve. their patients and their communities effectively.”

John Votava, a spokesman for Ralphs, told CNS that the store continues to bargain in good faith and that strike authorization does not mean there will be a strike or work stoppage.

“Our company is committed to continuing to bargain in good faith with union locals until an agreement is reached that meets the needs of our pharmacy associates and ensures our customers have access to medications. affordable while maintaining store competitiveness,” Votava said.

Votava called the unfair labor practice allegations a “fear tactic that UFCW can use to strike and disrupt our business, our associates and our communities.” He said the National Labor Relations Board had not investigated the allegations.

“Ralphs follows the law and has not been informed of any wrongdoing,” Votava said.

Albertsons, which owns Pavilions and Vons, did not respond to a request for comment.

Alfa Chemistry launches thiophenes as heterocyclic organic compounds for academic research and industrial manufacturing

New York, United States – July 23, 2022 – Found widely in nature, heterocyclic organic compounds are of paramount importance in medicinal chemistry, the discovery of new drugs in particular. Recognizing the market demand for such chemicals, Alfa Chemistry recently announced the launch of thiophenesa widely varied type of heterocyclic compound for scientists and researchers around the world dedicated to exploring the versatile synthetic applicability and biological activity of thiophenes.

Consisting of a planar five-membered ring and with the molecular formula C4H4S, thiophenes are commonly found in many biologically active compounds. With their substituted derivatives, thiophenes have interesting applications in the planning, organization and implementation of new drug discovery approaches.

“Having been reported to possess a wide range of antibacterial, antifungal, antiviral, anti-inflammatory, analgesic, and antiallergic properties, thiophenes are particularly prevalent among medicinal chemists who often use thiophenes as building blocks to produce a combinatorial library to look for leads molecules,” said an Alfa Chemistry representative. “In addition, thiophenes and their derivatives can also be used as metal corrosion inhibitors or in the manufacture of light-emitting diodes for materials science.”

Overall, the thiophene moiety is attracting great interest in both medicinal chemistry and materials science, thus attracting great interest in industry and academia. Here are some of the thiophenes supplied by Alfa Chemistry:

4,5-dihydro-3(2H)-thiophenone (CAS 1003-04-9), 2-bromothiophene (CAS 1003-09-4), N-tert-butyl-2-thiophenesulfonamide (CAS 100342-30-1), Apafant (CAS 105219-56-5), 4-dibenzothienylboronic acid (CAS 108847- 20-7), Thiophene (CAS 110-02-1), Zileuton (CAS 111406-87-2), 4,6-Dimethyldibenzothiophene (CAS 1207-12-1), Batimastat (CAS 130370-60-4), Dibenzothiophene (CAS 132-65-0), 2-benzoylthiophene (CAS 135-00-2), 2-bromo-3-methylthiophene (CAS 14282-76-9), tiotropium bromide hydrate (CAS 139404-48-1) , prasugrel (CAS 150322-43-3), Pizotifen (CAS 15574-96-6), Bethoxazine (CAS 163269-30-5), 3-thienylmethylamine (CAS 27757-86-4), ethyl-thiophene-2-carboxylate (CAS 2810-04-0), 2-thiophenecarboxylic acid (CAS 527-72-0), 5-bromothiophene-2-sulfonamide (CAS 53595-65-6), 3-chlorothiophene-2-carboxylic acid (CAS 59337-89-2), 2-nitrothiophene (CAS 609-40-5), etc.

Please visit the website https://www.alfa-chemistry.com/products/thiophenes-203.html to learn more.

About Alfa Chimie

Market-oriented and customer-centric, Alfa Chemistry has become a chemical supplier widely recognized by pharmaceutical companies, universities and research institutes around the world. Although this year is halfway through, Alfa Chemistry continues to intensify its efforts to enrich its supplies and offerings. Currently, a full range of chemicals and materials are readily available on the market, including but not limited to surfactants, ionic liquids, functional polymers, MOFs, polymer stabilizers , pheromones, organic silicon, semiconductor materials, reagents and graphene. More recently, a large number of heterocyclic compounds have been introduced to support academic and commercial research of a new generation of biologically active compounds.

Media Contact
Company Name: Alpha Chemistry
Contact person: Tylor Keller
E-mail: Send an email
Call: 1-516-734-6573
Country: United States
Website: https://www.alfa-chemistry.com

Irish history: 10 often overlooked game changers

Their names may not travel the world the way Oscar Wilde, Seamus Heaney or even Colin Farrell did, but that doesn’t mean these ten Irish historical figures haven’t had a global impact.

* This article was originally published in Welcome Ireland. Subscribe here.

Dr. James Barry (aka Margaret Ann Baukley) (1789 – 1865)

James Barry, painted between 1813 and 1816. (Public domain)

Dr James Barry was born in Cork, joined the British Army and became a renowned surgeon, performing the first successful Caesarean section operation where mother and child survived. Dr. Barry also became Inspector General of Military Hospitals and was widely known for improving conditions for wounded soldiers.

However, Dr. Barry is often known as the doctor who deceived the British Empire. Although posing as a man, Dr. Barry’s true identity was Margaret Ann Baukley. Her identity was not revealed until her death, but it made her the first fully qualified female doctor in Britain. Quite a feat, in more ways than one.

Maud Gonne (1866 – 1953)

Maude Gonne McBride.  (Public domain)

Maude Gonne McBride. (Public domain)

Maud Gonne, married Maud MacBride, was an actress, famous Irish patriot, feminist and one of the founders of Sinn Féin. She also turned down several marriage proposals from writer WB Yeats over the years.

She was passionate about Irish politics and as a result became a lecturer for the Land League, founded the Daughters of Ireland (a nationalist organization), while playing the role of heroine in one of Yeats’ early plays in the Abbey Theater in Dublin. . She had a huge impact as a revolutionary and was the mother of three children, including Nobel Peace Prize laureate Seán MacBride.

Lady Jane Wilde (1821 – 1896)

1896 – Lady Jane Wilde (Speranza), poet, nationalist and mother of Oscar, dies in London. pic.twitter.com/MefhAgrvVb

— National Library of Ireland (@NLIreland) February 3, 2016

The recognizable surname very clearly links her to her (somewhat famous) son Oscar, but Wexford’s wife, Jane, was also an important figure in the 19th century. She was a talented poet who published work under various names, including “Speranza”, and was also a women’s rights activist.

As well as documenting the famine and her work as an active nationalist calling for armed revolution in Ireland, her life took a dramatic and tragic turn, and within a few years she lost her daughter, her husband, his house and all his money. And then her son Oscar went to jail.

* This article was originally published in Welcome Ireland. Subscribe here.

Sir Hans Sloane (1660 – 1753)

A 1736 portrait of Sir Hans Sloan by Stephen Slaughter.  (Public domain)

A 1736 portrait of Sir Hans Sloan by Stephen Slaughter. (Public domain)

Although he looks vaguely like a character from Die Hard, we have this Irishman to thank for the chocolate. Yes, you read that right. He was an Irish-born doctor who served in the British Navy in the Caribbean. He was introduced to cocoa as a drink while in Jamaica, but found it not very palatable, so he mixed it with milk. Do you see where he is coming from?

He brought his ‘exotic’ recipe back to the UK where eventually the Cadbury family started replicating the mix. What a man. Incidentally, he also founded the British Museum, took his name to many streets in London, and succeeded Sir Isaac Newton as President of the Royal Society. But chocolate does it for us.

Eva O’Flaherty (1874 – 1963)

‘Portrait of Miss Eva O’Flaherty at Achill’ ~ Derek Hill, (1947)

Head and shoulders of a seated woman with gray hair and glasses looking left at a book, background is cream and gray with brown. pic.twitter.com/ud6xsEQcHB

— Hugh Lane Gallery (@TheHughLane) October 21, 2021

From Hans Sloane to Sloane Street, milliner and fashion icon Eva O’Flaherty lived on Achill Island for much of her life, but spent time founding a textile business and making hats for the London toast. She was also the founder of Ireland’s oldest summer school, Scoil Acla.

His friends including WB Yeats, Constance Markievicz, Douglas Hyde and Padraig Pearse visited him on Achill. A place at one of his parties would certainly have resulted in encounters with Irish celebrities.

Rosie Hackett (1892-1976)

Rosie Hackett.

Rosie Hackett.

Admittedly, yes, Rosie Hackett has a bridge named after her (in 2014 a shortlist of names for the bridge connecting Marlborough Street and Hawkins Street was voted on, and Rosie came out on top) but she flew somewhat under the radar until then, despite his incredible accomplishments.

When she was just 18, she helped organize a strike of 3,000 workers at Jacobs Biscuits. Later she co-founded the Irish Women Workers’ Union (IWWU) with Delia Larkin, and she was active in the 1916 uprising, occupying Stephen’s Green alongside Constance Markievicz.

Dr. William Brooke-O’Shaughnessy (1809 -1889)

Dr. William Brooke-O'Shaughnessy.  (Public domain)

Dr. William Brooke-O’Shaughnessy. (Public domain)

Born in Limerick in 1809, O’Shaughnessy was incredibly intelligent so was sent to study medicine at the University of Edinburgh in 1827. After graduation he moved to London and began working on blood analysis people with cholera.

His studies led him to cure cholera when he discovered that by replacing lost salt and water intravenously, the disease would cease.

He published several medical textbooks on chemistry and herbal medicine, and was also the first scientist to introduce cannabis into Western medicine. He was responsible for the invention of a type of telegraph cable, better suited to hot temperatures, and for this discovery he was knighted by Queen Victoria in 1856.

Agnes Clerke (1842 – 1907)

1905 photograph by Agnes Clerke.  (Public domain)

1905 photograph by Agnes Clerke. (Public domain)

Born in Skibbereen, County Cork, Agnes Clerke used her father’s telescope to observe the stars in the sky as a child, taking an interest in astronomy from an early age. Years later, his book, “A People’s History of Astronomy” was published, and is even now considered one of the seminal texts on the subject.

She won plenty of accolades, the type of which was (unfortunately and unfairly) reserved for men at the time. And in 1981, NASA named a crater on the Moon after it, near where Apollo 12 landed.

John Tyndall (1820 – 1893)

John Tyndall.  (Public domain)

John Tyndall. (Public domain)

John Tyndall, originally from Co Carlow, was an Irish experimental physicist, who literally discovered (and explained) why the sky is blue. His scientific interests were in everything from heat to sound to light, as well as environmental phenomena. He discovered the scattering of light by small particles suspended in the atmosphere, and the resulting color is known as Tyndall Blue.

On top of that – and as if that weren’t enough – he was the first to realize the greenhouse effect of certain gases on global warming, and thus several modern climate change institutes bear his name.

Mary Edgeworth (1767-1849)

Maria Edgeworth.  (Public domain)

Maria Edgeworth. (Public domain)

Edgeworth’s name does not seem to make it onto lists of the great names in Irish literature, despite the fact that she was one of the most successful novelists of her generation. Jane Austen was among many fans of her writing, and she was one of the first writers to portray the Irish “peasant class” as real people.

Four of her best-known Irish novels include ‘Castle Rackrent’ which she wrote in 1800, ‘Ennui’ from 1809, ‘The Absentee’ (1812) and ‘Ormond’ (1817), all of which were political novels that tested the legitimacy of land ownership. His work has been compared to iconic works like “Don Quixote” and “Gil Blas”.

* This article was originally published in Welcome Ireland. Subscribe here.

facebook story
Irish Central History

Do you like Irish history? Share your favorite stories with other history buffs in the IrishCentral History Facebook group.

Discrimination of Curculigo orchioides Rhizoma and Curculigo glabrescens Rhizoma using stable isotope and mineral element analyzes coupled with chemometrics

HPLC Feature Generator

Chemical characteristics can be used to describe and evaluate medicinal substances as a whole. The HPLC method has good accuracy, sensitivity and reproducibility, and can be used to quickly and specifically identify different herbs based on overall chemical composition. The HPLC chromatograms of COR and CGR are shown in Fig. 2. Component identities were confirmed based on retention time and UV spectra (285 nm) of chemical markers. The main chemical components of COR and CGR were similar. As expected, the content of curculigoside (peak 1), the indicator component of COR, was not significantly different from that of CGR. Interestingly, CGR contains a unique compound that was detected in HPLC chromatograms, but was not found in the COR profile. Therefore, this unique compound was specifically separated and purified, and the structure was identified by modern spectroscopic techniques. This was a new compound determined to be 5-(3′,4′-dihydroxyphenyl)-1-(4″-hydroxyphenyl)pentane-1,4-dione, 1D and 2D NMR spectra were available at Figs. S1 – S5. However, the low content of this compound was not sufficient to accurately distinguish between two plant sources.

Figure 2

High performance liquid chromatography (HPLC) chromatogram of curculigoside, COR and CGR samples. Peak 1: curculigoside.

Variations in the stable isotope ratios of COR and CGR

The variations of the stable isotopic compositions between COR and CGR have been presented in Fig. 3. Mean N% values ​​in COR and CGR samples were 1.898% and 0.720%, N% values ​​in COR were significantly higher (Fig. 3a). The mean C% values ​​of the COR and CGR samples were 40.052% and 39.998%, respectively (Fig. 3b). The average δ15The COR N value was -3.157‰, which was significantly lower than the CGR value, with a mean value of -0.173‰ (Fig. 3c). The average δ13The COR C value was -28.678‰, which was significantly higher than the CGR value, with a mean value of -31.487‰ (Fig. 3d). There were significant differences in the mean value of N%, δ15N and δ13C according to botanical origins (all PJ -test).

picture 3
picture 3

The relative content of element N (N%, a), element C (C%, b) and the nitrogen isotope ratio (δ15NOT, vs) and the carbon isotope ratio (δ13VS, D). Data were expressed as mean ± SD. (**P

The 3D point cloud of N%, δ15N and δ13The C values ​​have been presented in Fig. 4, and they showed excellent ability to predict COR and CGR. Overall, the COR had a high N% and δ13C, and a low δ15N value, so they gathered in the upper section of the 3D chart. However, the CGR, on the other hand, mainly appeared at the bottom. The stable isotope ratio shows a good effect to distinguish different sources of Curculigo Rhizome.

Figure 4
number 4

3D point cloud of N%, δ15N and δ13C values ​​in COR and CGR.

Analysis of mineral elements

The mineral element contents in the COR and CGR samples are shown in Table 1. The results appeared to be significantly different between the two source species except for B, Mg, K, Ca, Cu, Se, Ba. K and Ca were the most abundant inorganic elements in COR and CGR. The contents of Li, Al, Mn, Co, Ni, Zn and Cd were higher in the COR than in the CGR, while the concentrations of the elements Na, Ti, Fe, Sr and Mo were present at a lower level in the COR samples.

Table 1 Average mineral element concentrations (μg/g) of 10 COR samples and 9 CGR samples.

Principal component analysis of COR and CGR

Multivariate assessment is needed to improve the overall accuracy of COR and CGR. Based on the chemical analysis of the stable isotope ratios combined with the concentrations of 19 mineral elements, the result of the PCA analysis has been presented in Fig. 5a. The vectors and the cumulative contribution of the variance of the first three PCs (PC1-3) have been presented in Table S3. A three-factor model (the top three PCs with eigenvalues ​​>1) can explain 88.0% of the total variability in the original data, which showed that the top three PCs can reflect most of the information in the samples. PC1, PC2 and PC3 contributed 61.0%, 19.8% and 7.2% of the total variance respectively. The result showed that 10 COR samples grouped together and 9 CGR samples grouped into another category. It was presented that COR and CGR samples can be well distinguished by PCA. Notably, three batches of COR from Yunnan tend to be distinguished from Sichuan.

Figure 5
number 5

PCA ranking result. Scatter plots of the COR and CGR samples (a), PCA biplot for components PC1 and PC2 (b).

The PCA biplot of PC1 and PC2 has been shown in Fig. 5b. PC1 was mainly correlated with N% intensity, δ13C, Li, K, Mn, Co, Cu, Zn, Se, Cd and negatively correlated with δ15Signal N, Sr, Mo35.36. The intensity of B, Al, Fe, Ni, Ba was significant in PC2. COR samples (1–7) from Sichuan were mainly affected by the content of N% and elements Li, K, Mn, Zn, Co, Cd, while COR samples from Yunnan (8–10) were isolated. PC1 had a better ability to discriminate COR samples. However, CGR samples (11–19) were clustered with δ15N, Ti, Sr, Mo. The classification of RGCs was related to the content of these elements and can be distinguished by them. Plant metabolic activities were found to have a greater impact on the δ content13C that environmental factors24.26. Therefore, the difference between COR and CGR samples may be due to the different elements accumulated in plant metabolism.

Identification of COR and CGR by OPLS-DA

To further utilize the potential discrimination capability of stable isotope and phased array analysis, OPLS-DA was used to process the data of COR samples and counterfeit CGR samples, and the result was shown in Fig. 6. Genuine COR samples and counterfeit CGR samples were significantly differentiated, indicating that stable isotope ratios and element contents combined with OPLS-DA analysis was an effective method to separate COR and CGR samples . The number of important components is determined by calculating the explained variance X (R2X), deviation Y (R2Y), and the predictive ability of cross-validation (Q2) 37. The evaluation parameters of the OPLS-DA prediction models were: R2X = 0.800, R2Y = 0.993, Q2 = 0.991. Generally, the model has good fit when these values ​​are close to 1.0, the point of intersection of R2 and Q2 with the Y axis must be less than 0.3 and 0.05 respectively, and the difference between R2 and Q2is less than 0.338.39. Therefore, the results showed that this OPLS-DA model was reliable. In addition, VIP > 1 was considered a good identification marker27,34,40and OPLS-DA provided 13 effective potential markers (δ15N, Cd, Sr, δ13C, N%, Co, Se, Ti, Zn, Li, Cu, Mn, K) to determine the authenticity of COR samples and counterfeit CGR samples (Fig. S7). Notably, the three CORs from Yunnan were also separated from the COR samples from Sichuan based on their stable isotope ratios and element contents by the OPLS-DA model. The results indicated that stable isotope ratios combined with element contents may have the potential ability to predict the geographic origin of CurculigoRhizome. Based on these advantages, stable isotope ratios and element contents combined with OPLS-DA analysis provide an excellent method for discriminating COR and CGR samples.

Figure 6
number 6

Result of the OPLS-DA classification. Score charts showing the classification of genuine COR and counterfeit CGR samples.

Classification of Curculigo Rhizoma using LDA

To verify the reliability of the classification model, LDA was performed using a cross-validation procedure to calculate the classification and probability of the COR and CGR samples.23.28. The cross-validation result was displayed in Table 2. The LDA model gave a good classification rate (100%) and the cross-validation rate (100%), COR and CGR were identified successfully. So the predictive model worked well, LDA analysis combined with stable isotopes and elements could be used to discriminate the two source species of CurculigoRhizome.

Table 2 Classification of COR and CGR samples based on discriminant analysis.

Twenty unanswered questions: a college interviews a UTI pilot


“In the interest of patient safety”, the RACGP has again urged Queensland Health to reconsider its decision to continue prescribing UTIs in pharmacies.

The Queensland Government has made the decision to continue the trial indefinitely.

The RACGP has submitted a full critique of Queensland Health’s decision to make the UTI pharmacy prescription trial permanent.

The document, sent to Queensland Health’s acting chief executive this week, raises a host of high-profile questions, including unanswered questions about the protocol and the evidence collected.

“We are very concerned that the proposed health policy reforms have been decided on the basis of such poor quality evidence and are resulting in poor health outcomes for patients,” said the document, signed by RACGP Vice President and Queensland President, Dr Bruce Willett, States.

“We strongly urge the Queensland Government to reconsider this decision as a matter of priority, so that patient safety is not further compromised.”

Key issues are summarized in 20 questions, which highlight issues ranging from trial protocol to antimicrobial stewardship concerns.

The submission also challenges the results of a 118-page review of the Urinary Tract Infection Pharmacy Pilot Trial (UTIPP-Q) – authored by Professor Lisa Nissen of Queensland University of Technology, who also oversaw the implementation of the trial – which started in June 2020 for 18 months and was extended until the end of June.

The much-sought assessment was first published earlier this month, days before Queensland Health confirmed the trial would continue on a permanent basis.

The college criticized the ability to contribute to counseling following the decision to continue prescribing as being “severely limited”.

“The RACGP believes that these comments should have been undertaken prior to announcements from the Queensland Government regarding the continuation of this arrangement,” the document said.

The issue of antimicrobial stewardship features prominently in the submission, as does the lack of external regulatory oversight.

‘The pharmacist will not perform this [antimicrobial stewardship] role if they prescribe,” the college states.

‘[The Queensland] The government has not provided a legislative mechanism to provide external regulatory oversight for pharmacists who prescribe, meaning there is no avenue by which inappropriate prescribing can be reviewed.

The college also urges pharmacists ‘to be held to the same standard as GPs if they provide similar services’.

Fragmentation of care is another issue raised, with the RACGP asking the state government how record-keeping requirements will be maintained.

The submission also raises an imbalance in prescribing activity, pointing out that of the 817 pharmacies that participated, only five provided around 10% of the scripts during the pilot.

“This is certainly an outlier group to which the report offers little or no explanation,” he says.

Concerns about possible conflicts of interest are being raised, with the college warning that “commercial interests can influence the health advice provided by pharmacists”.

“The report indicates that half of the pharmacists surveyed find it difficult to charge a $19.95 service fee when they do not provide the antibiotic,” the brief states.

“If pharmacists can only feel comfortable recouping their service costs when prescribing, this risks significantly over-prescribing [the report shows 96% of women received antibiotics].

“This cannot be ignored and demonstrates potential for further overprescribing now that it has become permanent.”

A series of questions are asked about the scheme’s adherence to Pharmacy Board recommendations on prescribing, including managing conflicts of interest, access to patient records and ensuring independent checks and balances.

The submission also seeks clarification from the Queensland Government on the education and training of pharmacists providing the UTI prescribing service.

He cites unease surrounding the number of interns, new graduates or first-year pharmacists “with limited pharmacy experience” who may prescribe for UTIs and gather clinical information.

Concerns about patient outcomes
A “major flaw” in the trial, according to the college brief, is the lack of any process to assess whether there was a urinary tract infection in the first place, and whether an antibiotic was needed or whether the appropriate antibiotic was prescribed.

The evaluation report shows that 13% of those who responded to follow-up did not have their symptoms resolved.

“The failure to resolve UTI symptoms in 13% of ‘uncomplicated’ cases is clinically significant,” states the college’s submission.

Among the concerns raised about the protocol is the detail, included in the assessment, that 43 patients were not referred to a GP “even though they had reported to the pharmacist that they had not had resolution of their symptoms and had not sought further care”.

There were also 40 women who sought additional care outside of general practice, according to data collected from follow-up queries.

“The study did not provide information on where these women sought care, although it appears that at least four of them voluntarily stated that they went to a service urgently”, declares the RACGP in its brief.

“Presumably many, if not all, of the remaining women also attended an emergency department.”

Another cause for concern is that 112 patients who had unresolved symptoms and saw a GP were given another antibiotic.

“The study says this is consistent with normal UTI management; however, the study does not specify what type of antibiotics were administered or their indication,” she says.

“Many, if not all, of these antibiotics may have been given to treat STIs or other non-urinary conditions that were not diagnosed by the pharmacist.

“If so, then the search was incomplete and did not correctly identify the unwanted results.”

The report mentions that a urine test was not carried out in 52 of the 144 patients who consulted a GP with unresolved symptoms.

“This suggests that 36.1% of people who subsequently saw their GP may have had an obvious non-urinary cause for their symptoms and were inappropriately prescribed antibiotics by the pharmacist,” the college states.

“The GP was left to manage treatment failures.”

In its submission, the RACGP requests a further meeting with the Queensland Government and Queensland Health to discuss the concerns raised.

The full document can be read on the RACGP website.

Log in below to join the conversation.

Queensland Health UTI pharmacy prescribing UTIQ-PP trial

newsGP weekly poll
Which patients should be able to access Medicare reimbursements for longer phone consultations (>20 minutes)?

Millions of Indonesians use Chinese medicines to fight a wide variety of symptoms

Traditional Chinese medicine is packed at the Ban Seng medicine store in West Jakarta, Indonesia, February 5, 2020. [Photo Provided to CHINA DAILY]

Lily Heru and her husband still use traditional Chinese medicine when they feel unwell.

The well-educated couple, who run a textile and clothing store in West Jakarta, Indonesia, use the herbal medicine Lian Hua TCM for headaches, sore throats, coughs and also to relieve fatigue after a stressful day.

They are among millions of Indonesians, regardless of background, who believe in the effectiveness of traditional Chinese medicines, herbal remedies and supplements, commonly known as obat cina. These items are said to be effective in curing minor ailments and killing or stopping the spread of a particular type of bacteria and virus that cause serious illnesses.

As in other Southeast Asian countries, traditional Chinese medicines and herbal remedies have been popular in Indonesia for hundreds of years.

According to historians, Chinese doctors first settled in the archipelago in the 16th century after the arrival of Admiral Cheng Ho, a Muslim and special envoy to the Chinese emperor. Indonesians believe that the Admiral played a role in the development of Islam in Southeast Asia.

The latest evidence of TCM’s strong presence in Indonesia was found at this year’s 39-day Jakarta Fair trade exhibition, which ended on Sunday. Visitors to the popular annual exhibition could easily access TCM booths capable of accommodating a dozen visitors at a time.

The displays included those of the country’s largest TCM importer, Saras Subur Abadi, and SOHO Indonesia Pharmasi, one of its largest producers of traditional medicines.

These two companies and many others have exhibited their medicines, herbal remedies and supplements at the Jakarta fair in previous years, but not in the past two years due to the COVID-19 pandemic. This year, at Saras Subur Abadi’s stand, sales representatives met the needs of consumers in the 15 cities in Indonesia where its products are sold.

In addition to traditional herbs and medicines, cars, household appliances, furniture, electrical items, handicrafts, banking and service products and cosmetics are sold at the Jakarta fair, where some 2,500 businesses have stalls.

A recent visit to the exhibition found a number of potential customers at TCM booths displaying items such as Lo Han Juo, Fufang Ejiao Jiang and Yunnan Baiyao, which are designed to fight fever and sore throat, maintain the immune and gastrointestinal systems and heal wounds. .

A woman who bought Zheng Gu Shui at the Saras Subur Abadi stall said she would rub the ointment on her young son’s bruised limbs. She said her family uses traditional Chinese medicine as an alternative to traditional Indonesian medicines and more expensive “modern” medicines which are also on display at the exhibition.

In many parts of Indonesia, TCM products are sold in pharmacies, along with other pharmaceutical products.

A pharmacy owner in the northeastern city of Manado said the majority of customers in the region use TCM for heart failure and also for less serious illnesses.

Pien Tze Huang was among the most popular and expensive products offered by Saras Subur Abadi at the Jakarta fair. Consumers have reported that Pien Tze Huang can be taken on prescription by TCM practitioners or “modern” doctors, and that it helps cure infection after a C-section and also helps liver function.

According to a widely held TCM theory, Pien Tze Huang disperses body heat, cleanses toxins, promotes blood circulation, and relieves swelling and pain.

Marthina Narvathirosa, public relations manager at Saras Subur Abadi, said Fufang Ejiao Jiang is also selling well in Indonesia because it helps speed up the recovery of dengue fever patients. Indonesians usually buy this product for family members who have this disease, and doctors say that it significantly helps increase peripheral blood cells and mononuclear cells needed by these patients.

Since TCM products are effective in treating diseases, curing patients and helping the human body function, the Indonesian government has long permitted the import and consumption of TCM and related ingredients.

However, the authorities have strictly controlled the imports of these products since 2009, about eight years after the establishment of the Indonesian food and drug monitoring agency.

In mid-2020, as COVID-19 cases and related deaths in Indonesia began to rise significantly, fears over the growing number of fake drugs prompted authorities to impose even tighter controls on imports. TCM, including Lianhua Qingwen capsules.

Many sources said that this traditional Chinese medicine helps patients with COVID-19 by dispersing fever, eliminating toxins and improving lung ventilation.

Narvathirosa urged people to be smarter when buying MTC. She said they should make sure that the products they buy are registered with the authorities, that the information on the packaging is printed in Indonesian and that these products are imported by a reliable company.

Widespread recognition of the effectiveness of traditional Chinese medicine and other traditional medicines and supplements prompted the then President, Soesilo Bambang Yudhoyono, to promote studies of traditional medicine at Indonesian universities, including public institutions. leading such as Universitas Indonesia in Jakarta, Universitas Gajah Mada in Central Java, Universitas Airlangga in East Java and Universitas Hasanuddin in South Sulawesi.

Some private universities have also implemented traditional herbal medicine studies with TCM as part of their degree programs.

Roshamur Cahyan Forestrania, a professor at the Faculty of Pharmacy, Universitas Indonesia, said the institution offers a master’s program in herbal medicine. “TCM is covered in our ethnomedicine and ethnopharmacology conferences, but it’s not yet taught in specialist classes,” she said.

The school invites lecturers who are experts in TCM to speak in its courses and during the public seminars it organizes.

Forestrania, who obtained her doctorate in phytochemistry and pharmacognosy from Ohio State University in the United States, said that an increasing number of new students are studying at the herbal pharmacy school of Universitas Indonesia, partly because its teachers, including foreigners, are highly qualified and also because the school has excellent facilities.

However, she said the number of students has decreased because many of them want to put their knowledge into medical practice.

This is understandable, as TCM practices are becoming more prevalent in Indonesia and are a lucrative business. There is even a TCM department store about 200 meters from the presidential palace complex in Jakarta, near the city center.

Traditional Chinese medicine shows promise in treating lung cancer

The chemical berberine, which is found in the root of barberry (pictured above), is said to have health-promoting properties.

The natural compound berberine, found in plants like goldenseal and barberry, shows promise for treating lung disease.

According to a recent study, the natural compound berberine, found in plants like goldenseal and barberry, inhibits the growth of lung cancer cells in the laboratory. It also reduces airway inflammation and reduces damage to healthy lung cells exposed to toxins from cigarette smoke.

Approximately 1.8 million lung cancer deaths are reported each year, making it the leading cause of cancer-related death worldwide. Chronic inflammation increases the risk of lung cancer and other disorders, including chronic obstructive pulmonary disease (COPD) and asthma.

“Berberine has shown therapeutic benefits for diabetes and cardiovascular disease. We wanted to explore its potential in suppressing lung cancer and reducing inflammation,” says lead researcher Dr. Kamal Dua, senior lecturer in pharmacy at the University of Technology Sydney (UTS).

Doctor Kamal Dua

Dr. Kamal Dua in the UTS lab. Credit: Barnaby Downes/UTS

In a study recently published in the journal Pharmacy, the impact of berberine on non-small cell lung cancer was assessed. It demonstrates that berberine has significant anti-cancer activity, suppressing cancer cell growth in vitro.

By assessing tumor-associated gene mRNA levels and protein expression levels, the potential mechanism of action for anti-cancer efficacy was identified. He demonstrated that berberine regulates proteins involved in cancer cell migration and proliferation while upregulating genes known to decrease tumor growth.

The study follows research conducted by Dr. Dua that was recently published in the journal Antioxidants and demonstrated that berberine can inhibit oxidative stress, reduce inflammation, and slow cellular senescence caused by cigarette smoke extract in laboratory-grown healthy human lung cells.

Professors Phil Hansbro, Brian Oliver, Bikash Manandhar and Keshav Raj Paudel were also part of the research team. International colleagues from Qassim University in Saudi Arabia and the International Medical University of Malaysia also contributed.

Dr. Dua focuses on exploring the healing potential of traditional herbal medicines and how their active compounds work at the cellular level. He has a multifaceted research background with experience in drug delivery technology, biomedical sciences, immunology and microbiology.

Berberine has a long history of use in traditional Chinese and Ayurvedic medicine, however, its therapeutic benefits have been limited by its lack of water solubility and intestinal absorption, as well as its toxicity at higher doses. .

To overcome these challenges, Dr. Dua developed the use of liquid crystalline nanoparticles, an advanced drug delivery system that encapsulates berberine in tiny, soluble, biodegradable polymer beads to improve safety and efficacy.

Decades of research have shown that cigarette smoke is toxic to lung cells, causing airway inflammation and accelerating diseases such as cancer, chronic obstructive pulmonary disease (COPD) and asthma.

Researchers have found that berberine suppresses the generation of inflammatory chemicals, called reactive oxygen species, which cause damaging effects on cells. It also modulated genes involved in inflammation, oxidative stress and reduced premature cell senescence.

Dr. Dua is now in discussion and working closely with Sydney-based companies to take this research to the next level and identify the best formulation and delivery system for these nanoparticles so they can be translated to the bedside of the patient.

References: “Evaluation of cytotoxic activity and anti-migratory effect of berberine-phytantriol liquid crystalline nanoparticle formulation on non-small cell lung cancer in vitro” by Abdullah M. Alnuqaydan, Abdulmajeed G. Almutary, Mohd Azam, Bikash Manandhar, Geena Hew Suet Yin, Lee Li Yen, Thiagarajan Madheswaran, Keshav Raj Paudel, Philip M. Hansbro, Dinesh Kumar Chellappan and Kamal Dua, May 24, 2022, Pharmacy.
DOI: 10.3390/pharmaceutics14061119

“Attenuation of cigarette smoke-induced oxidative stress, senescence and inflammation by berberine-loaded liquid crystalline nanoparticles: an in vitro study in 16HBE and RAW264.7 cells” by Keshav Raj Paudel, Nisha Panth, Bikash Manandhar, Sachin Kumar Singh, Gaurav Gupta, Peter R. Wich, Srinivas Nammi, Ronan MacLoughlin, Jon Adams, Majid Ebrahimi Warkiani, Dinesh Kumar Chellappan, Brian G. Oliver, Philip M. Hansbro and Kamal Dua, April 28, 2022, Antioxidants.
DOI: 10.3390/antiox11050873

Three possible courses of action against regulated professionals | Nexsen Pruet, SARL

The recent criminal prosecution of nurse RaDonda Vaught in the state of Tennessee for a medication error has renewed questions about what action can be taken against a regulated professional when an unexpected outcome occurs. Now is a great time to review the three different courses of action parties can take and the types of relief each course offers.

1. Administrative complaint

The first and most common action is an administrative complaint against a professional license. In the state of South Carolina, anyone can file an informal complaint against a professional licensed by the Professional and Professional Licensing Commissions administered by the Department of Labor, Licensing and Regulation. LLR is the firm’s apex agency that administers the 42 councils responsible for regulating nearly every profession in our state except for lawyers, teachers, and mortgage loan officers, which is quite different from other jurisdictions. Due to differences between the laws of South Carolina and other states in which professionals may also be licensed, it is easy for professionals to violate an administrative requirement.

LLR’s mission is to protect the general public, rather than provide relief to any particular party. LLR, on behalf of the State, is the interested party in all cases where a formal complaint is opened. LLR bears the burden of proving any allegation made against a licensee by the preponderance of the evidence.

LLR investigators are not law enforcement officers and cannot arrest a licensed professional accused of violating applicable practice law. Although LLR investigators can issue subpoenas and interview witnesses during an investigation, they do not have the authority to issue warrants to seize documents or enter businesses without authorization, except in a few circumstances. limited. Only a few councils have the authority to inspect a licensed business, such as barbers, cosmetology, dentistry, and pharmacy. Statements provided to LLR investigators may be provided to law enforcement if they indicate a crime has been committed, and LLR often works with other regulatory entities.

If a licensee is found to have violated a law of practice, a civil penalty may be imposed, in addition to restrictions on the individual’s ability to practice their profession, as well as educational requirements complementary or remedial. All fines collected in an LLR case are remitted to the State of South Carolina, rather than the person who filed the complaint.

2. Civil litigation

A party alleging bodily injury or property damage against a licensed professional may also seek financial or other relief through civil litigation. In these cases, the person who initiates the complaint is the interested party and bears the burden of proof. If the claimant prevails, it may be entitled to recover monetary compensation, specific performance, or other equitable relief, depending on the nature of the claim.

Lawyers engaged in civil litigation use the discovery process to develop their cases. Some discovery tools include written interrogations, applications for admission, subpoenas and depositions. Although attorneys may coordinate site inspections during the discovery process, attorneys do not have the authority to enter an opposing party’s property without permission or a court order for an inspection during litigation.

3. Criminal prosecution

Finally, in some cases, the conduct of a licensed professional may be reported to law enforcement for investigation and, if appropriate, criminal prosecution. As with administrative action, the author of a criminal prosecution is the State, which replaces the injured party for the purposes of the prosecution. The state must prove a criminal charge beyond a reasonable doubt. The state has power not available to parties in administrative and civil actions, including the ability to arrest individuals, issue search warrants and seize property. The penalty in a criminal case can range from a fine and probation, to restitution, to a long period of detention, depending on the charges. Entering a guilty plea or finding of guilt for certain offenses automatically violates several professional practice statutes and triggers the requirement to report the conviction to the licensing board.

New Telangana TS ECET Exam 2022 Release Date; Admit card July 28

Revised TS ECET 2022 Exam Schedule Released

TS ECET 2022: Jawaharlal Nehru Technological University (JNTU) Hyderabad has announced the revised exam date for the Telangana State Common Entrance Engineering Test (TS ECET) 2022. JNTU will be holding the TS ECET 2022 exam now on 1st of August. Applicants will need to upload revised venue tickets starting July 28. Revised Telangana ECET 2022 Schedule is available on the official website — ecet.tsche.ac.in. The entrance exam was previously scheduled to take place on July 13, 2022.

Recommended: Download TS ECET Free Examples of Past Year Papers. Click here
Recommended: NIT placements: less than 80% of BTech students placed in the best NITs over 5 years. Read more

The ECET 2022 entrance exam for admission to engineering courses will take place in two shifts. The first shift is scheduled from 9 a.m. to 12 p.m. and the second shift is scheduled from 3 p.m. to 6 p.m. The duration of the exam will be 180 minutes (3 hours). JNTU Hyderabad is conducting the TS ECET Examination 2022 on behalf of the Telangana State Council of Higher Education (TSCHE). The exam is held for side entry admission into BE, BTech, BPharma courses at universities and non-assisted private vocational institutions.

TS ECET 2022 New Schedule

Events Date
TS ECET Exam Date 2022 August 1, 2022
Revised Hall Tickets TS ECET 2022 July 28, 2022

Paper pattern TS ECET 2022

For degree courses

Topics Brands
Math 50
Physics 25
Chemistry 25
Engineering paper (including civil, electrical and electronics, mechanical, electronics and communication, computer science and others) 100
Total 200

For BSc Mathematics

Topics Brands
Math 100
Analytical capacity 50
Communicative English 50
Total 200

For pharmacy lessons

Topics Brands
Pharmacy 50
Pharmaceutical chemistry 50
Pharmacognosy 50
Pharmacology & Toxicology 50
Total 200

Efficacy of treatment combining salmeterol and magnesium isoglycyrrhizinate in rats with chronic obstructive pulmonary disease

Preparation of MgIG and other drugs

MgIG injection was purchased from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Lianyungang, China). The main chemical composition of this product is MgIG, with the molecular formula of C42H60MgO164 hours2O. Sal (CAS: 89365-50-4) was purchased from LGM Pharma with a purity of 99% and a molecular formula of C25H37NOPE4. Salmeterol xinafoate and fluticasone propionate powder for inhalation (50 μg: 250 μg) were purchased from Glaxo Operations UK Limited. All drugs were stored at 4°C before use.

COPD and MgIG treatment rat model

Male Wistar rats (body weight, 180 ± 20 g; age, 6-8 weeks) were supplied by Charles River Laboratory Animal Technology Co., Ltd. (Pinghu, China) (Certificate No. SCXK (Zhe) 2019e001). Experimental procedures involving the use of animals were in accordance with the guidelines for animal experimentation of Jiangsu Vocational College of Medicine. The protocol was approved by the Animal Ethics Committee of Jiangsu Vocational College of Medicine. All animals were reared under standard environmental conditions and fed a standard laboratory diet and tap water ad libitum.

COPD model in rats was established by smoking and endotracheal atomization (ETA) of lipopolysaccharide (LPS) endotoxin according to previous reports20. The rats were randomly divided into groups (10 rats in each group): control group (CON), COPD model group (MDL), salmeterol xinafoate group (Sal), MgIG group (MgIG), salmeterol xinafoate group and MgIG (Sal/MgIG), salmeterol xinafoate group and fluticasone propionate (Sal/Flu). With the exception of the CON group, rats in the other five groups were anesthetized with isoflurane gas on days 1 and 15, followed by sensitization with 100 μL of 1 mg/mL LPS by endotracheal spray using liquid aerosols (MicroSprayer® Aerosolizer, model IA-1B, Penn-Century, Inc. Wyndmoor, USA), respectively. These rats were also passively exposed to 5% (v/v) cigarette smoke in several fumigation boxes for 30 min twice with an interval of 6 h per day, from the 2nd to the 14th day. Cigarette smoke was produced by Hademen cigarettes (each contains 10 mg of tar, 1.0 mg of nicotine, and 12 mg of carbon monoxide) (Jinan, China). As the COPD model rat was obtained, the rats were challenged with cigarette smoke alone daily from day 16 to day 45 with the above method. In addition, the Sal group received 0.40 mg/kg/day (w/bw/day) of salmeterol xinafoate dissolved in normal saline, the MgIG group received 0.40 mg/kg/day (w/ bw/day) of MgIG, the Sal/Flu group received 0.40 mg/kg/day (w/bw/day) of salmeterol xinafoate powder and fluticasone propionate dissolved in normal saline, and the group Sal/MgIG received 0.40 mg/kg/day (w/bw/day) salmeterol xinafoate and 0.40 mg/kg/day (w/bw/day) MgIG by endotracheal spray 1 h before treatment of cigarette smoke on days 30 to 45, respectively, while the MDL group received 100 μL of 0.9% normal saline with the same method of administration. Rats in the CON group were sensitized and challenged with 100 μL of normal saline in the same manner and exposed to normal air. After 45 days, the rats were sacrificed with an intraperitoneal injection of sodium pentobarbital (150 mg/kg; Sigma-Aldrich; Merck KGaA). All methods were conducted according to ARRIVE guidelines (https://arriveguidelines.org).

Pulmonary function measurement

Rat lung function was assessed using the AniRes2005 lung function analysis system (Beilanbo Technology Co., Ltd, Beijing, China) according to the manufacturer’s instructions. Briefly, after 45 days of treatment, rats were anesthetized with 3% sodium pentobarbital (70 mg/kg; Sigma-Aldrich; Merck KGaA) and placed in a fixed supine position in a capacity box, to which a airway tube connected to ventilator and signal conditioner, transmitting airflow and change data to computer. Then, endotracheal intubation was performed on the rats. Breath rate and expiration/inspiration time ratio have been preset to 75/min and 1.5:1, respectively16. The forced vital capacity (FVC) and the forced expiratory volume in 0.3 s (FEV0.3) were detected, and the ratio of the two (FEV0.3/FVC) was used as an index to assess lung function in rats.

Classification of cells in bronchoalveolar lavage fluid (BALF)

To assess airway inflammation, inflammatory cells accumulated in bronchoalveolar lavage fluid (BALF) were analyzed16. Briefly, the tracheas of anesthetized rats were surgically exposed and intubated. The lungs were washed with 3 sequences of 1 ml of Hank’s balanced salt solution without calcium or magnesium, and BALF was harvested and centrifuged (400g) at 4°C for 10 min. The total number of cells was counted with a standard hemocytometer after resuspending the cell pellet in 1 ml of Hank’s balanced salt solution. Another aliquot of cell resuspensions was used to prepare cell slides, followed by staining of cells with Liu’s staining solution (PS0290, Beijing Jin Ming Biotechnology Co., Ltd. China). According to standard morphological criteria, approximately 200 cells were counted and classified as macrophages, lymphocytes, neutrophils and eosinophils.

Measurement of inflammatory factors

To detect inflammatory factors, serum from rats of all groups was respectively collected. Levels of inflammatory factors, interleukin (IL)-6, interleukin (IL)-1β and tumor necrosis factor (TNF)-α, were determined at 1:40 dilution with ELISA kits (Beyotime, Shanghai, China ) following the manufacturer’s protocol.

Histopathological analysis

To assess histopathological changes in lung tissue, left upper lobe tissue was removed from anesthetized rats to prepare paraformaldehyde-fixed, paraffin-embedded tissue specimens with the usual method. The sample was cut into 4 μm thick pieces and stained with hematoxylin and eosin (H&E) according to standard protocols. Histopathological changes were observed under the light microscope. We randomly selected three visual fields (200×) from each H&E stained section and then divided the number of alveoli in each visual field by the area of ​​the visual field to obtain MAN (mean alveolar number). Finally, bronchial wall thickness was measured directly under a 10× microscope. Cellular infiltration was scored as follows: 0, no cells; 1, a few cells; 2, a ring of cells and 1 cell deep; 3, a ring of cells and 2–4 cells deep; and 4, a ring of cells and >4 cells deep. The scores of ten rats were averaged. Histopathology was assessed independently by three blinded pathologists.


To study mucus secretion in rat lungs in each group, an immunohistochemistry test was performed with the mucin antibody MUC5AC 21. Briefly, paraffin-embedded slides were deparaffinized with 100% xylene and rehydrated (100, 95, 90, 85, 80% ethanol). Subsequently, the deparaffinized slides were rehydrated and soaked in sodium citrate buffer to expose the antigen, followed by treatment with 3% hydrogen peroxide (10 min) to block endogenous peroxidase. After being washed with PBS, the slides were incubated with the MUC5AC antibody (Abcam, Cambridge, UK) in a 1:500 dilution of the original antibody dilution buffer (Beyotime, Shanghai, China ) for 12 h at 4℃. Secondary antibodies were detected using SignalStain DAB Substrate Kit (Cell Signaling Technology, Beverly, MA, USA). Slides were counterstained with hematoxylin (Ligen, Beijing, China) and mounted. Each group was examined using the positive fluorescence microscope DM6B (Leica, Frankfurt, Germany). Semi-quantitative image analysis was used to measure average optical density (AOD) to assess MUC5AC expression with Image Pro plus software version 6.0 (Media Cybernetics Corporation, USA).

Western blot

Western blot analysis was performed as previously described19. Briefly, lung tissue was homogenized using lysis buffer with 1 nM phenylmethanesulfonyl fluoride (PMSF) (Beyotime, Shanghai, China), followed by centrifugation (8000g, 10 min) to collect the supernatant. The protein concentration in the supernatant was determined using a bicinchoninic acid (BCA) protein assay kit (Beyotime, Shanghai, China). For separated proteins, 300 μg of protein from each sample was loaded onto a gel for 10% SDS-PAGE. Then, proteins were transferred to polyvinylidene difluoride (PVDF) membranes and blocked with 5% bovine serum albumin (BSA) solution for 1 h, followed by overnight incubation with antibodies. primers anti-JAK2 (EPR23073-1, 1:1000, Abcam, Cambridge, UK), anti-phospho-JAK2 (EPR23028, 1:1000, Abcam, Cambridge, UK), anti-STAT3 (ab138483, 1 :1000, Abcam, Cambridge, UK) and anti-phospho-STAT3 (ab137521, 1:1000, Abcam, Cambridge, UK) at 4°C. Then, the membranes were continuously incubated with secondary antibodies (1:10,000 dilution in TBST containing 5% skimmed milk) and the bands were detected using a Western blot detection kit (Beyotime, Shanghai, China). The blot was scanned and analyzed using open source software ImageJ (downloaded free from https://imagej.nih.gov/ij/) to determine the band densitometry.

statistical analyzes

All data are presented as mean ± SD, and analyzes were performed with Graphpad Prism software version 8.0 for Win (GraphPad Software, San Diego, CA, USA). Comparisons between experimental groups were made using Tukey after one-way ANOVA for group-to-group comparison, p values ​​

Ethical approval and consent to participate

Laboratory animals were handled according to a protocol approved by the Center for Laboratory Animal Care, the Jiangsu Experimental Animal Ethics Committee and the Jiangsu Provincial Health Commission of China (Z2019053).

Global Narcolepsy Therapeutics Market to Reach $4.91 Billion by 2032, BIS Research Study Suggests

FREMONT, Calif., July 19, 2022 /PRNewswire/ — BIS Research’s premium study titled Narcolepsy Therapeutics Market – A Global and Country Level Analysis projects the market to achieve $4.91 billion in terms of revenue by 2032, at a CAGR of 15.93%.

In this in-depth study of the Global Narcolepsy Therapeutics Market, BIS Research covers the following in detail:

  • Market figures on micro segments that influence the market
  • Analysis of regulatory framework and reimbursement scenario in developed and developing regions
  • Potential of current and future therapies
  • Detailed country-level market share analysis, including scrutiny of seven major markets
  • Study of data from more than nine companies actively involved in the development of advanced treatments for narcolepsy

Apart from these parameters, the study also encompasses market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of all significant products.

To get a comprehensive view of the market, data from different market segments have been thoroughly analyzed. These segments include Indications, Therapeutics, and seven major markets, including the United States, United Kingdom, Germany, France, Spain, Italyand Japan.

The detailed study is a compilation of 25 market data tables and 112 figures spread over 151 pages and an in-depth table of contents on “Global Narcolepsy Therapeutics Market – Analysis and Forecast, 2022-2032”

Demand – Drivers and Limits

Following are the demand drivers for the global narcolepsy therapeutics market:

  • Large population of undiagnosed and untreated narcolepsy
  • Increase funding for neuroscience research
  • Approval of advanced therapies with a new mechanism of action (MoA)
  • Existing unmet needs of patients and healthcare professionals (HCP)

The market is expected to face some limitations owing to the following challenges:

  • Delayed diagnosis
  • Unconscious

Reasons to buy this report

This exclusive Global Narcolepsy Therapeutics Market Report will help in the following ways:

  • Product development assistance
  • Help targeting a segment for the launch of a new product
  • Offer market access strategies
  • Support in the diversification of the basis risk of the product portfolio
  • Aid in the analysis of therapeutic substitutes and comparison of specifications
  • Assist in gaining holistic views regarding key countries and understanding country market potential
  • Support in analyzing the competitive landscape to gain an understanding of business strategies incorporated by companies

Market Analyst’s View:

According Abdul Wahid, Senior Consultant – BIS Research, The United States is the global market leader in narcolepsy treatments. In 2021, the United States accounted for 93.48% of the global narcolepsy therapeutics market. The country is expected to maintain its position and grow significantly during the forecast period 2022-2032.”

See the report in the Global Narcolepsy Therapeutics Market

Key Companies Operating in the Market and Competitive Landscape

The companies profiled have been selected based on input gathered from primary experts and analysis of company coverage, product portfolio and market penetration.

Some prominent players in this market are:

• Jazz Pharmaceuticals PLC
• Harmony Bioscience, LLC
• Axsome Therapeutics, Inc.
• Avadel Pharmaceuticals PLC
• Takeda Pharmaceutical Co. Ltd.
• Sumitomo Pharma Co Ltd
• Suven Life Sciences Limited
• NLS Pharmaceuticals AG
• Therapeutic balance

Request a sample of this report

Key questions answered by the report:

  • What are the key market drivers, challenges and opportunities in the Global Narcolepsy Therapeutics Market?
  • What are the key development strategies implemented by the major players to stay in the competitive market?
  • What is the dominant therapeutic type developed by leading and emerging players for narcolepsy?
  • What are the major drug classes considered by the major players in the global Narcolepsy Therapeutics market?
  • What are the most promising emerging and experimental therapies in narcolepsy?
  • Which companies are expected to be highly disruptive in the future, and why?
  • What are the reimbursement scenarios and regulation of narcolepsy in the aforementioned seven major markets?
  • What are the narcolepsy treatment guidelines in seven major markets?

About BIS Research:

BIS Research is a global B2B market intelligence and advisory firm that focuses on deep technologies and related emerging trends that are likely to disrupt market dynamics in the near future. We publish over 200 market intelligence studies annually that focus on multiple deep technology verticals.

Our strategic market analysis emphasizes market estimates, technology analysis, high growth emerging applications, deeply segmented country-level granular market data, and other significant market parameters helpful in making strategic decision making for senior management.

BIS Research offers group studies as well as custom studies and expert consultations to companies, providing them with specific and actionable insights into new technology markets, business models and the competitive landscape.

BIS Healthcare vertical offers health technology market insights for medical devices, digital health, life sciences, robotics and imaging, information technology, precision medicine and other emerging health technologies, spanning the entire industry spectrum.

Marketing Director
E-mail: [email protected]
BIS Research Inc.
FREMONT CA 94538-1686
Visit our blog @ https://bisresearch.com/news
Join us on LinkedIn @ https://www.linkedin.com/company/bis-research
Join us on [email protected] https://twitter.com/BISResearch

Logo: https://mma.prnewswire.com/media/495163/BIS_Research_Logo.jpg


CCDH: Are there safe and natural alternatives to psychotropic drugs?

Pamela Seefeld is a clinical pharmacist and consultant in pharmacognosy

CCHR Florida's head office is located in downtown Clearwater.

CCHR Florida’s head office is located in downtown Clearwater.

According to data from the IQVia Total Patient Tracker database for the year 2019, extracted in February 2020, 61,262 children aged 0-5 years are prescribed antipsychotics in the United States.

According to data from the IQVia Total Patient Tracker database for the year 2019, extracted in February 2020, 61,262 children aged 0-5 years are prescribed antipsychotics in the United States.

With more than 34 million Americans taking antidepressants in 2013-2014, addiction and psychiatric withdrawal is a growing problem.

With more than 34 million Americans taking antidepressants in 2013-2014, addiction and psychiatric withdrawal is a growing problem.

Antipsychotics have many serious and debilitating side effects.

Antipsychotics have many serious and debilitating side effects.

For those dealing with mental anguish, there are safe solutions that don’t risk addiction, mania, or violence unlike many prescription drugs.

For those who suffer from mental anguish, or the myriad of mental disorders manufactured by the psychiatric industry, there are safe and humane solutions available which will be discussed.

— Florida Citizens Commission on Human Rights

CLEARWATER, FLORIDA, USA, July 19, 2022 /EINPresswire.com/ — The Citizens Commission on Human Rights (CCHR) is hosting an online webinar on July 23 on the dangers of psychoactive drugs. Health professionals, doctors, nurses and social workers are invited to attend as well as anyone wishing to know about alternative solutions.

Featured speaker, pharmacist and consultant in pharmacognosy (pharmacognosy is the science of using plants for medicinal purposes) Pamela Seefeld, will hold an hour of information on this vital topic of public interest.

For those faced with a loved one or friend suffering from mental anguish, or one of the myriad “mental disorders” fabricated by the psychiatric industry from normal human trauma, there are solutions. safe and human available which will be discussed. These alternatives do not risk addiction, mania, or violence like many prescription drugs do. [1]

For more than 30 years, Ms. Seefeld has practiced in the field of pharmacognosy, advising people on metabolic support, therapeutic vitamins and natural medicinal products. His work is meticulously documented and referenced. [2]

At this event, attendees can expect:

1. Learn about alternatives to achieving good mental health.
2. Become familiar with effective natural formulas to increase your
3. Be able to identify key action steps in the face of mental distress.
4. Learn about the effects of psychiatric drugs on the body.

Rallying lawyers, alternative health practitioners, psychiatric whistleblowers and other like-minded people to its social justice cause, CCHR Florida has won the 2022 International Social Impact Award for its role in the adoption of the Parents’ Bill of Rights, as well as another bill prohibiting the involuntary psychiatric examination of children of children without parental consent.

Anyone interested in learning more is invited to visit their center located at 109 N. Fort Harrison Ave in downtown Clearwater, Florida. To register for the webinar, please call 800-781-2878.

About CCHR: Originally established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuse under the guise of mental health and enact protections for patients and consumers . L. Ron Hubbard, founder of Scientology, was the first to make psychiatric imprisonment known to the general public: , you are. All in the name of ‘sanity’,” he wrote in March 1969.


[1] Patient Safety: Aggression, Irritability, and Violence: Drug-Induced Behaviors https://pharmacy.uconn.edu/wp-content/uploads/sites/2740/2020/05/Aggression-Irritability-and-Violence-revised-FINAL . pdf

[2] Pamela Seefeld https://botanicalresource.com/about-us

Diane Stein
Florida Citizens Commission on Human Rights
+++1 (727) 422-8820
write to us here
Visit us on social media:

Marketing madness: Are we all mad?

Register for the Medicare Payment Principles webinar on July 27

July 18, 2022
Hobbies: Public payers Advocacy

Due to a confluence of statutory payment reductions, a lack of inflationary updates, significant administrative burdens and tax uncertainties faced by pandemic-related medical practices, the Medicare payment system is on an unsustainable path.

The American Medical Association (AMA) is hosting a free webinar on Wednesday, July 27, 2022 at 10:00 a.m. Central Time that will dig deeper into some of the causes of current systemic issues and chart the way forward.

Hosted by Sandra Fryhofer, MD, Chair of the AMA Board of Directors, the webinar will review the AMA’s new Medicare Payment Reform Principles, outlined in Features of a Rational Medicare Physician Payment System— that provide a framework to reshape the Medicare payment system so it works better for patients and doctors, and end the annual advocacy exercise to stop impending payment cuts.

The California Medical Association is one of 120 organizations that have endorsed these reform principles. The AMA framework represents the first step in medicine’s efforts to develop and propose substantial changes to the payment system to improve the financial viability of medical practices and alleviate its administrative burdens.

Enroll now and learn more about Medicare Physician Payment Principles.

Come back

Learn how to stay ahead of payer policy changes in biosimilar coverage in oncology pharmacy practice

With the rapid pace of change in the design of biosimilar payer benefits, efforts to stay regularly informed of policy changes in advance are becoming critical to patient care.

There has been a significant gain in clinical confidence in the process of demonstrating biosimilars, explained panel moderator Jorge García, PharmD, MS, MHA, MBA, FACHE, during a session at the 2022 ATOPP Summit. , the challenge remains to learn how to overcome and manage the various obstacles and opportunities that the evolution of biosimilars continues to present to pharmaceutical practices in oncology.

“One of the biggest challenges we face is really preparing and staying ahead of the design of payer benefits and the changes that happen throughout the year, sometimes on a quarterly basis. “, Garcia said.

In light of this rapid pace of evolution of biosimilars in terms of the design of payer benefits, García noted that finding a method to stay ahead of policy changes that may ultimately have an impact on downstream operations.

Panel participant Mandy C. Leonard, PharmD, BCPS, system director of medication use policy and formulary management at the Cleveland Clinic, noted that at her institution, due to the ever-changing nature designing the benefits of biosimilar payers, pharmacists in his organization have had to learn how to adapt to these frequent changes by monitoring what’s happening at the Cleveland Clinic, not only from an inventory standpoint, but also from a form management perspective.

“I think we would all like to say that if we could select a biosimilar to a reference product in our organization, that would be best for us in terms of controlling many aspects of it, but that’s not always the case,” Leonard said. “So I think some of the hard things over the last few years after some of the biosimilars have been introduced is how do you deal with all of that, and I think one of the biggest lessons that I learned is that I thought we were doing such a fantastic job of streamlining biosimilars within our organization once we got buy-in from medical staff, but then I learned that it could have an impact on patient care because [of issues] on the other side of things with insurance.

Also, pharmacists do not always know when there will be a change in payer coverage. Leonard noted that in light of this, it’s important to work with a strong team within the facility who can help ensure the pharmacist stays on top of these coverage changes. Whether this team is part of billing, marketing, or network strategy, they can help pharmacists assess in advance what they are going to do about coverage changes in the electronic health record (EHR) so to help providers to their end.

Panel participant Kenneth Komorny, PharmD, BCPS, the Chief of Pharmacy at Moffitt Cancer Center, noted that at his facility they have embraced the managed care service for effective collaboration on this front at Moffitt Cancer Center and meet on a quarterly basis to ensure a high level of communication regarding changes in biosimilar payer coverage.

“We’ve tried to be proactive, combing them through payor policy changes to make sure we’re on top of that. Otherwise, you’re surprised,” Komorny said. “So they maintain a spreadsheet for us, and we try to capture the majority of them. They have hyperlinks on them; it’s a living document, and we can click on it and find out in real time what the insurance policy [a biosimilar].”

With the living document noting payor policy changes in real time, Komorny noted pharmacists at Moffitt Cancer Center can create a one-page guide for pharmacy staff to ensure everyone stays informed. medications available. In addition, pharmacists note the main payers in the system as well as the different products, and whether or not they are covered by the insurance company, and whether they are on formulary or off formulary.

“It works as a guide for pharmacy staff to know which drugs we have available and which ones we don’t. But again, it’s really about reaching out to your managed care department and your payment strategies department and working with them to create this [spreadsheet]. We don’t have the expertise to comb through these insurance policies — they’re very, very long,” Komorny said. “So we kind of lean on them to do that part, and then we wrap it up from a pharmacy perspective.”

Komorny noted that even with this living document noting payer policy changes that impact pharmacist practice, it also remains important to conduct benefit surveys for each patient and service date as policies can change from quarter to quarter.

“In fact, that’s what we see in practice,” Komorny said. “We also have patients changing jobs in Florida, we have temporary Medicaid, where patients may have insurance one month but not the other. So it’s a lot of work to stay ahead of the politics and then investigate the benefits every time.


García J, Leonard MC, Komorny K, Rozenblyum E. Real impact of biosimilars on healthcare costs. San Diego, CA: ATOPP Summit 2022; July 16, 2022.

Saudi backpacker twins embark on new adventures

JEDDAH: Have you always wanted to know what the songs of Abdulmajeed Abdullah, Dalida, Amr Diyab, Fairuz or other Arab artists would sound like if they were in a video game?

The answer? Watch the creations of Saudi digital artist and music producer Emarati Moath Bin Hafez, who reimagines popular Arabic songs in video game settings.

For the 50th UAE National Day, Hafez came up with the idea of ​​creating an 8-bit chiptune version of the UAE national anthem, which was his pilot project.

“Since Instagram is primarily a visual platform, I made a simple animation of the United Arab Emirates flag being hoisted in the Super Mario universe,” he told Arab News.

“To my surprise, the video game got a lot of attention and became my most watched video within days,” he said.

Following his success, he decided to focus on making chiptune remixes of Arabic pop music as there was clearly an “appetite” for this type of content.


• For the 50th National Day of the United Arab Emirates, Hafez had the idea of ​​creating an 8-bit chiptune version of the national anthem of the United Arab Emirates, which was his pilot project.

• For one of his works for the 2000s game show “Man Sayarbah Al-Malyoon” (Who Will Win the Million), he used the famous Las Vegas scene from Street Fighter II.

• He chiptuned Fairuz’s song “Habaytak Bisayf” (I loved you in the summer), which is about loneliness and longing, with visuals of empty landscapes to match the lyrics

“With modern software, you can emulate the sound of those older chips, but without having to learn anything about programming, so you just focus on the creative side like instrumentation, arrangement and such,” did he declare.

“I’m a kid of the 80s, so I played a lot on my Sakhr (MSX) and NES. For me, the music was always the most memorable part of those old games.

He said the sound chips in those old consoles were very primitive, so the composers worked around the limits by being really creative with the composition and the techniques they used.

“The idea of ​​working with limited tools to fuel your creativity resonates a lot with me,” he said.

In terms of music, Hafez has said electronic bands Daft Punk and Justice are his biggest inspirations.

Video games have changed so much over time, but his favorite is “Donkey Kong Country 2” from the classic generation and the “Fallout series” from the modern generation.

“I juxtaposed the singers with mostly fighting game backgrounds like Street Fighter II and the King of Fighters series. They’re very dynamic and often have animated characters staring at them,” he said.

“I try to match the background with the way the music sounds and with the way the singer appears to me,” he said.

He explained that for one of his works for the 2000s game show “Man Sayarbah Al-Malyoon” (Who Will Win the Million), he used the famous Las Vegas scene from Street Fighter II.

“It’s really crazy and over the top with the dancers and the spectators betting because I feel like it matches the greatness of this show in the Arab world,” he said.

Highlighting his work on Lebanese singer Fairuz, he chiptuned her song “Habaytak Bisayf” (I loved you in the summer), which is about loneliness and longing.

“It made sense to scroll Fairuz through empty landscapes through different seasons to match the lyrics and emphasize loneliness and isolation,” he said.

New COVID-19 antibody test helps keep track of variant immunity

Jul 15, 2022 1:00 PM

A newly developed blood test that measures immunity to COVID-19 could be a valuable tool in deciding who needs a booster and when, according to an international team of researchers. Photo credit: Getty Images

This press release has been adapted from material provided by the University of Toronto.

New COVID-19 antibody test helps keep track of variant immunity

Experts agree that the pandemic is not over. Infections resume, fueled by new variants that our immune systems are ill-prepared for.

That’s according to a study that found that antibodies generated in people vaccinated and/or recovered from COVID-19 before 2022 failed to neutralize variants circulating today.

The study was conducted by Shawn Owen, Ph.D., assistant professor of pharmacy and pharmaceutical chemistry at Utah Health University and Igor Stagljar, PhD, professor of biochemistry and molecular genetics at the University of Toronto Temerty School of Medicine.

The newspaper Nature Communication published their findings.

The researchers say the antibody test they developed to measure the immunity of study participants will be a valuable tool in deciding who needs a booster and when, which will help save lives and avoid future lockdowns.

“As the pandemic spreads, we need ways to determine if people are protected from infection or reinfection,” says Owen. “Our test can help monitor a person’s level of immunity after being vaccinated or infected. It can also reveal the level of protection against new variants, which can help guide decisions about when to get a booster or if a new vaccine is needed.”

covid testing
Shawn Owen, PhD, assistant professor of pharmacy and pharmaceutical chemistry at the University of Utah Health.

Many antibody tests have been developed over the past two years. But only a few licensed tests are designed to monitor neutralizing antibodies, which coat the viral spike protein so it can no longer bind to its receptor and enter cells.

This is an important distinction, as only a fraction of all Sars-CoV-2 antibodies generated during infection are neutralizing. And although most vaccines have been specifically designed to produce neutralizing antibodies, the degree of protection they provide against variants is unclear.

“The truth is, we don’t yet know how often our injections should be to prevent infection,” Stagljar says. “To answer these questions, we need rapid, inexpensive, and quantitative tests that specifically measure Sars-CoV-2 neutralizing antibodies, which are the ones that prevent infection.”

To meet this need, the research team developed Neu-SATiN, which stands for NOTSerological neutralization Asay. The effort was led by Sun Jin Kim, a postdoctoral fellow in Owen’s lab and Zhong Yao, a senior research associate in Stagljar’s lab, who are the paper’s co-first authors.

The method is as accurate, but faster and cheaper than the current gold standard, and it can be quickly adapted to new variants as they emerge, the researchers say.

“The biggest advantage of Neu-SATiN over other surrogate assays is modularity,” says Kim. “Each of the components of the Neu-SATiN test are genetically modified and recombinantly expressed, making them relatively easy to modify and produce. This allows Neu-SATiN to be a truly mix-and-read test.

The pinprick test is powered by fluorescent luciferase protein from a deep-sea shrimp. It measures the ability of the viral spike protein to bind to the human ACE2 receptor, each of which is attached to a fragment of luciferase.

The binding brings the luciferase pieces together so that they reconstitute a full-length protein, which emits a glow of light that is captured by the instrumentation. When the patient’s blood sample is added to the mix, the neutralizing antibodies bind to the spike protein, preventing it from coming into contact with ACE2. The luciferase remains in pieces, accompanied by a drop in the light signal.

The plug and play method can be adapted to different variants within weeks by creating variant mutations in the spike protein.

The researchers applied Neu-SATiN to blood samples taken from 63 patients with different histories of COVID-19 infection and vaccination up to November 2021. Their antibody neutralizing ability was assessed against the strain original from Wuhan and the variants, Alpha, Beta, Gamma, Delta and Omicron.

The neutralizing antibodies lasted about three to four months. At that time, their levels dropped by about 70%, regardless of infection or vaccination status. Hybrid immunity, acquired by both infection and vaccination, initially produced higher antibody levels, but also dropped significantly four months later.

More worryingly, infection and/or vaccination offered good protection against the previous variants, but not Omicron, nor its subvariants, BA.4 and BA.5.

The researchers point out that vaccines still provide significant protection against serious illness and death. However, the findings of Owen’s team and others call for vigilance in the coming period, given that the more transmissible BA.4 and BA.5 subvariants can evade immunity acquired during previous Omicron infections. as evidenced by the rise in reinfections.

In the future, researchers hope to expand its availability.

“We are working with a few companies to evaluate the effectiveness of their candidate vaccines against Omicron and are also negotiating a license with another company to commercialize the test,” Owen said.

The research was funded by the Office of the Vice President for Research and the University of Utah 3i Initiative, and the Toronto COVID-19 Action Fund.

COVID-19 Research News Faculty of Pharmacy Medicinal Chemistry

Health care network’s new CEO says focus is on ‘closing the gaps’ in access to care

A new CEO has taken the helm of Healthcare Network, the nonprofit organization that is the medical home for many of Collier County’s most needy residents.

Jamie Ulmer, 51, replaces Emily Ptaszek, who left her CEO role earlier this year for a position in Colorado. Ulmer started on July 11.

Healthcare Network is a federally licensed, not-for-profit health center dedicated to providing primary medical care to everyone, regardless of insurance status, income, or employment. It also provides dental care and behavioral health services.

In order to receive federal support, the health care network and other qualified centers must focus on underserved communities and provide services on a sliding scale basis based on patients’ ability to pay.

Related:Health care network hires six more outreach workers to fight chronic disease among the needy in Collier County

Roaming :Homelessness in Southwest Florida: Mixed results but the lack of affordable housing is grim

Healthcare Network staff in 2021 cared for approximately 50,000 patients for nearly 148,000 patient visits. Of the total patients, nearly 27,000 are children. Nearly $13 million in unpaid care was provided to patients last year.

This year’s operating budget is $51 million for 18 practice sites, three mobile units and two pharmacies. The health network has 380 employees.

“After a comprehensive nationwide search process, the Board is pleased to have found the most qualified individual to take on the leadership of this organization,” said Haris Domond, Chairman of the Healthcare Network Board of Directors, in a press release. “(Ulmer’s) combination of experience, results and drive makes him an ideal candidate for Healthcare Network today and for our next stages of growth.”

Health Care Network Community Health Workers prepare for a COVID-19 testing event on Wednesday August 4, 2021 in Immokalee.

Ulmer comes to Collier from Marion County where he served as the general manager of Heart of Florida for the past four years. Heart of Florida shares the same mission as Healthcare Network to serve the needy and is a federally licensed health center.

Ulmer said he jumped at the chance to interview for the position at Healthcare Network, a process he said began in late February and ended in May.

Working at Heart of Florida prepared him to lead Healthcare Network, he said.

The Nichols Community Health Center in Golden Gate opened on June 2, 2020.

When he started at Heart of Florida in 2018, the center had 19,000 patients a year and it grew to 30,000 patients during his tenure, according to the Ocala Star Banner.

“It was a great stepping stone and paved the way to being here,” he said.

His first week of work

He praised the Health Network’s board of directors for their concern to find someone suitable for the position.

“I know it’s the right choice and the time has come,” he said.

He plans to spend two to three days a week in Immokalee, where Healthcare Network was launched 45 years ago, because it is in the migrant farmworker community where the need is greatest to fill the gaps in health care. ‘Health care access.

He has been busy meeting with community leaders, which so far includes Eileen Connolly-Keesler, president and CEO of the Collier Community Foundation.

“I’m thrilled to be working with (him),” she said in an email. “He knows very well how to connect the health care network to the needs of the community and will be a great asset to us in Collier County.”

While fundraising is important for nonprofits like Healthcare Network, the organization’s true mission is to care for the underserved, Ulmer said.

Guest review:“It has been a true privilege to serve as CEO of Healthcare Network”

“We never want to lose sight of that,” he said. “One of my strengths is vision. I bring vision and the ability to execute and accomplish things in a relatively short period of time.

One service that the health care system does not currently provide, but needs, is drug treatment for people with addiction problems.

Prisoners must seek treatment: www.naplesnews.com/story/news/local/2021/07/09/grant-provide-funding-treatment-opioid-addictions-inmates-collar/5322680001/

He has started talking to staff about it, which he says will take some work to get started, but the staff who will be involved already have their licenses with the US Drug Enforcement Administration to prescribe controlled substances.

“We have to get into this,” he said.

What is his background?

Ulmer said he’s known for some time that when he plans to retire, which would be a second time after retiring from a military career, he wants to live somewhere between Tampa and Naples.

However, he said he sees himself staying with Healthcare Network for 10 to 15 years.

That’s about as long as a CEO should stay in an organization, which is best for the organization.

“You need fresh ideas,” he said.

While at Heart of Florida, he increased the organization’s operating budget from $8 million to over $30 million and established an elder care contract to serve center patients living in a assisted living facilities and nursing care nearby. The project generated over $3 million in revenue in its first year.

It opened four pharmacies and a stand-alone pharmacy so patients could have drive-up access and after-hours service. The pharmacies made $4 million in revenue in the first year.

Ulmer served in the US Army for 24 years with multiple deployments. He retired from active duty in 2013 as an Executive/Operations Officer at Fort Bragg, NC He also served as Public Health Administrator for the Army at Fort Jackson, SC

Additionally, he worked for the South Carolina Department of Health and Environmental Control as the State Public Health Administrator for Children’s Emergency Medical Services. He was recruited for the position of Chief Operating Officer of Rural Health Services, a federally qualified health center in Aiken, SC

He earned his bachelor’s degree in psychology from South Carolina State University and a master’s degree in human resource development and health services management from Webster University in St. Louis.

He serves on several committees of the Florida Association of Community Health Centers, which represents the interests of community organizations such as Healthcare Network. He is an active member of the National Association of Community Health Centers.

Enveda Appoints Pharmacy Veteran Vanitha Sekar as Chief Commercial Officer

BOULDER, Colorado–(BUSINESS WIRE)–Enveda Biosciences, a pioneer in transforming small molecule drug discovery using machine learning and metabolomics to unlock the potential of natural products, today announced the appointment of Vanitha Sekar, Ph.D. ., R.Ph., to the new position of Commercial Director. Dr. Sekar will play a key role in Enveda’s continued growth and will be responsible for shaping the company’s business development strategy.

Dr. Sekar brings to Enveda more than 20 years of experience in business development, corporate strategy and R&D in the pharmaceutical and biotechnology fields. She joins Enveda from Gilead Sciences Inc., the global biopharmaceutical company, where she was responsible for business development for its flagship therapeutic area of ​​virology.

Prior to joining Gilead, Dr. Sekar was Executive Director, Business Development & Licensing, for Merck Research Laboratories. Prior to joining Merck, she held several roles at Janssen Pharmaceuticals, including business development and R&D, and led the evaluation of multiple opportunities with cross-functional teams and business partners. During her career, she has completed numerous transactions for preclinical and clinical stage assets.

Dr. Sekar also helped develop and execute strategies for new chemical entity development, lifecycle management, and post-marketing of HIV and Hepatitis B and C drugs. Prior to his tenure at Johnson & Johnson, she led clinical pharmacology at Tibotec US, which was acquired by J&J and became part of Janssen Pharmaceuticals.

Dr. Sekar also spent five years as the Acting Team Leader and Senior Reviewer for Antiviral and Neuropharmacology Drugs at the United States Food and Drug Administration. She received her Ph.D. in Pharmaceutical Sciences from Virginia Commonwealth University and a Bachelor of Pharmacy from Birla Institute of Technology and Sciences, Pilani.

“Vanitha is an exceptionally experienced and knowledgeable pharma and biotech executive who has forged key partnerships in our industry and understands it well,” said Viswa Colluru, Ph.D., CEO of Enveda. “We are delighted to welcome Vanitha to Enveda, where her 20 years of experience creating value for companies, their partners and their investors is a key addition to our team and our business efforts. She joins Enveda at a fantastic time as we are making significant and rapid progress with our platform and our pipeline is showing great progress. We all look forward to working with Vanitha as we continue our work to bring hope to patients around the world.

Dr. Sekar brings to his new role at Enveda a wealth of scientific background, a passion for patients, extensive drug development experience and acumen for business.

“Growing up and studying to be a pharmacist in India, I learned to appreciate and respect herbal medicines for their therapeutic properties,” Dr. Sekar said. “Therefore, joining the Enveda family is very much like stepping back to the future. I am thrilled to join a company that is on its way to revolutionizing drug discovery by integrating machine learning and metabolomics to turn natural products into Equally important, I am privileged to have the opportunity to partner with Viswa and his uniquely talented team.

Dr. Sekar’s commitment to the healthcare industry extends to his passion for recruiting, mentoring and supporting women and minorities in early career and leadership roles. She is a member of the life sciences board of Springboard Enterprises, the premier platform for building great women-led businesses and a member of BIO’s Healthcare Businesswomen’s Association.

“Vanitha’s impact can be seen not only in the companies she has worked with, but also in her influence on efforts to mentor women in our industry. We look forward to doing a great job together at Enveda,” said Dr. Colluru.

About Enveda Biosciences

Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for the nearly limitless breadth of nature’s unknown chemistry, building on years of cutting-edge advances at the intersection metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of pharmaceutical industry experience working alongside world-renowned data scientists. For more information about Enveda, visit envedabio.com.

A quest to find the perfect rasam ship

What chicken soup is to millions of people in the West, rasam is to people in southern India (and southern Indian countries, like Sri Lanka). A panacea, rasam is a quick and easy broth for clearing colds, soothing sore throats, resting grumbling bellies, calming split heads, feeding grumpy kids, and calming grumpy adults.

And no, I’m not making wild claims here; the clinical benefits of rasam have been documented by other experts. “Rasam is a classic example of a traditional functional food with all of its ingredients claimed in medicine for various ailments. Preclinical and clinical studies on rasam and its ingredients support their traditional claim,” write researchers Agilandeswari Devarajan and MK Mohanmaruaraja in a article titled A Comprehensive Review of Rasam: A Traditional Functional Food from South India in the open access peer-reviewed medical journal, Journals of pharmacognosy.

Read also : Burmese cuisine has a new culinary ambassador

For me, rasam is soul food, even ambrosia, especially when it’s made in pure traditional tin eya chombbu.

My earliest memory of rasam is of the spicy, flavorful liquid gently simmering in a eeya chombbu sitting precariously over a coal fire on a signi. We were then living in a Gujarati settlement in Nagpur, and our enterprising owner had made this special stove using cement and an old iron bucket. When he and his family saw my father eating his rasam rice, they laughed at him. “Arre, aa rasam soon che? Do you Madrasis have to lick it from your hand to your elbow?” (We children were given a thicker version of rice mixed with rasam, and we didn’t have to lick the rasam from our elbows. )

at Grandma’s house eeya chombbu shone in the kitchen with its meticulous cleaning routine, unlike the brass vessels of our Gujarati and Maharashtrian neighbours, which did not retain their inner luster for too long. About every two months, the kalaiwala would be called upon to line the inside walls of these vases with tin. How fascinating it was to see the kalaiwala dig a hole in the mud, set up his little oven and burn the coals red hot with air pumped through his bellows! Once the container was hot, he would drop a piece of pewter inside, sprinkle some magic powder (ammonium chloride, I found out decades later), then coat the container with the fast-melting pewter. We watched with wide eyes and clenched noses (ugh, the smell of ammonia!) as the man pointed to the ship glowing like a magician.

One of the most treasured items in my kitchen is the eeya chombbu, part of my kit. That it was pushed into an invisible corner soon after the wedding is a testament to my love for world peace. How, you ask? My dear mother-in-law did what never should be done with this chombbu with its low melting point. She lifted him from the stove with a iddukki, a metal clamp. The tongs ripped a hole in the hot pot and the rasam squirted onto the stove, causing the gas to leak out. This alerted my stepfather, who yelled from somewhere, “WHAT’s going on in the kitchen?”

“Don’t tell him,” Amma begged. And that’s why the body had to be hidden from the crime scene.

Years later, when they both left, I thought it was time to get my eeya chombbu and I recast it because I had never felt fully satisfied with rasam made in what we called “always silver vessels” – stainless steel. But at that time, some people understood that eeyam meant lead in Tamil, and this lead would cause poisoning. Throw your eeya pathirams, was their battle cry. I discreetly put mine away in the back of a cupboard.

It took a few years of consuming the least pungent, lead-free rasams for the collective brain to wake up and realize that eeyam also meant tin in Tamil. Vellai eeyam or lead white for pewter, and karu eeyam or black lead, the toxic version. And took out the eeya pathirams in many Tamil homes, the rasam made there fills homes with heavenly aroma.

That our grandparents and all of us north and south of the Satpuras survived should be proof enough that tin is not a killer element. Every Tamilian household had these pewter vessels of different shapes and sizes. Traditionally, craftsmen in the temple town of Kumbakonam in Tamil Nadu hammered sheets of tin and shaped them into vessels. The craftsmanship continues to this day, although very few craftsmen remain.

By then, I had developed an urge to only buy things from the source. If I had to buy one eeya chombbu or have my old one recast, I should go to Kumbakonam. But years have passed chasing deadlines, with meals being lightning-fast dishes cooked simultaneously on four burners over high heat or in minutes in the microwave. Who had time to go to Kumbakonam or slowly make rasam in delicate vessels that tended to melt in the fire?

Read also : The myths and legends behind the versatile “poha”

A few years ago, while visiting Chennai, I succumbed to temptation and decided to treat myself to a new eeya chombbu. Back in Bangalore, I did rasam slowly after many years. First, fill the jar with tamarind water; add rasam powder, salt and crushed tomatoes. Only then place the pan on the stove. Simmer. Add the cooked dal. Simmer. Wait for the rasam to slowly foam up. Turn off the stove. Prepare the filling by heating a spoon of ghee and adding mustard seeds, asafoetida and curry leaves. Add the coriander leaves. Inhale Exhale. Some people go to the Himalayas to achieve peace of mind. Me? I just did rasam in the eeya chombbu and savor every piece of rasam rice.

Mala Kumar is the author of Up the Mountains of India, written while swallowing many goblets of rasam and dreaming of kahwa and rhododendron wine.

Supers approve 2 new ambulances


Neshoba County Supervisors at their regular meeting last week voted to acquire two new ambulances.

The department received two offers. Horn Lake Emergency Equipment Professionals had the lowest bid at $421,653. The second bid was $470,684. This will be a lease-purchase agreement for the Neshoba County Ambulance Company.

“The delivery time for these ambulances is 18 to 24 months,” said County Administrator Jeff Mayo. “We still haven’t received the two ambulances we ordered in May 2021. It looks like we will have two new ambulances this year and the others will arrive the following year.”

The ambulance service operates six frontline vehicles. When the new ones arrive, they will be replaced and two of the oldest will be retired. The oldest vehicles date from 2013.

Neshoba Ambulance Enterprise is a joint venture between Neshoba General Hospital and the county.

In addition, supervisors at the July 5 meeting voted for:

• Approve quarterly budget allocations of $383,471 for the Sheriff’s Department and $381,472 for County Jail Operations. Sheriff Eric Clark said there were 114 inmates in the 66-bed jail Monday morning.

• Approve that the Sheriff’s Department is applying for a $5,000 75/25 Justice Assistance Grant (JAG). Supervisors also approved payment of Mississippi Deputy Sheriff Association dues ($23-20 = $460);

• Accept the June Meal Diary and Jail Billing Report;

• Solicit bids from sub-contractors for state-subsidized road projects in the county. The county is the prime contractor;

• Approve the quarterly budget allocation of $118,949 for the Office of the Tax Collector/Assessor. The supervisors also approved the filing of the property and personal assessment roll. The office will equalize the property and personal assessment rolls;

• Approve the establishment of the annual salary of Advocate Court Coordinator Kenny Spencer at $50,000 plus benefits;

• Approve the transportation of a rockfill load to Lake Neshoba;

• Approve the 16th Section Commercial Lease for the Neshoba County School District;

• Approve a request from the Park Commission to seal potholes at Northside Park;

• Approve two salary increases for emergency management employees. Supervisors also accepted two resignations for the department;

• Approve the payroll of county employees ending June 27 and totaling $197,708;

• Approve the payroll of elected officials ending July 1 and totaling $48,461;

• Authorize tenders for the renovation of the Burnside Park auditorium.

Strong Russian private sector interest in Sino-Belarusian industrial park noted

MINSK, July 13 (BelTA) — The Russian private sector is showing strong interest in the Sino-Belarusian Great Stone Industrial Park, BelTA has learned from the first deputy general manager of the SZAO industrial park development company, Kirill Koroteyev.

Kirill Koroteyev said: “We are seeing tremendous interest from the Russian private sector, Russian business and government communities in the industrial park. We hold meetings with Russian delegations almost every day.

According to him, as an industrial and investment platform, Belarus was quite competitive in the European market given the prices of energy resources and local wages. “Now, given the complicated economic and foreign policy situation, we intend to turn to the Russian market and we already see a response. Together with Russian businessmen, we are developing projects for vehicles unmanned aerial vehicles, helicopter construction, fine chemical projects. All in all, we strive to create a wide range of interactions,” he noted.

Kirill Koroteyev added: “There are several Russian resident companies in the park. They specialize in the manufacture of veterinary drugs, medical products and in R&D in the field of electrical transmissions for transport and new materials. Overall, the potential for interaction between the Sino-Belarusian Great Stone Industrial Park and the Russian Federation is quite large. We are determined to actively advance our cooperation.

The Sino-Belarusian Great Stone Industrial Park is a special economic zone with a special legal regime. It is located 25 km from Minsk. The park’s priority areas of development are mechanics, electronics and telecommunications, biotechnologies, pharmaceuticals, new materials, logistics, digital commerce, storage and processing of big data.

CRSI honor for 3 IICT scientists

Posted: Posted Date – 6:22 PM, Tue – Jul 12, 22

Hyderabad: Top scientists from the Hyderabad-based Indian Institute of Chemical Technology (IICT) have won three major honors from the Chemical Research Society of India (CRSI).

Senior Principal Scientists Dr. Prathama S Mainkar and Dr. Debendra K Mohapatra who are involved in technology development have been shortlisted for CRSI 2023 Bronze Medals while IICT Director Dr. D Sreenivas Reddy has been selected for the prestigious Darshan Ranganathan Memorial Lecture by CRSI, says a press release.

The awards were announced during the 29th CRSI National Symposium in Chemistry and CRSI-ACS Symposium Series in Chemistry, held recently at the Indian Institute of Science Education and Research (IISER), Mohali under the aegis of the CRSI in collaboration with the American Chemical Society (ACS) .

Dr. Prathama’s research interest is in the field of medicinal chemistry, synthetic organic chemistry and drug discovery while Dr. Debendra K. Mohapatra’s research interest is in the field of organic chemistry with special emphasis on the asymmetric total synthesis of complex natural products of medicinal importance.

Dr. Sreenivas Reddy has extensive experience in the pharmaceutical industry as well as CSIR labs with research focused on application-oriented organic synthesis towards human well-being with a combination of organic and medicinal chemistry, the press release adds. .

Exam date postponed, new timetable to be published later; check details

While the TSCHE previously issued the TS ECET 2022 hall tickets, the admission cards will be reissued once the new exam date is announced.

Representative image. Wikimedia Commons

The Telangana State Common Entrance Engineering Test (TS ECET) 2022 has been postponed by the Telangana State Council of Higher Education (TSCHE). The exam was previously scheduled to take place on July 13.

The TSCHE has postponed the state-level engineering entrance test due to torrential rain. The revised exam schedule has not yet been announced by the TSCHE.

A notice on the official website of TS ECET reads, “In view of the torrential rains in Telangana State, the conduct of the TSECET-2022 exam scheduled for 13.07.2022 is postponed and the date postponed for TS ECET-2022 will be announced later.”

While the TSCHE previously issued the TS ECET 2022 hall tickets, the admission cards will be reissued once the new exam date is announced. The TS ECET will be conducted by Jawaharlal Nehru Technological University Hyderabad on behalf of TSCHE.

The TS ECET will take place in two sessions. The first session will take place from 9:00 a.m. to 12:00 p.m., in accordance with the official invitation. The second session of TS ECET will be held from 3 p.m. to 6 p.m. on the same day.

TS ECET 2022 paper model for diploma courses will have questions from Mathematics, Physics, Chemistry as well as related engineering branch subjects.

For the BSC Mathematics course, the paper will consist of 100 questions related to Mathematics and 50 each of Communicative English and Analytical Ability. For the Pharmacy course, applicants will be tested on Pharmacy, Pharmacognosy, Pharmacology and Toxicology, and Pharmaceutical Chemistry. See the paper pattern here.

The examination is arranged for lateral admission into the regular 2nd year BE/BTech and Pharma courses in universities as well as non-assisted private vocational institutions (minority and non-minority) which have been approved by the All India Council for Technical Education.

For more information, you can visit TS ECET website.

Read all Recent news, New trends, Cricket News, bollywood news,
India News and Entertainment News here. follow us on Facebook, Twitter and instagram.

How to travel with one bag

Worried about checking a bag during a chaotic travel summer? Consider perfecting the art of minimalist packaging with tips gleaned from Reddit.

Share this article

AAttention all chronic overpackers: we hear you and we see you, but you really don’t need to pack twenty pairs of underwear for your four-day trip. Let’s face it, some of us are blessed with travel anxiety and we pack it on our poor suitcases, stretching those zippers to their limits. But with so many recent reports on woes of summer air travel, maintaining the lifestyle of an overpacker (which certainly requires at least one checked bag) is dodgy at best. The solution? Commit to carrying only one travel bag, courtesy of r/OneBag.

When faced with a problem in modern times, most today turn to the internet for an answer. And there’s no better way to crowdsource a solution than to turn to the myriad online communities of Reddit, a website all about discussion forums. There are dozens of subreddits dedicated to travel, like r/DigitalNomad, r/TravelHacks, r/SoloTravel, r/small, and, of course, r/OneBag, which describes itself as “a minimalist urban travel community devoted to the idea of ​​carrying less bullshit.” Getting feedback and reading about the experiences of seasoned travelers is essential, but learning how to make the most of those experiences without drowning in excess toiletries and clothing? You could call the advice invaluable.

So step out with the freedom to travel unburdened and remember, don’t pack your fears!

Traveling with just one bag can seem impossible.  But with a little careful planning, anything can happen.

What is a trip with a bag?

A travel bag is a bit explicit: it’s traveling with only one bag. No check-in suitcase, no extra personal items, just the only luggage you can take on the plane. What’s the point? There are several advantages to traveling with one bag:

  • Freedom: Traveling with just one bag frees up the rest of your body and makes it easier to navigate to your exciting new destination.
  • Peace of mind: There’s a lot less chance of your luggage being lost by the airline (or just losing track of a suitcase) if you store it in an overhead compartment.
  • Economic : Forget checked baggage fees.
  • Win time: No more moping and sighing around the baggage carousel. Imagine being able to disembark, bypass the baggage carousel, and simply drive straight to your hotel with all your belongings. Plus, since you’ll be traveling with less, it’ll also take less time to pack (and unpack).
  • Security: For those who like to travel solo, packing your belongings in one bag is a great way to provide maximum protection for you and your belongings, since everything is in one place, your belongings will be easier to keep track of.

Of course, there is a small inconvenience when it comes to traveling with only one piece of luggage: since you will only be traveling with hand luggage, you will have to respect TSA regulations when it comes to liquids. So, don’t plan on bringing back a souvenir bottle of wine or liquor during a single bag.

Focus on packing a little less than you need and washing - and buying - any extra items you might need at your destination.

How to travel even with one bag?

Chronic over-packers might find the idea of ​​using just one travel bag absolutely absurd. But all it really takes is a little wise planning.

Of course, not everyone will be able to comfortably take a one month European vacation with a Fjallraven Kanken backpack. But for those who have mastered the art, the benefits of traveling as (almost) free as possible, the pros outweigh the cons.

The bulkiest thing in everyone’s luggage is clothes. And while it’s not advisable to bring just one outfit for a trip, there are ways to simply bring less. Consider bringing fewer pairs of underwear than you would need and washing the unspeakably dirty in the hotel bathtub or washing bag. These pocket size biodegradable detergent sheets make the chore easier. Investing in a few pairs of woolen socks or other woolen pieces is a great idea. Thanks to the wool fibres’ hydrophobic propertiesBO particles have a hard time absorbing into woolen clothes, so you can wash them less often.

It’s a good idea to wear your biggest and bulkiest items on the plane, like jackets or boots (and they’ll keep you warm in that chilly cabin air). To save space in your bag, consider investing in a few synthetic fabric parts, which are easier to roll up or fold (rolling is believed to save more space than folding, but each their own side) compactly than traditional fabrics, have better wicking properties moisture and dry quickly. For some eco-friendly alternatives (polyester, acrylic and nylon fabrics are among the biggest contributors to microplastic pollution), invest in herbal linen, lyocell, rayon, bamboo and viscose garments, which perform much like their synthetic cousins.

Since shoes can’t be folded, consider sticking with the one pair of shoes you’ll wear on the plane and packing a compact pair of slippers or sandals if you need them.

As for toiletriessolid shampoo, lotion, conditioner and bar soap are your friends. Lush has a slew of in-bar beauty products, but brands like the New Zealand company Ethics (which also happens to be 100% plastic free) and Obia are great options. Not only do they pack away more neatly thanks to their naturally contoured shapes, but you won’t have to worry about them exploding in your bag either. Also, rather than carrying all the toiletries you need with you, consider packing only the essentials and buying anything you might need from a local pharmacy at your destination. Who knows, you might find yourself a fan of a new italian toothpaste.

Electronics can also be a problem. Consider investing in lightweight laptops and tablets if you know you’ll be on the go a lot. A multiport adapter is also a good idea, so you can bring just one charger for all of your tech. While packing, ask yourself: do I really need this electronic equipment? Do I really have to bring my Nintendo Switch? Or should I focus my efforts on connecting with the culture around me?

One of the most important decisions of a traveler: what bag should you bring?

The best options for a bag

Although the internet can give you all the advice in the world, it’s a decision that only you can make.

A way to facilitate by r/OneBagis to decide in which camp you are: do you prefer “buy a bag and adapt your packing list to fit or pack your finalized packing list and measure LxWxH of it all and search for a bag with similar dimensions? »

Either way, there are a few things to consider when choosing a single bag. Do you want a backpack, a sports bag or a suitcase? If it’s the latter, is it important for you to have four wheels over two? Likewise, would you prefer a soft or hard shell? Regardless of the type of baggage, you also need to consider the airlines you commonly fly: are they the ones with strict baggage policies or are they more generous with baggage weight?

Here are some bag options frequently recommended by Redditors:

  • Duffel bags: Cotopaxi Allpa 70L sports bag and Patagonia Black hole gym bag (which comes in 40L, 55L, 70L and 100L) are perennial favorites on the bulletin board. The sturdy bags are made of weather-resistant recycled materials and can be carried by hand or worn as a backpack (and the straps for either option are stowable and removable).
  • Backpack: Scrolling through the subreddit, you’ll notice that backpacks are the preferred system for baggers. And there are so many choices. The one that appears frequently is the Bellroy Transit Plus Backpack because it respects carry restrictions, has a removable sternum strap and concealed hipbelt to take the strain off your shoulders, and has internal compression straps to reduce bulk. Another popular option is the Osprey Fairview Travel Kit. It comes with a zippered backpack for extra storage or just for walking around town during the day. For those looking for a hybrid wheeled backpack, the Fairpoint Osprey also good reviews. For something smaller, Redditors also suggested Cotopaxi’s Allpa 35L travel bag because it is light and has a full zipper like a suitcase.
  • The suitcases: r/OneBag enthusiasts aren’t very fond of suitcases – the wheels weigh the bag down, and they’re not as easy to move around crowded streets or cobblestones. Yet, if they had to choose one, it would be the Briggs & Riley Compact Cabin Spinner Where Away is the carry-on. Both are sized to meet most airline carry-on limits and come with a lifetime limited warranty.

Keep these tips and tricks in mind when planning your one-bag excursion.

One Bagg Travel Hacks

  • Use packing and squeezing cubes: Easily keep your clothes separate from your power cords (or, more importantly, your dirty underwear from your clean underwear) with these storage bags. They’re especially handy because they make it easier to pull out what you need (instead of emptying your bag looking for your tweezers). Compression bags also help crush items into more manageable packs – it won’t save you weight, but it will give you more space.
  • Choose a rectangular shaped bag: Because squeeze cubes are usually rectangular, it is best to use a similar shaped bag, this helps to maximize packing efficiency.
  • Bring a carabiner: A carabiner attached to the outside of your bag can be useful: it can hold an extra pair of shoes, a water bottle, a hat or a jacket.

First and foremost, it’s important to remember that you don’t need to pack for every eventuality. And just because you’re on vacation doesn’t mean you’re going to be a drastically different person from back home, so only pack what you’ll actually use.

Global Health Research Collaborative roundtables open to everyone starting July 22 – School of Medicine News

The Global Health Research Collaborative at Wayne State University School of Medicine will present a series of Zoom presentations and panel discussions on global health issues starting July 22.

Presentations, open to all, will cover topics such as “COVID-19: Long COVID-19 and Future Pandemics” and “Tackling Health Challenges in Ukraine and Ukrainian Refugees”, as well as panel discussions on emergency medicine, refugee trauma research, breast cancer research in African American populations, and conducting effective collaborations with international organizations.

The Friday series is a component of the 2022 session presented by the collaborative, which aims to extend quality global health education to local and foreign professionals at the start of their careers. The program aims to develop a network of highly qualified global health researchers who will conduct research aimed at improving health, capacity development, evaluation and monitoring of evidence-based interventions for health problems in their own country.

It is not necessary to be registered in the program to participate in the sessions.

Events open to the public include:

July 22, 11:35 a.m. to 12:30 p.m.: “COVID-19: Long COVID-19 and Future Pandemics”. Join an engaging conversation with the city of Detroit’s leading COVID-19 experts as they dissect their experiences driving their healthcare and academic institutions’ response during the pandemic. They will place the discussion in the context of the changing roles of researchers and the careers of health care providers. Participants include Teena Chopra, MD, MPH, professor of medicine, Division of Infectious Diseases, for the School of Medicine, corporate medical director of infection prevention, epidemiology, and antibiotic stewardship for WSU and the Detroit Medical Center and co-director of Wayne State University’s Center for Emerging and Infectious Diseases; Marcus Zervos, MD, associate dean of global affairs for the School of Medicine and co-director of the Center for Emerging and Infectious Diseases; Anita Chopra, MD, internal medicine physician at the University of Washington Medical Center and member of the long covid center at UW Medicine; and Uzma Syed, DO, Southshore Infectious Disease and Travel Medicine Consultants board-certified infectious disease specialist, and chair of the COVID-19 task force and director of the Antimicrobial Stewardship Center of Excellence for Good Samaritan Hospital Medical Center. At New York.
Zoom link: https://wayne-edu.zoom.us/j/98064585998?pwd=L0QweE5majIzQkY4eU9mckdMRnB5QT09
Reunion: 980 6458 5998

July 29, from 10 a.m. to 11 a.m.: “Global Perspectives Panel”. Participants and topics include Arash Javanbakht, MD, WSU associate professor of psychiatry and behavioral neuroscience, and director of the Stress, Trauma, and Anxiety Research Clinic, which will focus on the importance of research on refugee trauma. Evelyn Jiagge, Ph.D., research specialist at Henry Ford Hospital, will focus on breast cancer research in African American populations. Indryas Woldie, MD, WSU assistant professor of oncology and hematology, specialist at the Barbara Ann Karmanos Cancer Institute, will focus on conducting effective collaborations with international organizations.
Zoom link: https://wayne-edu.zoom.us/j/99417515857?pwd=VTh0Y3lLUjl5UVEvRzhJQTlZNU9Tdz09
Reunion: 994 1751 5857

July 29, 11 a.m. to 12:30 p.m.: “Meeting health challenges in Ukraine and Ukrainian refugees”. An in-depth discussion on the crisis in Ukraine and the challenges faced by Ukrainian refugees due to displacement will feature Paul Kilgore, MD, MPH, WSU associate professor of pharmaceutical practice and co-director of the Center for Emerging and Infectious Diseases; Arash Javanbakht, MD, WSU associate professor of psychiatry and behavioral neuroscience, and director of the Stress, Trauma, and Anxiety Research Clinic; Victor Burlaka, LMSW, Ph.D., WSU associate professor of social work; and Brian True, Managing Director of Eye Care For Ukraine.
Zoom link: https://wayne-edu.zoom.us/j/99417515857?pwd=VTh0Y3lLUjl5UVEvRzhJQTlZNU9Tdz09
Reunion: 994 1751 5857

August 5, 10 to 11 a.m.: “Round table on emergency medicine networks”. Valerie Mika, Associate Director of Clinical Research Operations for WSU’s Department of Emergency Medicine, will moderate a panel discussion on professional networking in the field of emergency medicine. She will be joined by several emergency medicine professionals from the WSU School of Medicine.
Zoom link: https://wayne-edu.zoom.us/j/93381469806?pwd=UzN2RmtGNGk0VEFLbjVxK2h3eVFWZz09
Reunion: 933 8146 9806

August 12, 11:35 a.m. to noon: “Infectious Disease Research Expert Group”. Three leading professionals will discuss how they got involved in infectious disease research and their experiences in the field. With Indira Brar, MD, infectious disease specialist at Henry Ford Health; Linda Kaljee, Ph.D., principal investigator for Henry Ford Health and associate professor at WSU’s Center for Pediatric Prevention Research; and Paul Kilgore, MD, MPH, WSU associate professor of pharmacy practice and co-director of the Center for Emerging and Infectious Diseases.
Zoom link: https://wayne-edu.zoom.us/j/91825563985?pwd=MDZDQWwyVWpyYmFxb2FPSEl4SktBdz09
Reunion: 918 2556 3985

For more information, email Zahraa Ghosn at [email protected]

Rock Solid Event: The First ABC Rock Scavenger Hunt Was a Success | Community

One of the rocks from the ABC Rock Scavenger Hunt held at Anderson Farm County Park in May.

Although it didn’t go on all summer as planned due to a theft, an event combining nature and art at Anderson Farm County Park in May was still “overall a success”, a declared its organizer to the Observer.

Oregon City resident Jann Kalscheur has always had a deep connection to the wooded park at 914 Union Road, which borders her backyard. In April 2021, in honor of the passing of her husband and Oregon Youth Baseball founder, Gary, Kalscheur funded the design and installation of a metal sculpture along the Anderson Park bike path.

“I really like this park,” Kalscheur said. “Anderson Park Friends is great. It’s small, but takes a healthy and thriving family park seriously. It is a newer park. It’s on the map because of the dog park. People are delighted with the cycle path. It’s not just about plants and animals, but also about activities that public parks promote. The group of friends work hard to make it a family park.

She said she also loves seeing art in parks, which is why she decided to host the first annual ABC Rock Scavenger Hunt in May.

“My goal is to promote nature and art and show how therapeutic they are when we introduce them into our lives,” Kalscheur said. “I want children to be connected to nature, in a wild environment, with fresh air, birds and bees, enjoying art.”

Leveraging connections in the area, she enlisted the skills of 20 artists from Wisconsin communities including Brooklyn, Cross Plains, Fitchburg, Madison, Milwaukee, Oregon, Prairie du Sac, Stoughton, Sun Prairie, Waunakee – and even locals. artists from Washington and Texas.

Kalscheur previously taught English at Stoughton High School and was able to call on a former colleague and art teacher, Ruth Phillips, to help with recruitment.

She was also helped by representatives of the organization 14 South Artists, Inc. Some artists also came by word of mouth. Planning had been underway for about a year, Kalscheur said.

The artists were tasked with creating alphabet rocks, letters from A to Z. At one point she was worried about having enough artists, but in the end, with a few duplicates, there were 34 rocks in everything, and all the letters were artistically represented.

All artists gave generously of their time and talent and received no compensation for their work.

“No money was involved, it was all from the kindness of their hearts,” Kalscheur said. “I gave them the stones, they provided non-stone supplies and did all the painting.”

The intent was to scatter these rocks around Anderson Park trails, for people to search for all summer long. However, after several boulders disappeared, the rest were removed for the season. Kalscheur is undeterred and plans to try the activity again next year, but must think of a way to anchor or secure the rocks in place.

“I don’t want to make it negative,” she told the Observer. “I don’t want to give it up.”

Most of the rocks represented activities or animals associated with Wisconsin. Many were also alliteration or assonance. There was a badger riding a bike, a moose eating maple syrup, and a skunk in a sailboat.

Although some letters were less easy to relate to Wisconsin, such as the letter U being represented by a unicorn. But there were always other ties to the state, like this whimsical unicorn painted by an Oregon High School grad who is now majoring in art at the University of Wisconsin-Milwaukee.

ABCRocks (6).JPG

One of the rocks from the ABC Rock Scavenger Hunt held at Anderson Farm County Park in May.

Although originally aimed more at children, Kalscheur promoted the event as being for all ages.

Originally, she planned to just get the stones out, but one of her sons convinced her to have a launch event as well.

A special ABC Rock Hunt launch event was held on May 6 at the park with over 100 people in attendance.

“For the first year of the event, I thought it was a good performance,” Kalscheur said. “Hopefully it’s an annual event.”

Area businesses donated prizes, time and money to help defray the costs of the event.

There was a walking meditation led by Wishing Tree Yoga Studio. JL Richards Prime Meats served BBQ pork. Prizes were given away, such as bird feeders, flower seeds, a nature-themed gift basket from Hometown Pharmacy, a Kopke’s Greenhouse gift card, a floral hanging basket from Fitchburg Farms, and doorbells. bike bags, mirrors and water bottles donated by Budget Bicycle Center in Madison.

Smaller painted rocks were also offered as prizes.

The library purchased two copies of the book “Rhoda’s Rock Hunt”, which Kalscheur specifically requested for a history walk.

Thysse donated several hundred dollars in printing costs for posters to be put up at area businesses and flyers to be sent home with every elementary school student in the Oregon school district.

“I reached out to all of these companies and was overwhelmed with the generosity,” Kalscheur said. “We ended up getting so many businesses and artists involved and sharing their love of art and the community we live in and promoting family activities and they were thrilled.”

To give back, she plans to auction off this year’s rocks to donate funds to the park.

ABCRocks (7).JPG

One of the rocks from the ABC Rock Scavenger Hunt held at Anderson Farm County Park in May.

Kalscheur has long had a creative connection with the great outdoors and has turned his passion for nature photography into his own art form.

She co-wrote with her sister and took the pictures for the 2003 children’s book “ABCs Naturally: A Child’s Guide to the Alphabet Through Nature.”

She also previously ran a business with her sister called Wild Alphabet where she took photos of elements of nature – branches, vines, leaves, flowers – that looked like letters – and customers could stitch together and frame names or words. with its natural representations of letters.

Kalscheur’s idea was inspired in part by another recent art project she helped bring to Anderson Park – the Fairy Gates. She was one of three members of the Anderson Park Friends group who planned and coordinated a project that placed 13 “gates” for mythical beings throughout the park in April. It was while doing research for this project and having fun finding them with her granddaughter that she came up with the idea of ​​organizing an A to Z type treasure hunt, which then became rocks .

She’s already thinking about next year and now she’s trying to come up with a plan to make the rocks less walkable, maybe just by having bigger rocks. She is also looking to recruit more artists and said if anyone would like to have their art in the park, she encourages them to contact her.

“It’s interesting how my brain goes right to next year, ‘how can I improve on this?’ my brain is there,” Kalscheur said. “One thing I need is a committee, with more voices. There’s a lot to think about. I need more people involved. in the process.

“People love art,” she added. “I love tapping into creative energy and sharing it and bringing smiles.”

ABCRocks (3).JPG

One of the rocks from the ABC Rock Scavenger Hunt held at Anderson Farm County Park in May.

Chattanooga family practice plans expansion in early 2023

Dr. Matthew Hitchcock is preparing to begin a long-awaited expansion of his business, but he hasn’t quite found his new location — he kind of found it.

“I got a cold call from a realtor in 2020,” said Hitchcock, who started Hitchcock Family Practice in 2015. “That’s how this whole long ordeal started.”

It ended last month when, according to Hamilton County records, HFP paid $1.6 million for the former Ryan’s Steakhouse and Crazy Buffet location at 5104 Hixson Pike.

“I’ve wanted to do this for a while,” Hitchcock said. “We were running out of square footage.”

Hitchcock estimated renovations to the nearly 11,000 square foot building will cost an additional $1 million. He expects the new building to open next spring.

Photo gallery

Hitchcock Family Medicine set to move into former restaurant

A graduate of the McCallie School, Hitchcock joined the United States Navy after earning his undergraduate degree in microbiology from Clemson University. He earned his MD from the University of Tennessee and spent seven years in the Navy in California before returning to Chattanooga.

It opened its first HFP site in Hixson in 2015, followed by the Eastgate site four years later.

He said he was the only doctor in the practice at first, but the practice now has three other doctors, a physiotherapist who splits his time between Hixson and Eastgate, two nurses and two pharmacists.

“The two buildings we have now are about 5,000 square feet in total,” he said. “Bringing everyone together under one roof, where we can look after each other and support each other, will be gold.”

Hitchcock said the practice will have room in the new location for another family doctor. He also hopes to expand HFM’s offerings by adding a dietitian and a mental health professional, and transform the prescription service available to HFM patients into a comprehensive, open-to-all pharmacy.

“Our patients would still get the best deals, but any doctor could send in a prescription,” Hitchcock said. “I hope this will reduce prescription costs for patients.”

Hitchcock also wants to dedicate some of his new space to what he called less expensive “cash-only” imaging services.

“I’m thrilled to be able to do this,” he said. “We hope to offer a simpler process that will certainly be competitive, if not outright cheaper, than insurance. You would pay a lump sum, upfront, and you wouldn’t have to worry about receiving a bill longer than six weeks. later – no hassle, no headaches, much easier.”

New US Ambassador to Ghana has ties to Williamsburg – Daily Press

Virginia E. Palmer, whose family has resided in the Williamsburg area for 42 years, is the new US Ambassador to Ghana.

She was nominated by President Joe Biden in late 2021, and after confirmation by the US Senate in March, Palmer assumed the West African post in April.

“I have been very well received by Ghanaians here,” she said in a phone call from Accra, Ghana’s capital. “They’re very high in the United States, and about 45,000 Americans live here now.”

During an appearance last fall before the Senate Foreign Relations Committee, which was considering his appointment to Ghana, Palmer said “the close partnership with Ghana spans more than 60 years and is rooted in our commitment common cause for democracy and human rights for all, peace and security, economic opportunity and prosperity.

Human rights for all, she elaborated in the interview, “is a challenge that all of us – Ghanaians and Americans – must continue to work on. In Ghana, for example, there is a bill which would severely restrict the human rights of the LGBTQ community.

“As the Bill is considered, I hope that Ghana will be faithful to its constitution and its democratic principles, as well as the international instruments to which it adheres, because everyone deserves to live a life free from harassment and discrimination. .”

Regarding civil rights, Palmer recalled that “Ghana was a very important symbol of civil rights having been liberated from colonial rule. People like Dr. Martin Luther King saw Ghana as a beacon.

She also told the Senate committee that Ghana is a “key security partner and that its leadership is critical to U.S. efforts to promote regional stability and counter violent extremism.”

Elaborating on these comments, Palmer stressed that one of his main challenges for the future “is to ensure that West African coastal states are not centers of terrorism. It is an increasingly difficult area and Ghana has an important role to play.

Palmer explained that she would like to see an increase in bilateral trade and investment between the two countries. Bilateral trade now stands at $2.7 billion a year. The United States buys a lot of gold and cocoa from Ghana, while supplying pharmaceuticals, agricultural equipment and automobiles. Increases would benefit everyone, she added.

His parents, Richard and Becky Palmer, came to Williamsburg in 1980 when he joined the faculty of William & Mary. She was in college at Washington University in St. Louis, Missouri, at the time, but has traveled to Williamsburg frequently over the years.

“I’ve always considered Williamsburg my home,” she said. “The State Department lists it as my home base. Back home is where your family is.

The 36-year-old senior foreign service officer, who began his career in 1986, previously served as the United States Ambassador to the Republic of Malawi from 2015 to 2019.

During his career, Palmer served twice as Deputy Chief of Mission and Chargé d’Affaires in South Africa, 2011-2014 and Vietnam, 2008-2011. Other postings in his career included postings to Canada, Zimbabwe, China and Hong Kong, according to his biography at the State Department.

Prior to his appointment in Ghana, Palmer served as Principal Deputy Assistant Secretary of the US State Department’s Bureau of Energy Resources.

Palmer’s family traveled frequently and “I always had the international bug,” she says. “When I was 15 I was an AFS exchange student in apartheid South Africa. I saw then what it was like to live without the freedom we took for granted and also the impact positive that the United States could have.

“I think I wanted to be a foreign service officer back then. So I went to university and graduate school to study international relations.

She received her undergraduate degree from Georgetown University and her master’s degree from the University of Virginia, where she also completed doctoral studies.

Palmer’s husband, a retired foreign service officer, traveled with her to Ghana. They have two adult children, one of whom is a William & Mary graduate.

Her father was on the William & Mary faculty of the Department of Theater and Expression (it later included dance) for 36 years until his retirement in 2016. He served as Department Chair for 10 years and for many years artistic director of the William & Mary Theater and general manager of the Williamsburg Shakespeare Festival. He died in 2020.

His mother was a professional piano teacher for many decades and still lives in the Williamsburg area.

Wilford Kale, [email protected]

NRG Therapeutics and Domainex partner for drug development project for Parkinson’s disease

NRG Therapeutics and Domainex aim to develop new small molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.

NRG Therapeutics, a UK-based neuroscience company targeting mitochondrial dysfunction, and Domainex, a UK-based integrated drug discovery services company, have formed a collaboration to develop novel disease-modifying drugs to small molecules to treat Parkinson’s disease, motor neurone disease (MND), and other chronic debilitating neurodegenerative disorders.

Under the agreement, Domainex will provide fully integrated lead optimization services, including assay biology and medicinal and computational chemistry, according to a company press release dated June 30, 2022. period of one year, NRG Therapeutics is expected to potentially invest over £1 million (US$1.2 million) in the project. This program follows a £2.68 million (US$3.2 million) Biomedical Catalyst Prize awarded to NRG Therapeutics by Innovate UK.

Previous work by NRG Therapeutics, funded by Parkinson’s Virtual Biotech, the drug development arm of Parkinson’s UK, resulted in the identification of a series of small molecules that inhibit the mitochondrial permeability transition pore (mPTP), a transmembrane protein in mitochondria inner membrane essential for cell signaling and regulation of cell death. Inhibition of mPTP in brain cells has been shown to have neuroprotective benefits, as demonstrated in several preclinical models of Parkinson’s disease and other neurodegenerative diseases, according to the press release.

Previous work by Domainex, which was also funded by Innovate UK, includes a project targeting kinase IκB epsilon/TANK binding kinase 1 for the treatment of inflammatory diseases.

As part of their collaboration, NRG Therapeutics and Domainex will implement an integrated lead optimization program to optimize the pharmaceutical properties of small molecule mPTP inhibitors. Their ultimate goal is to name a preclinical candidate for the treatment of Parkinson’s disease or MND.

“We hope this program will lead to a new treatment for neurodegenerative diseases, such as Parkinson’s disease, which will ultimately benefit patients who desperately need new treatment options for these devastating diseases,” said Tom Mander, CEO of Domainex, in the press release.

“Mitochondrial dysfunction is a common underlying pathology in many degenerative diseases, and there is a substantial body of preclinical data available, which demonstrates that inhibiting mPTP in the brain prevents neuronal cell death, reduces neuroinflammation and prolongs animal survival. We look forward to working with Domainex to advance the development of these compounds into potentially life-changing medicines,” said Neil Miller, co-founder and CEO of NRG Therapeutics, in the release.

Source: Domains

Innovation or stagnation? Europe’s pharma industry at crossroads ahead of rule overhaul – EURACTIV.com

War, the COVID-19 pandemic and vulnerable supply chains are pushing the EU to be more resilient and self-sufficient in pharmaceutical production. Reviewing existing legislation offers the possibility of unlocking investment and research in this area.

Europe’s pharmaceutical industry has warned that the bloc is lagging behind in innovation and losing its position in the global market.

For example, pharmaceutical research in the American industry grew twice as fast as that in Europe between 2017 and 2019.

The disparities between the United States and Europe are also evident from the perspective of patients who are concerned about the accessibility of new drugs.

Currently, it takes an average of 150 days longer to get an innovative drug approved in Europe than in the United States – a delay that could be crucial for some patients.

As Sini Eskola, Director of Regulatory Strategy for the European Federation of Pharmaceutical Industries and Associations (EFPIA) stated, 48% of innovative medicines are currently developed in the United States, while in Europe it is only 22%.

The main focus should therefore be on supporting the resilience and growth of the industry, said Heike Prinz of pharmaceutical giant Bayer.

A unique opportunity in 20 years

The EU currently finds itself at a crossroads represented by the bloc’s upcoming pharmaceutical legislation review. The new legal framework should guarantee access to affordable and quality medicines, make the pharmaceutical system more resistant to crises and increase the security of supply.

The review will also emphasize innovation, a crucial component for the industry. The new legislation could reduce the regulatory burden and help in areas where diagnosis, prevention or treatment is insufficient.

“But development can either be for innovation or for stagnation,” warned Bayer’s Prinz

In particular, representatives of the innovative pharmaceutical industry are calling for more flexibility, which will make it easier for innovative technologies to enter the market and should help to improve the availability of medicines.

This should also be addressed in the review, as the European Commission has stressed that the new legal framework for pharmaceuticals should now be adapted to new scientific and technological developments.

“It is extremely important that people coming directly from the industry can participate in the legislative process. A bad decision would affect the entire sector for the next 20 years”, underlined Nathalie Moll, director of the EFPIA, during a pharmaceutical strategy conference organized in the Czech Senate before the start of the Czech EU Presidency.

According to the Commission’s provisional work programme, the initiative will be presented in December 2022.

Digitization of the health sector

In order to be adaptable and able to respond to new challenges, the EU must also keep an eye on current trends and fill market gaps. One of them could be, for example, biotechnology, in which the EU currently invests little.

Another, even more important, is the area of ​​data. This is what should be the next step towards European resilience, in particular through the digitization of the health system and the sharing of health data. It is by sharing and making data comparable that countries can better identify the sources of problems and solve them effectively.

However, data sharing is currently only voluntary. The legislative proposal for a European Health Data Area presented by the Commission last March aims to change this.

Work will be taken over by the Czech EU Presidency in the second half of 2022.

Given the timing of the process, it is important to continue the work already started, said Antonius Rodiadis of the European Commission’s Directorate-General for Health (DG Health).

The Czech Republic’s key role will be to draw the attention of EU health ministers to individual member states and the implementation of legislation at national level.

[Edited by Gerardo Fortuna and Benjamin Fox]

TS ECET Hall Ticket 2022 Exit; Direct link here

TS ECET 2022 Hall Ticket Download

Image credit: Shutterstock

New Delhi:

TS ECET 2022 room ticket: The Telangana State Engineering Common Entrance Test (TS ECET) Admission Card 2022 has been released today, 08th July. Candidates can download the TS ECET Admission Card 2022 by entering the Registration Number, Qualifying Examination Hall Ticket Number and Date of Birth in the direct link provided here.

Recommended: Colleges of engineers accepting TS-PGECET. Click here

Telangana ECET 2022 is a computer-based test (CBT) to be held on July 13, 2022. The entrance test for admission to engineering courses will be held in two shifts. While the first shift is scheduled from 9:00 a.m. to 12:00 p.m., the afternoon shift will be from 3:00 p.m. to 6:00 p.m.

TS ECET Admission Card 2022 – Direct link

TS ECET 2022 paper model for diploma courses will include questions from Mathematics, Physics, Chemistry and related engineering branch subjects.

Topics Brands
Math 50
Physics 25
Chemistry 25
Engineering paper (including civil, electrical and electronics, mechanical, electronics and communication, computer science and others) 100

For BSc Mathematics, the TS ECET 2022 paper pattern is

Topics Brands
Math 100
Analytical capacity 50
Communicative English 50

The TS ECET 2022 paper pattern for Pharmacy is based on the following pattern

Topics Brands
Pharmacy 50
Pharmaceutical chemistry 50
Pharmacognosy 50
Pharmacology & Toxicology 50

Christian Theological Seminary Elects Leaders to its Board of Trustees – Inside Indiana Business

Myra Selby and Dana Sherwood

The Christian Theological Seminary elected its board members: Myra Selby, president; Fred Green Vice President; Dana Sherwood, Treasurer and Jo Taylor, Secretary.

Selby is an attorney and partner at Ice Miller LLP in Indianapolis. Selby is a graduate of Kalamazoo College (BA) and the University of Michigan Law School (JD), and she served as Director of Health Care Policy for the State of Indiana under Governor Evan Bayh. . She holds the distinction of being the first female and first African-American associate justice of the Indiana Supreme Court (1995-1999). There, Selby increased the court’s public transparency and wrote more than 100 majority opinions. In 2016, President Barack Obama appointed her as a United States Circuit Judge on the United States Court of Appeals for the Seventh Circuit. The recipient of numerous awards, including the Madame CJ Walker Award, Selby has served on the CTS Board of Directors since 2017.

Green recently retired as Chief Strategy Officer and Chief Operating Officer at Cripe, where he held several different leadership positions, such as Head of Architecture. He earned a BFA from Indiana University and a BA in Architecture from the University of Kansas. Green is a member of several boards and professional organizations, including the American Institute of Architects; the Andrew J. Brown Academy Board of Trustees; the University of Kansas School of Architecture, Design and Planning Advisory Council; the Indy Public Safety Foundation Board of Directors; and the City of Indianapolis Board of Contractors.

Sherwood is president and CEO of C-Tech Corporation Inc., in Boggstown, which installs guardrails, fencing and other traffic safety devices throughout the state. She is a Certified Account Professional who earned a BS in Accounting from Butler University. Sherwood is a member of the First Christian Church of Shelbyville, where she served as a Sunday School teacher and chair of the congregational research committee, budget committee, Christian education, and strategic planning committee. Sherwood has served on several community boards, including the Shelby County United Fund, Shelby Senior Services, and the Indiana Construction Association, and she has also served on the Blue River Foundation Grantmaking Committee. She has been a member of the CTS Board of Directors since 2014.

Taylor is president of JAT Executive Coaching and Consulting. She earned a BS in Psychology and Communication from Goshen College and an MBA from Indiana University Kelley School of Business. Taylor has held numerous positions during her 31-year career at Eli Lilly and Co., including Vice President and Global Head of Ethics and Compliance (2011-2014) and Chief Client Officer and Vice President of global research (2014-2017). Taylor serves on the Development Board of the AMPATH/IU Center for Global Health and the Strategy Committee of Timmy Global Health, and she has been a member of the CTS Board of Directors since 2016.

Additionally, CTS has added five new members to its Board of Directors:

Dr. Judith G. Apple-VanAlstine lives in Fishers and is a member of the Geist (Disciples of Christ) Christian Church. She holds a doctorate in education, as well as a bachelor’s and master’s of science in elementary education, from Indiana University, Bloomington. For more than 16 years, Apple-VanAlstine has worked in higher education and is dedicated to lifelong learning. She is Dean Emeritus of the School of Adult Learning at Indianapolis University. Apple-VanAlstine has also served as Director of Academic Programs at Indianapolis University and Director of Curriculum and Assessment at Center Grove Community School Corporation. Judith received the Accelerated Programs Commission’s Excellence in Teaching Award in September 2008.

Belinda Drake is the Director of Youth Services at Indiana Youth Group, where she serves youth ages 12-24 who identify as LGBTQ+, and their allies. A resident of Indianapolis and a member of the New Revelation Baptist Church, she has a bachelor’s degree in political science and law from IUPUI and has dedicated her career to community service. Drake has worked with the Indiana Family Social Services Administration and the Indiana Department of Child Services. In 2020, she ran for Indiana State Senate in District 32. Drake mentors local youth, volunteers for the Indianapolis NAACP Young Adult Committee and other community groups , organizes local voter registration and hosts STUDS Who Lead events to promote gender and sexual identity acceptance and inclusion.

Rev. Dr. William J. Smith, Jr. is pastor at Second Missionary Baptist Church in Kokomo. A native of Mathews County, Virginia, he was licensed and ordained in the Lebanon Baptist Church and served as an associate minister in the Third Baptist Church under Dr. Joe B. Fleming. William earned a BA and MA from Virginia University and Seminary, an MDiv from CTS, and a DMin from United Theological Seminary. Under his leadership, Second Baptist recently launched a Community Development Corp. Embracing Hope of Howard County and renovating Douglass School, a historic African-American school to serve as a community museum and cultural center and developing land for community transitional housing.

Timothy K.Sullivan is Chief Financial Officer of Thompson Thrift Construction. He lives in Bloomington and is a member of the First Christian Church. Tim holds a Bachelor of Science in Accounting from Indiana University and an MBA from Butler University. Previously, he served as vice president of finance and director of global financial planning and analysis at Bemis Co. He currently serves on the board of directors of Union Hospital and is a member of the accounting advisory board of the ‘Indiana State University. Active in numerous professional organizations, he is a member of the American Institute of Certified Public Accountants and a mentor at Indiana University’s Kelley School of Business. In 2005, he was a member of the Six Sigma green belt of the task force for the promotion of liberal arts education at ISU.

Dr. Alana Jamil Washington is executive pastor of Amazing Grace Christian Church in Indianapolis. She holds a Doctor of Pharmacy, an MBA in Leadership, Entrepreneurship and Innovation, and a Masters of Business Administration from Butler University. Since 2018, she has worked for Eli Lilly and Co. and is currently Senior Director, US Alliance – Diabetes, Global Medical Affairs. She has also worked with the Methodist Medical Group and at St. Vincent Women’s Hospital and St. Vincent Hospital, where she served as Director of Pharmacy Services. She currently serves on the board of the Indiana Pharmacists Association. She co-directed the first fundraising campaign for Amazing Grace Christian Church, where she served as a board member and secretary from 2013 to 2018.

Teens explore careers at SIUE Healthcare Diversity Summer Camp

EDWARDSVILLE – Southern Illinois University Edwardsville once again welcomed high school students to explore its facilities and connect with faculty experts to boost their interest in health-related fields during the annual Care Diversity Summer Camp. health.

Approximately 20 students participated in the June Camp, a collaborative effort organized by SIUE Schools of Pharmacy (SOP), Nursing, UES School of Dentistry, and the School of Nutrition Program. education, health and human behavior. It focuses on experience and enrichment as students gain an understanding of the many opportunities that exist in each area of ​​health, through lessons and interactive activities.

“The goal of the camp is to expose high school students who are underrepresented in healthcare fields to careers in pharmacy, nursing, dentistry and others,” said camp coordinator Lakesha Butler. , PharmD, Clinical Professor in the SOP Department of Pharmacy Practice and Director of Diversity, Equity and Inclusion. “It is recognized that diverse representation of healthcare students translates to diverse representation in healthcare, which is essential to meet the growing needs of our local community, our region, our country and the world.

The camp experience rekindles campers’ interest in pursuing and graduating in health-related fields. One example is SIUE alumnus Christian Watts, PharmD, who began his pharmacy journey by attending camp nine years ago.

“The beginning of my exposure to pharmacy happened when I attended SIUE’s Healthcare Diversity Camp,” said the former president of the SIUE chapter of the National Association of Pharmaceutical Students. “The camp informed me of several careers available in the field of pharmacy.”

ChibuIke Azogini’s mother, a native of Collierville, Tennessee, enrolled him in the program because of his growing interest in the health field.

“Being in labs synthesizing molecules that can be useful in helping the world today is interesting,” Azogini said. “I learned that pharmacists do more than just dispense medication. There are hundreds of jobs in the field.

Paulina Gutierrez, a senior from Collinsville, heard about this opportunity through the Upward Bound program at SIUE East St. Louis Center. She attended to help him narrow down his choice of a college program. The camp helped her discover the vast nature of the healthcare field.

“The faculty offered us tips and advice on what we should do to prepare for the course we chose,” she shared. “My camp experience has helped me navigate what I plan to study.”

Maya Tolentino of Chatham discovered the program because of her interest in the health field.

“The faculty was engaging and interactive,” Tolentino said. “An interesting moment was when we were in the lab at the School of Nursing and they showed us a simulation of labor and delivery.”

The Healthcare Diversity Camp expands the reach of SIUE throughout Illinois. . Importantly, Butler noted, “Not only does camp provide opportunity and exposure, but it also provides a network of peers with similar interests who can serve as mutually beneficial motivators and friends.”

10 reasons to incorporate grapeseed oil into your skincare routine

If you have dry skin, grapeseed oil could help revive it and give you back that sought-after glow. All oils suitable for skin care are hydrating, but grapeseed oil is very special. The reason? It is suitable for all skin types, even if you are prone to breakouts and have oily skin. That’s because grapeseed oil is noncomedogenic, which means it won’t clog your pores or leave your skin looking like a ball of grease, said Vince Spinnato, a cosmetic chemist. Seduce.

Speaking to Bustle, cosmetic dermatologist Marnie Nussbaum said the linoleic acid in grapeseed oil is responsible for its moisturizing properties. “Part of what makes grapeseed oil so beneficial for the skin is that it contains linoleic acid, which is a polyunsaturated fat that forms a protective layer on the skin maintaining a moisture barrier,” she said. The vitamin E in grapeseed oil also plays a vital role, dermatologist Tsippora Shainhouse, MD, told Prevention.

Vitamin E works to replenish your skin’s natural lipids (fats), which helps keep your skin barrier intact. Although it seems counterintuitive, this process also helps the skin produce less oil. Shainhouse says skin usually produces too much oil because it thinks it’s dry. Replenishing your skin’s natural lipids gives it a boost of hydration and, in turn, slows sebum production. Amanda Hume, a green beauty expert, told Bustle that you can use grapeseed oil as a moisturizer or cleanser to reap the aforementioned benefits.

Mzuni in industrial and medical cannabis research – Malawi Nyasa Times

Mzuzu University has embarked on a major research project to test samples of industrial and medical cannabis to assess the effectiveness of certain varieties in the industrial and healthcare sectors.

Chemistry department head John Kamanula told local media that the university was working with the Cannabis Regulatory Authority (CRA) and other stakeholders in the research project.

Mzuzu University

Kamanula added that most of the chemicals used to test cannabis strains are very expensive and the university needs sufficient support.

“They bring in different strains of cannabis, and then for them to know which one is marketable, you have to do the chemistry. Based on the chemistry, they can then know the quality of the varieties they have that can reach market prices,” Kamanula explained.

The research also involves chemistry students from the university, and a company working with the university has called for a collaboration to raise awareness about cannabis and its potential for national development.

Executive Director Tania Clerk emphasized the importance of research.

“We should set aside funds and engage academia to access the role they can play in industry development. We have to recognize that this is something that needs to be nurtured,” Clerk remarked.

Malawi passed and accentuated the Cannabis Act in 2020.

Follow and subscribe to Nyasa TV:

Sharing is caring!

Cannabis vs COVID-19: a match made in Oregon

In the history of the world there has never been a plant more versatile than Cannabis-sativa. Not even close. With some 25,000 hemp-infused products to its credit, cannabis has no equal. For centuries, this verdant little botany has amazed us with its seemingly limitless usefulness and is once again in balance. This time in health, as a hopeful new weapon in the war against COVID-19 and its subsequent variants.

For precision, the only determining factor classifying Cannabis-sativa like hemp or marijuana is the percentage of tetrahydrocannibinol (THC) produced by the plant. Any level above 0.3% and it’s by law, marijuana. Hemp’s level of THC production is so low, well, it’s hemp. But hemp doesn’t need THC to work its magic.


SARS is a despicable virus, with SARS-CoV-2 being the etiological agent (cause) of COVID-19 (Coronavirus disease-2019) and the ensuing pandemic. Acronym for Severe Acute Respiratory Syndrome, SARS swept the world in a tsunami of death. Few places on Earth have been spared from this scourge. Closer to home, over 40,000 deaths have been reported in Canada and one million in America in just under 3 years.

Doctors, immunologists, researchers and scientists around the world are constantly searching for effective ways to fight and treat this deadly disease. And on the west coast of America, a change in the viral matrix can occur.

The search for a cure

In a research lab at Oregon State University, progress is being made in this fight and perhaps even in history. And once again, the irrepressible Hemp plant is at the forefront of a scientific breakthrough. A team of scientists from Oregon has made a startling discovery. They identified two acidic compounds found in hemp that have been shown to prevent the SARS virus from entering cells in the body.

These findings were recently published in the prestigious Natural Products Journal. The potential implications of this pioneering discovery are staggering. COVID-19 infects the body by entering epithelial cells in the airways, then spreads to other areas as it replicates. But if he can’t infiltrate the cell, then what does he do?

I wanted to know more about this promising new development and contacted the project’s lead scientist. He was kind enough to grant an interview. Before you begin, here are a few words you should know.

  • ligand – A molecule that binds to another molecule, often larger.
  • peak protein– In virology, a spike protein is a protein that forms a large structure called a spike or peplomer that projects from the coated molecule. This structure is used by the SARS virus to penetrate and enter the cell. It’s like a ruffled crown. Latin word for crown, wreath. As in the Virus.
  • Mass spectrometry– Is a laboratory analytical technique for separating the components of a sample by their mass and electrical charge.
  • Test– Balance sheet, analysis.

The scientist behind the science

Richard Van Breemen is a professor of pharmaceutical sciences at Oregon State’s College of Pharmacy and the Linus Pauling Institute Global Hemp Innovation Center in Corvallis, Oregon, and a busy man. Especially if he has to write his title very often.

Professor Van Breemen and his team along with scientists from Oregon Health & Science University are being congratulated on their promising new discovery. A discovery that could potentially stop the SARS virus in its tracks.

High Times: Thank you very much Professor, I really appreciate that you took the time out of your busy schedule for this interview.

Professor Van Breemen: You’re welcome. I am delighted to speak with you.

Please tell me about your background.

I received my undergraduate degree in chemistry from Oberlin College in 1980 and my Ph.D. in Pharmacology in 1985 from Johns Hopkins University. I joined North Carolina State University and taught chemistry until 1993. Then I moved to Chicago where I taught medicinal chemistry and pharmacognosy at the University of Illinois College of Pharmacy until 2017 before move my lab to Oregon State University. I have been a Professor of Pharmaceutical Sciences at Oregon State University since 2018 (4½ years).

How long have you been studying hemp?

I have been studying hemp since the creation of the Global Hemp Innovation Center in 2018.

I understand that you also invented the mass spectrometry process by which you measured these encouraging results. To correct?

Yes. In 1996, my research group invented pulsed ultrafiltration (PUF) mass spectrometry, which is one of several affinity selection mass spectrometry approaches for screening mixtures of compounds in the early stages of drug discovery.

In 2008, we invented an even faster affinity selection mass spectrometry method that uses magnetic beads that we call MagMASS for magnetic bead affinity selection screening. MagMASS was used for our recent SARS-CoV-2 discovery of cannabinoid acids that prevent viral entry into human cells.

Isn’t working with a live virus dangerous?

Working with live SARS-CoV-2 requires special containment facilities and expertise, and I was fortunate enough to begin a collaboration in 2020 with Dr. Fikadu Tafesse from Oregon Health & Science University, who had just established a laboratory for cell culture experiments using living cells. SARS-CoV-2.

When did you start your cannabis and COVID project and how long before your trials showed positive results?

Our COVID research began in the spring of 2019. As lab director, I focused my group’s affinity selection-mass spectrometry project on the discovery of natural anti-SARS-CoV-2 compounds.

In the summer of 2020, we had a working MagMASS assay targeting the viral spike protein and obtained the first data indicating that cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), and Δ9-tetrahydrocannabinolic acid-A (THCA-A) were spike protein ligands. This research was conducted primarily by Dr. Ruth Muchiri, who is my lab director.

When Dr. Tafessse’s group reported observing antiviral effects due to cell entry prevention by CBDA and CBGA in late 2020, I knew that our breakthrough protein ligands were active against live virus.

So, to be clear, your team’s specific findings were…?

Our team found that cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA) can bind to the spike protein of SARS-CoV-2. We also found that these compounds can block cell entry using live SARS-CoV-2.

And what does this mean in terms of possible treatment?

This means that cell entry inhibitors, such as hemp acids, could be used to prevent SARS-CoV-2 infection and also to shorten infections by preventing virus particles from infecting human cells.

It is an extraordinary discovery and a perfect sequel. What happens to the virus when it fails to enter the cell?

If the virus cannot enter a cell, it will be recognized as a foreign object and destroyed by the immune system. By blocking cell entry, the virus cannot replicate. Without more copies to overwhelm the body’s defenses, the virus particles will be eliminated by leukocytes.

Do we know if these virus-fighting cannabis compounds would be safe for humans?

According to the Center for Disease Control, there has never been a fatal overdose of cannabis, hemp, or cannabinoids. This includes the cannabidiol drug called Epidiolex which is FDA approved for controlling certain types of seizures. This level of safety is remarkable and unusual for any drug or natural product.

So what are you waiting for now?

I look forward to expanding our natural drug discovery program using mass spectrometry and affinity selection. Nature remains a vast and largely untapped source of new therapeutic agents. Probably less than 10% of natural products have been discovered and tested for therapeutic activity.

By applying our original mass spectrometry approach to natural drug discovery, I hope to make many more contributions to human health in my career while training a new generation of biomedical researchers to pursue research.

Pharmacy Appointment – The Hindu

GITAM School of Pharmacy, Hyderabad will organize a one-day national conference on Pharmacy and Pharmaceutical Sciences” (CPPS-2022) on its campus on August 5. The CPPS focuses on the theme “Data Science, Artificial Intelligence (AI) and Flexible Manufacturing”, according to GS Kumar, Director of the School of Pharmacy.

The event is sponsored by the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, and in association with the Indian Association of Pharmacy Graduates, branch of the Telangana State.

The primary goal of health-related AI applications is to analyze the relationships between clinical techniques and patient outcomes. Industrial Flexible Manufacturing System (FMS) consists of robots, computer controlled machines and the use of robots in the production segment of manufacturing industries promises a variety of benefits ranging from high utilization to high volume of productivity.

Abstracts are invited in manuscript form and must be from original research in areas such as pharmacy and biopharmaceuticals, new and targeted drug delivery, nanotechnology and nanomedicine, phytochemistry

The abstract submission deadline is July 18 and the registration deadline is July 20. Interested persons can contact Kingston Rajiah, President of the organization, 91593 09257 or email [email protected] or Dr Jitendra Patel, Organizing Secretary, [email protected].

Community health centers ask for additional protections / Public News Service

Community health centers are asking state and federal lawmakers for additional protections against drugmakers for drastically excluding them from a federal drug rebate program.

The 340B Drug Pricing Program allows health centers to purchase outpatient drugs at reduced costs, so they can then provide them to more patients while pharmaceutical companies are reimbursed. But over the past two years, drug producers and third-party prescription drug benefit managers have restricted the centers, threatening their financial stability.

A survey by the National Association of Community Health Centers shows that more than half of their patients would go without necessary medications, including insulin for diabetic patients and inhalers for children with asthma, if they were excluded from the program.

Ben Browning, vice president and CEO of the Florida Association of Community Health Centers, explained the importance of the program.

“These contractual arrangements are really the cornerstone,” Browning argued. “They are the lifeline for many patients who otherwise might not have access to these discounted, discounted drugs.”

But Pharmaceutical Research and Manufacturers of America, the drug manufacturing industry’s lobbying arm, countered that the program needed to change, saying there was little to no evidence that patients benefited. They are also asking the centers to share data in an effort to combat potential fraud and abuse in the system.

Browning argued that the centers continue to meet a critical need, as many health care providers do not have the financial resources to support an in-house pharmacy. The survey showed that 86% of health centers use contract pharmacies, allowing them to serve hundreds of postcodes.

“Put protections in the law, in the regulations, in the law, that say the 340B program is an essential part of the health care system,” Browning urged. “This is an essential part of maintaining and securing the safety net.”

It is estimated that enrolled hospitals and other entities covered in 340B can achieve average savings of 25% to 50% on pharmaceutical purchases. The issue is also playing out in court with conflicting rulings across the country.

Disclosure: The National Association of Community Health Centers contributes to our fund for reporting on policy and budget priorities, and health issues. If you would like to help support news in the public interest, click here.

get more stories like this via email

The great migration of pharmacists in hematology-oncology is caused by problems other than burnout that could be quickly solved

Pharmacy hours interviewed Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, in a 2022 ATOPP Summit session they will co-present to address the research they conducted to assess the underlying causes of the great migration of pharmacists in hematology- oncology.

Question: What is the great migration of pharmacists in hematology-oncology, and when did it start?

Zahra Mahmoudjafari: That’s an excellent question. I honestly couldn’t put my finger on exactly when it started. I think we all started to understand and recognize this about a year ago when we met for a brief conference in June 2021 and recognized that many of our colleagues and team members who have worked with us and alongside us in direct patient care roles, since moving into different roles, were doing different things.

It allowed us to start asking ourselves why this was happening and led us to ask these questions directly to our colleagues, and we came together at the end of this conference, and at the time we framed it as “ the great migration. There are other publications that are available for the entire workforce, especially on what is called the “big quit”. But we chose to call it the “great migration” because our pharmacists are still working in pharmacy in some respects, but not necessarily in the direct patient care role. So we were motivated to understand why some of these reasons were happening to motivate our team members to move into non-direct roles with patients.

Kamakshi Rao: I think I would just add to that to say that I think pharmacists have been migrating between clinical and other roles for a long time. It is therefore nothing new for pharmacists to move or change roles. I think what we talked about was, I think it was 2 things.

The first was the rate of change, like how quickly it seemed like every few days, every week, we heard from someone we knew pretty well, and I think the three of us are connected pretty well to know the oncology pharmacists across the country, and so it kind of surprised us to see the pace of change.

Then I think there were probably for each of us a few people that we knew in our heads that you never thought would happen. He was someone who, when you met them, you’re like, he’s a person who’s going to be taken care of for the duration, that’s completely his zone. Then to see these people make the decision to leave patient care, I think those 2 factors kind of stung our ears, because something different is going on here, something has changed.

Question: How has the pandemic contributed to this migration?

Zahra Mahmoudjafari: Yes, I think the pandemic may have accelerated what was already happening and potentially made it even more painfully obvious, thinking this was a time when pharmacists really needed to sit down and assess what matters to them . So sometimes what mattered to them was increased flexibility and the ability to work from home. What mattered in terms of mental health or career advancement, they took time to really assess that specifically, and I think that just made it worse and really highlighted it and really cleared the rug from under us.

So I think that really made me see things in a more positive light and allowed us to really look at some of the things that are causing the problem and allows us to have much more honest conversations. So as a result, our patient-facing pharmacists can really have the time to spend with our patients and care for our patients, and we now have more honest conversations than we ever had before. So I like to think it’s positive. But it was definitely a tough two years, and I think for all of us in many ways, just when you thought you had overcome one thing, the next problem came along.

The other facet of this situation is certainly the direct scarcity which has never gone away, and the situation is only getting worse, it seems, in the end. Again, I think the pandemic helped highlight it, but also helps us understand some of those fundamental factors and the main reasons why it was already happening, maybe it just accelerated it.

Alison Gulbis: I think adding to what Zahra said about all the work from home and flexibility that people have come to realize there is – many institutions have taken on these clinical pharmacy specialists who had direct roles with the patients and made them work from home. So it’s really started to realize that flexibility is helpful for some, but, on the other hand, I think working from home has also blurred the boundaries of when you stop working. Also, I think it got people thinking about their personal time and what they needed, so I think that helped as well.

Question: What are the causes of the great migration, and is it above all burnout?

Zahra Mahmoudjafari: Burnout is a big facet, but it’s not the only reason. In fact, our research revealed many emerging trends, some of which were more obvious than others. Some of these are surprising things that we would call low-hanging fruit that institutions can implement quite quickly in an attempt to retain their staff.

One thing that came out pretty clearly is that team members want more support and potentially better patient ratios. They feel a lack of recognition, they don’t necessarily feel valued.

One thing that stood out loud and clear was the number of administrative responsibilities our pharmacists took on both in military spending and as QA lead. Another facet was the flexibility of wanting to work from home potentially, and then there are other facets, including career advancement – ​​I think our pharmacists are extremely high achievers and they want to keep working towards something. Some of them have different strengths that don’t necessarily mean they want to be in direct patient care, offering them ways to explore those opportunities are all facets of some of the trends we’ve identified in our research. .

Again, there are other fruits at hand, as I said, which include things like support for board certification, the ability to attend conferences and network with other co-workers, which we see as something that could easily be done, if given the right resources, but it’s not just about burnout.

Kamakshi Rao: I should draw attention to, I think, burnout and well-being are very important. And you consider that so many things overlap and contribute to a person’s risk of burnout and well-being. These things can include more than just workload. We’ve heard of a lot of people who felt their desires for advancement didn’t fit the strict narrative of the job descriptions they had, feeling like their time was nickel and dime and reduced to things that really didn’t use their skills. , so when a pharmacist spends an inordinate amount of their days on insurance authorizations trying to navigate the system rather than being able to provide patient care.

We also heard from oncology pharmacists who are also involved in so many different things – teaching, research, committee work, representation and service to local, regional and national organizations, and most of them do so during their free time.

Also, going back to the pandemic discussion, our own time has become more important than ever. So when things started to seep in, and the idea was that whatever you wanted had to happen in your free time. It really changed people’s level of satisfaction that their career advancement was not tied to the proper metrics. So I think we’ve heard a very strong call for more appropriate measures that drive clinical pharmacy practice and career ladders and advancement opportunities that are more than just administering pharmacy as 3 people who have made these transitions to administrative roles. I think 3 of us had really healthy discussions about how this was the only option for advancement, and we pursued those options. But if we could go back and look at advancement using different avenues, whether it’s securing protected time for education research fellowships, it would have changed the course for many pharmacists who have chosen the administration as a pathway that may have changed the choices they made.

Researchers call for better use of chemical tools to improve biomedical research

Biomedical research experts are calling for better use of chemical probes to improve our understanding of protein function and the foundations upon which much of modern drug discovery and development rests.

In a maintenance in Nature CommunicationProfessor Paul Workman, Harrap Professor of Pharmacology and Therapeutics at the Institute of Cancer Research in London, and Professor Cheryl ArrowsmithChief Scientist for the Structural Genomics Consortium (SGC) Toronto Laboratories and Professor of Medical Biophysics at University of Torontoexpose the main problems associated with the use of chemical probes in biomedical research and highlight new projects aimed at increasing the number and quality of chemical tools available to researchers.

Chemical probes are small molecules used to test the activity of a protein in a cell, often by inhibiting it.

Expert advice on chemical probes

One of the projects discussed is a new and improved version of an easy-to-use online resource for chemical probes. The portal of chemical probesrelaunched in 2021, relies on the expertise of an international community of 200 researchers in chemical biology, chemistry and pharmacology, and relies on the analysis of big data.

The portal aims to solve a central problem in biomedical research by encouraging the use in laboratory experiments of better and better chosen chemical probes – the molecular tools, usually protein inhibitors, which facilitate the understanding of biological processes and that are important to support the conclusions of the research.

A probe for each protein

Goal 2035 is a community-based research initiative aimed at accelerating the development of a chemical probe for every protein in the human proteome by 2035. Led by the SGC, Target 2035 brings together scientists from various fields of drug discovery, including biochemists, structural biologists, medicinal chemists, testing scientists and computer scientists. chemists.

With a focus on open and collaborative science and new technologies, Target 2035 aims to accelerate the development of new, high-quality chemical probes for the 90% of human proteins that have yet to be studied for the potential discovery of medications.

Powerful tools for biomedical research

Chemical probes are powerful tools routinely used to uncover how individual proteins are involved in health and disease, including in cancer, dementia and recently Covid-19, and ultimately lead to the discovery of new drugs.

But the quality of these reagents varies widely, and the use of suboptimal tools in research is widespread. Using poor or poorly selected compounds as tools can produce misleading results.

Better use of chemical probes could also save the biomedical research sector billions of pounds, by ensuring that new disease therapies are developed from a better and more robust understanding of their biological effects, and are therefore less likely to fail in expensive clinical trials.

Quickly provide expert information

Developed by ICR scientists with support from organizations including the SGC, Welcome and Cancer research in the UKThe new Chemical Probe Portal aims to encourage the widespread selection and use of the most appropriate high-quality chemical probes, particularly within the academic biology community.

One of the major updates from the previous iteration of the portal is a new process for sifting through massive datasets, recommending compounds of interest to consider as probes for further analysis by experts.

Researchers from academia and industry can also submit promising tools to the portal, which will be reviewed by an expanded panel of nearly 200 experts before the information is released free of charge to researchers around the world.

Expand and improve data

Other major portal updates include information and expert advice on hundreds of new chemical tools.

They include inhibitors of proteins previously considered largely non-drug-like, such as KRAS, agonists of cell surface receptor molecules, GPCRs, including the serotonin receptor HTR2A, as well as new chemical tools such as PROTACs and molecular glues – dual function molecules that guide proteins to the cellular degradation system to be broken down.

In the past year alone, the number of probes listed on the portal has increased by 60% to 520. Hundreds of new protein targets have been added, increasing the variety of tools researchers can use and expanding the impact in different research fields, including neurology and immunology.

Data sources include KPIs canSARthe world’s largest public cancer drug discovery resource, and probe minera leading community resource for evaluating chemical probes based on large-scale medicinal chemistry data.

The AI-enabled canSAR contains data on 500,000 protein structures and three million surface cavities of nearly 110,000 macromolecules, all of which are annotated and organized so that machine learning algorithms can easily analyze the data , as well as clinical and other data.

Probe Miner has evaluated over 1.8 million small molecules for their potential to act as chemical probes against 2,200 human protein targets.

Laying a solid foundation for research

Dr. Albert Antolin, ICR Fellow and Junior Team Leader at ICR, and one of the principal investigators of the Chemical Probe Portal, said: “The Chemical Probe Portal contains a host of new updates. day, including detailed information on hundreds of new molecules, a more effective use of big data and, above all, renewed support from hundreds of leading international experts in the best use of chemical probes in research.

“The portal provides all the key information to facilitate the selection of chemical probes in an easy to use way. It helps guide the use of chemical probes in thousands of experiments, laying a stronger foundation for basic research and drug discovery in a wide range of diseases, including cancer.

Professor Paul Workman, Harrap Professor of Pharmacology and Therapeutics at ICR and Executive Director of the Chemical Probes Portal, said:

“The incorrect selection and use of chemical probes is widespread in biomedical research and, unfortunately, leads to misleading or erroneous conclusions being drawn from the results of experiments. In extreme cases, this can derail drug discovery and clinical trials and result in the unnecessary waste of hundreds of millions of pounds of research funding.

“With the Chemical Probe Portal and its close interaction with the Target 2035 initiative, our goal is to give the research community an accessible resource, backed by the best data and world-renowned experts in using the best chemical probes for the study of particular proteins New developments on the portal will now further improve the selection and use of the best available tools for experimental research and thus increase the quality and robustness of biomedical research.

Reviews | What I learned from talking to strangers

For the editor:

Re “Strangers are good for us”, by David Sax (Opinion guest essay, June 17):

As a faculty member of a university pharmacy department, I developed an elective course in geriatric pharmacy that focused on understanding the geriatric patient.

Part of the course required the student to approach any very old stranger and strike up a conversation. Some were reluctant to do so.

The results were enlightening: students helped cross the road and carry packages, and one student took a lonely senior for coffee.

All reported the feeling of having accomplished a worthwhile mission, of having brought a ray of light into the life of a complete stranger.

Janet Landau
Port Washington, New York

For the editor:

Kudos to David Sax for saying the right thing, that technology in the name of bringing us closer together actually drives us further apart.

How often do you see two people at a cafe table, crouching over their device instead of talking to each other? These things are social poison!

Personally, I will not be drawn into the Apple universe; I’ll stick to a simple flip phone. It’s time to ignore Big Tech’s selling points and reclaim our common humanity.

Waul McMahan
Redding, California.

For the editor:

While David Sax argues that technological change and the pandemic have alienated us from deep human interactions, modern life has sparked a thirst for community.

From Covid-19 to uprisings against police brutality, international conflict and the fight for reproductive justice, the world has had a transformative experience. Yet, without denying the great suffering that has occurred, it is in times like these that strangers have come together in a spirit of solidarity to support their fellow citizens, defend basic rights and connect with the natural world. .

The past few years have powerfully revealed how vulnerable and dependent on each other we are. It remains to be seen whether the solidarity that we have collectively created will last. But as Mr. Sax argues, we should experience the subtle ways in which a stranger’s smile, question, or palpable gaze can nurture a precious sense of connection.

Maria Clara Cobo
Quito, Ecuador

For the editor:

Reading David Sax’s article reminded me of an experience I had in the summer of 1987 when I had just graduated from high school in Manhattan. I was doing a grueling data entry job that provided an hour’s respite in the middle of the workday for lunch.

My best friend had lent me his Walkman, a state-of-the-art device that allowed you to listen to music privately with headphones. During my lunch hour, I would go to a nearby park and sit on a bench, having fun, numbing myself to the songs of my favorite pop stars.

One day a woman approached me while I was zoned out on the park bench and started talking to me. I took my headphones off so I could hear what she was saying and found out that she was basically scolding me for wearing headphones in public.

I defended myself: “It doesn’t hurt you!”

To my surprise, she replied, “But it hurts me!”

I was at a loss for words. Feeling irritated by this unwelcome interruption to my lunch break, I put my headphones back on and stared at my feet until she was gone.

I have never forgotten that encounter. At the time, I called this woman “crazy”. But looking back in the context of our current situation, I now suspect that she was truly the sane one.

Liz Rogers
Dummerston, Vermont.

For the editor:

Regarding “The United States is losing its military advantage in Asia, and China knows it”, by Ashley Townshend and James Crabtree (opinion guest essay, nytimes.com, June 15):

I agree with the authors’ call for increased resources in the Indo-Pacific, but I disagree with their singular focus on improving US military resources in the region. Instead, the United States must focus on increasing diplomatic and development resources in the Indo-Pacific if we are to effectively counter China’s growing aggression.

Over the past decade, US foreign assistance to East Asia and the Pacific has hovered around 3-5% of the world’s total US foreign assistance in our core budget. US aid to the wider Indo-Pacific region has barely exceeded 10% of the global total over the past five years.

An overemphasis on defense resources will continue to allow Beijing to employ political and economic coercion with impunity. It is precisely these actions that often prevent regional partners from working more closely with the United States on deterrence than Messrs. Townshend and Crabtree hope to reinforce.

Certainly, the United States must maintain a solid military position in the region. But any discussion of expanding US resources in the Indo-Pacific must begin with diplomatic and development resources.

Friend Bera
The writer, a California Democrat, is chairman of the House Foreign Affairs Subcommittee on Asia, the Pacific, Central Asia, and Nonproliferation.

For the editor:

Regarding “Is the thin blue line getting thinner?” by Jay Caspian Kang (Opinion, Sunday Review, June 12):

I was a sheriff’s deputy from the 1980s to the early 2000s, in Los Angeles and Seattle, and I can tell you there was an uphill struggle to find qualified recruits. This is not a new problem. I have long advocated for much better pay and benefits (not just for cops but for all essential services) to improve the candidate pool.

But what this job requires is more a “vocation” than a search for a salary. Police officers must be guardians, warriors, social defenders and many other personalities to be effective. And every time there is a “bad shoot” or any other criminal or negligent behavior by any of us, it defiles us all.

Of course, the discouraged staff leaves. Self-defeating slogans such as “defund the police” do not help.

Cops need to be trained in community policing. My fellow deputy ministers and I have used it to good effect in some of our most problematic areas. We won over the residents by showing that we really care about them.

It is a difficult profession. We know it. But the real solution lies in creating sincere alliances with communities. Without it, it’s rinse and repeat, forever.

MacKenzie Allen
Santa Fe, New Mexico

For the editor:

Regarding “The Wonderful World Only Animals See,” by Ed Yong (opinion guest essay, June 21):

After a year dedicated to promoting biodiversity and planting more native plants on our five-acre property, I pointed out to my husband that the big difference between experiencing the typical manicured lawn landscape that we are used to and what we have forged by allowing our earth (plants and animals) more self-determination is that instead of a static scene that is the same every morning, I see and hear a slightly different landscape every day .

There are new plants finding a place to grow, a greater variety of birds taking up residence, and evidence of more activity behind my back: peach trees and oak seedlings growing where squirrels have planted peach pits from compost and acorns, a groundhog bringing him new kits come out from under the bridge for their first outing over clover and grass, a hawk and a fox setting up stakes for their prey early in the morning.

My 90 year old husband replied, “The human imagination is nothing compared to what nature has to offer when you stop trying to control it and learn to live as a part of it.

Janis Richter
Rochelle, Virginia.

For the editor:

Regarding “Microsoft removes AI facial analysis tools” (Business, June 22):

Microsoft’s artificial intelligence emotion recognition tool is being phased out because biases related to subjects’ age, race, gender, or culture may make it inaccurate or unreliable.

The presumption that a impartial Emotion recognition tool would be acceptable is weird. Such an app would reinforce intrusive marketing, government overreach, and vicious personal attacks to an unprecedented degree.

Jeff Freeman
Rahway, New Jersey

Great Stone will cooperate with Zhiguli Valley Technopark

MINSK, July 4 (BelTA) — Great Stone will cooperate with Zhiguli Valley Technopark, BelTA learned from the press service of the industrial park.

Great Stone hosted a delegation from Samara Oblast in Russia. Guests learned about the development of the park, its preferential and legal regimes, and the progress of infrastructure construction.

During the visit, the administrations of Great Stone and Zhiguli Valley signed a memorandum of cooperation. According to the document, the parties will cooperate in developing high-tech entrepreneurship, promoting innovation and applying scientific achievements in production.

The Sino-Belarusian Great Stone Industrial Park is a special economic zone with a special legal regime. It is located 25 km from Minsk. The park’s priority areas of development are mechanics, electronics and telecommunications, biotechnologies, pharmaceuticals, new materials, logistics, digital commerce, storage and processing of big data.

Zhiguli Valley High-Tech Technopark is located in Samara Oblast in Russia. It federates more than 260 resident companies working in the fields of information, telecommunications, space technologies, chemistry and the development of new materials, medicine, ecology, etc.

Pharmacists could close the healthcare gap by offering more sexual health services

Pharmacists could reduce barriers for people seeking sexual and reproductive health services, according to new research from the University of Alberta.

Many pharmacists already provide some sexual and reproductive health support, including administering contraceptives and human papillomavirus (HPV) vaccines. But further training and the expansion of these services could help increase access and reduce inequities in this key area of ​​health care.

As part of the study, researchers from the University of Alberta interviewed pharmacists working in community pharmacies in Alberta to determine what sexual and reproductive health services they were already providing and the areas in which they wanted expand their training. They found that most participants were confident in educating patients on many sexual and reproductive health topics, but many wanted additional education on sexually transmitted and blood-borne infections as well as child health issues. members of the LGBTQ+ community.

Many people face barriers to accessing needed sexual and reproductive health services, including limited clinic hours, lack of primary care physicians, and confusion about where to approach issues such as as screening for sexually transmitted infections. With more training and a coordinated effort across the country, pharmacists could become a critical resource to help increase access to these services.

“Pharmacies are one of the most accessible entry points for people to enter the system,” says Javiera Navarrete, research assistant at the Faculty of Pharmacy and Pharmaceutical Sciences. “COVID has highlighted how important it is to use all the healthcare resources we have.”

Study co-author Javiera Navarrete says the accessibility of pharmacists in communities makes them a valuable resource for people seeking sexual and reproductive health services. (Photo: provided)

Canadian pharmacists are well positioned to expand their scope of practice to include more sexual and reproductive health services. Their training has changed significantly in recent years, says Christine Hughes, and a doctorate in pharmacy has now become the entry-to-practice credential in Canada. Additionally, provinces like Alberta have a compensation framework that allows pharmacists to be paid for services other than just dispensing, which would help counter the extra workload, she adds.

“The focus is much more on patient assessment and clinical interactions with patients, as opposed to historically where it was primarily about drug delivery,” says Hughes, professor and acting dean of the Faculty of Pharmacy and Pharmaceutical Sciences.

Most pharmacies in Alberta have private consultation rooms, which provide the pharmacist and the patient with space and more privacy to discuss sensitive topics. Since many patients may find it difficult to discuss sexual and reproductive health topics at the public counter, these rooms are an ideal space for more private discussions, says Navarrete.

Pharmacists would need more training and professional education before pharmacies could become a go-to community touchpoint for sexual and reproductive health, Navarrete says, and patients would also need education. People who may benefit from these services should be informed of their options and the services they can access through pharmacists.

Hughes and Navarrete are collaborating with researchers in Japan and Thailand to get a more comprehensive view of what pharmacists around the world provide in terms of sexual and reproductive health services. One of the World Health Organization’s Sustainable Development Goals is to ensure universal access to sexual and reproductive health services by 2030, but there is currently no coordinated effort around the world. Research identifying the current state of pharmacy practice could be a key step towards creating a more unified strategy.

“All countries are at different stages of this process, so showing that with data and providing pharmacists’ perspectives is a powerful tool that can enable countries to implement the best models in line with their regulations,” says Navarrete.

“It’s definitely an area for future growth,” adds Hughes.

The EPICORE Center and the Alberta SPOR Support Unit Consulting and Research Services supported survey development and distribution, data management and statistical services. Navarrete has received funding from the National Agency for Research and Development (ANID-Becas Chile) scholarship program.

/Release from the University of Alberta. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors. See in full here.

CNS Pharmaceuticals receives an A – GuruFocus.com

Expanded eligibility for patients who have received multiple therapies as first-line therapy for GBM

The company continues to recruit patients for the trial with 19 clinical trial sites open to date and 42 additional sites selected across the United States, Italy, France, Spainand Swiss who will be initiated and register soon

Interim analysis of the trial when 30 to 50% of subjects reach 6 months of study

HOUSTON, June 23, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has received Food and Drug United States Administration (FDA) for its potentially pivotal ongoing global study evaluating the efficacy and safety of Berubicin compared to Lomustine (Gleostine) given after first-line therapy for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

“We are delighted to have received this positive response from the FDA and to continue to advance the clinical development program for berubicin. The primary goals of the protocol amendment are based on feedback we received from investigators and on a more in-depth consideration of the needs of patients on the We have also incorporated the recent WHO classification of glioblastoma1 with relevant guidelines, ensuring that these patients meet specific criteria that allow us to precisely position the program for success. I am proud of the progress we continue to make on the clinical and regulatory fronts and look forward to moving this important trial forward,” commented John ClimacoCEO of CNS Pharmaceuticals.

Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety.

The potentially pivotal trial is an adaptive, multicenter, open-label, randomized, controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line treatment. The primary endpoint of the study is overall survival (OS), which is a stringent endpoint that the FDA has recognized as the basis for approving oncology drugs when a statistically significant improvement can be demonstrated by compared to a randomized control group. The trial results will compare berubicin to a current standard of care (lomustine), with patients randomized 2 to 1 to receive either berubicin or lomustine. The amended protocol extends study eligibility to patients who have received additional treatments as part of the first-line treatment of their disease in light of advances in this area. This change was made due to the complexity of new agents being introduced as a component of first-line treatment, which allows for an additional group of patients to enroll in the study after what may amount to several procedures as initial treatment. .

A pre-planned, non-binding futility analysis will be performed after 30-50% of all planned patients have completed 6 months of treatment. This evaluation will include safety as well as secondary efficacy endpoints. Registration will not be interrupted during this interim analysis.

“The operational objectives of this study remain our priority, including the use of patient-reported outcomes, stratification based on MGMT methylation status (a prognostic factor in glioblastomas), and the provision of both drug to the study, berubicin, as well as the comparator drug, lomustine, for all sites. With recent regulatory approvals received in Europewe are currently in the process of opening clinical sites around the world, including France, Italy, Spainand Swiss, to expand the scope and reach of patients for this trial. We remain committed to advancing this study and ultimately hope to provide a much-needed option for the treatment of GBM as a safe and effective therapy,” added Sandra L. SilbermanMD, Ph.D. Medical Director of CNS Pharmaceuticals.

The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin, which allows for more frequent interactions with them to provide guidance on expediting the development and review process. Additionally, the Company has also received orphan drug designation from the FDA, which can provide seven years of market exclusivity upon approval of an NDA.

For more information on the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069.

About Berubicin

Berubicin is an anthracycline, a class of anticancer drugs that are among the most potent and effective chemotherapy drugs against more types of cancer than any other class of chemotherapy drugs. Anthracyclines are designed to use natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, an essential enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include a durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin was developed by Dr. Waldemar Priebeprofessor of medicinal chemistry at University of Texas MD Anderson Cancer Center.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which uses anthracycline and distamycin-based scaffolds to create small molecule agents and is said to be 500 times more potent than daunorubicin in inhibiting proliferation. tumor cells. Preclinical studies of WP1244 demonstrated strong brain uptake with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic, ovarian and lymphoma cancers.

For more information, please visit www.CNSPharma.comand connect with the Company on Twitter, Facebookand LinkedIn.

Forward-looking statements

Certain of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. . Forward-looking statements in this press release include, but are not limited to, the timing of the opening of new sites in Europe. These statements relate to future events, future expectations, plans and prospects. Although CNS believes that the expectations reflected in these forward-looking statements are reasonable as of the date they are made, the expectations may turn out to be materially different from the results expressed or implied by these forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ”believes” ”estimates” ”anticipates” ”expects” ”plans” ”projects” ”a l ‘intent,’ ”potential”, ”may” ”could” ”could” ”will” ”should” ”approximately” or other words that convey uncertainty future events or results to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed in 1A. “Risk Factors” in CNS’s most recent Form 10-K filings with the Securities and Exchange Commission (“SEC”) and as updated from time to time in its Form 10-Q filings and other public filings with the SEC. All forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unforeseen events.

1 Editorial Board of the WHO Classification of Tumours. World Health Organization classification of tumors of the central nervous system. 5th ed. Lyons: International Agency for Research on Cancer; 2021

favicon.png?sn=DA97639&sd=2022-06-23 Show original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-receives-approval-from-us-fda-for-protocol-amendment-to-ongoing-potentially-pivotal-global-trial-evaluating-berubicin- for-processing-gbm-301573601.html

SOURCESNC Pharmaceuticals, Inc.

FTC takes aim at PBMs, warns against legal action

Last month, the Federal Trade Commission (FTC) voted unanimously (5-0) to review rising insulin list prices, but also to probe possible anti-competitive practices by Pharmacy Benefit Managers (PBMs). regarding the use of rebate agreements. Rebates are payments from drug manufacturers to PBMs in exchange for shifting market share to formulary preferred products. The FTC cites cases in which cheaper generics and biosimilars are excluded from PBM formularies because doing so may violate competition and consumer protection laws.

Separately, in early June, the FTC opened an investigation into six major PBMs. The FTC also voted unanimously (5-0) to continue this investigation which will require CVS Caremark, Express Scripts, OptumRx, Humana, Prime Therapeutics and MedImpact Healthcare Systems to file information regarding their dealings with pharmacies.

The FTC has warned of legal action against PBMs if its investigations find evidence of anticompetitive practices.

Here, in addition to rebates, the FTC will investigate direct and indirect compensation (DIR) fees and spread pricing. PBMs assess DIR fees for pharmacies that dispense Medicare Part D (outpatient) drugs. These fees are often charged long after a pharmacy has filled a Medicare prescription. PBMs say they get money back because of a pharmacy’s performance on certain quality measures. However, observers point to the arbitrary and opaque nature of these quality measures. Tiered pricing is PBM’s practice of pocketing the difference between the payment PBM receives from a health plan and the reimbursement amount it pays the pharmacy.

There appears to be some overlap between the two investigations the FTC voted on in June. The FTC has announced that it will use “every tool at its disposal” to investigate PBMs and drugmakers, with a focus on the insulin market.

Insulin has long been a hot topic in Washington DC, given the ever-increasing out-of-pocket expenses of patients. Even insured patients spend an average of more than $750 a year on insulin. Uninsured patients spend at least twice as much. Insulin is an essential treatment for approximately 8 million Americans to control diabetes.

The insulin saga epitomizes the challenges facing US health care in access, equity, pricing and discounts. For years, voters have demanded that lawmakers and the executive branch make changes that reduce their non-cost burden, but also establish a more transparent market. So far, to no avail.

The FTC upped the ante because the agency included terms such as “commercial bribery” in its statements to describe what it perceives to be anti-competitive rebates in the insulin market.

The FTC’s latest investigation follows a recent investigation by Senators Grassley (R-Iowa) and Wyden (D-Oregon), who blamed rebate programs for much of the prescription drug market’s ills. Additionally, nearly two years ago, Sen. Klobuchar (D-Minnesota) and his colleagues tasked the General Accounting Office (GAO) with reviewing rebates. The GAO report is due out this fall.

There are many problems with the discount system as it currently exists in the United States. In the conventional rebate system that has been in place for decades, PBMs receive rebates from drug manufacturers in exchange for preferred positioning on the formulary, which in turn increases market share. Experts have criticized discounts for the fact that payers often do not base their decisions to include a drug on comparative cost-effectiveness. On the contrary, the decisions strictly depend on the financial conditions, namely which manufacturer offers a higher discount to the PBM. This applies to insulin as well as many other therapeutic classes.

What’s worse is when traps or rabbet walls are involved. Branded manufacturers leverage their market-leading position by offering financial incentives to PBMs and health insurers in the form of “all-or-nothing” conditional volume-based discounts, in exchange for (virtually) exclusive positioning on the form. This may mean excluding competitors from the formulary altogether, or severely limiting access to the formulary for a competing drug with drug usage management tools such as staged edits. Here, a patient must use a preferred drug and fail (a so-called “fail-first” policy) before switching to a non-preferred drug.

Since the portion of the discount retained by PBMs is often calculated as a percentage of a drug’s list price, PBMs may have an incentive to establish formularies that favor branded drugs with higher list prices and higher discounts. significant compared to cheaper biosimilars, specialty generics or even branded products. competitors. Competing drugs entering the market do not have sufficient sales volume to be able to offer the same level of discounts to PBMs that innovator companies can provide.

A growing number of states have called for more oversight regarding PBM transactions. However, the FTC survey offers a comprehensive review of PBM practices nationwide. Evidence of the establishment of anti-competitive practices could lead to legal action against PBMs.

president appointed at Pitt’s Bradford and Titusville campuses | Community News

BRADFORD — Rick Esch, who served as interim president of the University of Pittsburgh’s Bradford and Titusville campuses for the past year, has been named president of both campuses.

The appointment took effect Friday and was announced to the university community by Ann Cudd, president and senior vice chancellor of the University of Pittsburgh.

This page requires JavaScript.

Javascript is required for you to play premium content. Please enable it in your browser settings.

kAm“#:[email protected]?DEC2E65 566A [email protected]>>:E>[email protected] !:[email protected]’D 2?5 !:EE%:EFDG:==6’D DEF56 ?ED[ 724F=EJ 2?5 DE277[” rF55 D2:5[ 255:?8 E92E tD49 5C2HD @? 9:D @H? 6IA6C:6?46 2D 2 !:[email protected] 2=F>?FD [email protected] [email protected] @? 6?DFC:?8 E92E E96 24256>:4 6IA6C:6?46D 2E 9:D 2=>2 >2E6C 2?5 2E !:EE%:EFDG:==6 2C6 6I46==6?E 2?5 7F=7:==:?8]k^am

kAm“xE 92D 366? 2 8C62E AC:G:=686 2?5 [email protected][email protected]@ D6CG6 2D :?E6C:> AC6D:56?E @7!:[email protected] 2?5!:EE%:EFDG:= =6 E9:D A2DE J62C[” tD49 D2:5] “x [email protected]@[email protected][email protected]? [email protected] 42>AFD6D 2?5 [email protected]@FE E96 6?E:C6 F?:G6CD:EJ [email protected] 96=A @FC DEF56?ED DF44665[ 6?DFC6 E96 G:23:=:EJ @7 [email protected] 42>AFD6D[ 2?5 [email protected] 6249 @E96C 😕 E96D6 [email protected]]”k ^ Am

[email protected]=J 27E6C 36:?8 ?2>65 :?E6C:> AC6D:56?E =2DE yF=J[ tD49 AC:@C:E:K65 6?92?4:?8 6I:DE:?8 2?5 [email protected]:?8 ?6H C6=2E:@?D9:AD @? [email protected] 42>AFD6D 2?5 😕 E96:C C6DA64E:G6 [email protected]>>F?:E:6D[ H9:49 925 366? 5:77:4F=E 5F6 [email protected] E96 C6DEC:4E:@?D 😕 A=246 5FC:?8 E96 A2?56>:4]k^am

kAmtD49 3682? 9:D 42C66C 2E!:[email protected]:? `hhd 2D E96 5:[email protected] @7 2FI:=:2CJ D6CG:46D 2?5 7:G6 J62CD =2E6C H2D ?2>65 49:67 3FD:?6DD 2?5 25>:?:DEC2E: G6 2772:CD @77:46C]x? a B[ 96 H2D [email protected]>@E65 [email protected] G:46 AC6D:56?E [email protected] 3FD:?6DD 2772:CD]k^am

kAmx? a_`a[ 96 H2D ?2>65 G:46 AC6D:56?E [email protected] 3FD:?6DD 2772:CD 2E !:EE%:EFDG:==6]k^am

kAmw6 2?5 9:DH:76[ {:D2[ =:G6 😕 [email protected] 2?5 92G6 E9C66 [email protected]? 49:=5C6?]k^am

Plug-and-play test to track immunity to Sars-CoV-2 variants

Experts agree that the pandemic is not over. Infections resume, fueled by new variants for which our immune system is ill-prepared.

That’s according to a study by Canadian and American researchers who found that antibodies generated in people vaccinated and/or recovered from COVID-19 before 2022 failed to neutralize variants circulating today.

The study was led by Igor Stagljar, professor of biochemistry and molecular genetics, at the Donnelly Center for Cellular and Biomolecular Research, Temerty School of Medicine, and Shawn Owen, associate professor of pharmacy and pharmaceutical chemistry, at the of Utah. .

The newspaper Nature Communication published their findings.

Researchers expect the antibody test they developed to measure the immunity of study participants will become a valuable tool in deciding who needs a booster and when, which will help save lives and avoid future lockdowns.

“The truth is, we don’t yet know how often our injections should be to prevent infection,” Stagljar said. “To answer these questions, we need rapid, inexpensive, and quantitative tests that specifically measure Sars-CoV-2 neutralizing antibodies, which are the ones that prevent infection.”

Many antibody tests have been developed over the past two years. But only a few of the authorized ones are designed to monitor neutralizing antibodies, which coat the viral spike protein so that it can no longer bind to its receptor and enter cells.

This is an important distinction, as only a fraction of all Sars-CoV-2 antibodies generated during infection are neutralizing. And although most vaccines have been specifically designed to produce neutralizing antibodies, the degree of protection they provide against variants is unclear.

“Our method, which we named Neu-SATiN, is as accurate as the gold standard, but faster and cheaper, and it can be quickly adapted to new variants as they emerge,” he said. he declares.

Neu-SATiN stands for Neutralization Serology Test Based on Fractionated Three-Part Nanoluciferase, and it is a newer version of SATiN, which monitors the full pool of IgG, which they developed last year.

The development of Neu-SATiN was led by Zhong Yao, senior research associate in Stagljar’s lab, and Sun Jin Kim, postdoctoral fellow in Owen’s lab, who are co-first authors of the paper.

The first of its kind, the pinprick test is powered by a protein supplementation strategy using fluorescent protein luciferase from a deep-sea shrimp. It measures the ability of the viral spike protein to bind to the human ACE2 receptor, each of which is attached to a fragment of luciferase. The binding brings the luciferase pieces together so that they reconstitute a full-length protein, which emits a glow of light that is captured by the luminometer instrument. When the patient’s blood sample is added to the mix, the neutralizing antibodies bind to the spike protein, preventing it from coming into contact with ACE2. Consequently, the luciferase remains in pieces, accompanied by a drop in the light signal. The plug and play method can be adapted to different variants within weeks by creating variant mutations in the spike protein.

The researchers applied Neu-SATiN to blood samples taken from 63 patients with different histories of COVID-19 infection and vaccination up to November 2021. The patient’s neutralizing ability was assessed against the strain original from Wuhan and the variants, Alpha, Beta, Gamma, Delta and Omicron.

“We thought it would be important to monitor people who have been vaccinated to see if they still have protection and how long it lasts,” said Owen, who did his postdoctoral training at the Donnelly Center with bio- distinguished engineer and university professor Molly Shoichet. “But we also wanted to see if you were vaccinated against one variant, does that protect you against another variant?”

Neutralizing antibodies were found to last about three to four months, when their levels would drop by about 70%, regardless of infection or vaccination status. Hybrid immunity, acquired by both infection and vaccination, initially produced higher levels of antibodies, but these also dropped significantly four months later.

More worryingly, infection and/or vaccination offered good protection against the previous variants, but not Omicron, nor its subvariants, BA.4 and BA.5.

The data matches those of a recent UK study, which showed that neutralizing antibodies and cellular immunity, a type of immunity provided by memory T cells, against infection, vaccination or both, do not offered no protection against Omicron’s capture. In a surprising twist, the British group also found that Omicron infections boosted immunity against earlier strains, but not against Omicron itself, for reasons that remain unclear.

Importantly, vaccines still provide significant protection against serious illness and death, Stagljar said. Still, he added that the findings of his team and others call for vigilance in the coming period given that the more transmissible BA4 and BA5 subvariants may evade immunity acquired from previous Omicron infections. , as evidenced by the increase in reinfections.

“There will definitely be new variants in the near future,” Stagljar said. “Monitoring and building immunity against circulating variants will become increasingly important and our method could play a key role in this regard as it is rapid, accurate, quantitative and inexpensive.”

His lab is already collaborating with Canadian vaccine maker Medicago to help determine the effectiveness of their candidate vaccines against Omicron and its subvariants. Meanwhile, the U of T is negotiating a license for Neu-SATiN to a company that will scale it up so it can be used for population immunosurveillance and in the pharmaceutical industry for vaccine development.